日本臨牀　75/増刊5　動脈・静脈の疾患(下)

出版社： 日本臨牀社
発行日： 2017-07-20
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 動脈・静脈の疾患（下）―最新の診断・治療動向
電子書籍版： 2017-07-20 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

17,600 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

17,600 円(税込)

購入する

目次

  • 日本臨牀　75/増刊5 動脈・静脈の疾患（下）

    ―目次―

    特集　動脈・静脈の疾患（下）―最新の診断・治療動向

    VI. 動脈・静脈の疾患（臓器別）
    　1．虚血性心疾患
    　2．脳血管疾患
    　3．肺血管疾患
    　4．腹部大血管疾患（腹部大動脈疾患、腹部末梢血管疾患）
    　5．消化管
    　6．腎臓
    　7．動脈硬化に起因する大動脈便狭窄症

    VII. 血管炎
    　1．血管炎の現状と課題
    　2．血管炎の分類
    　3．血管炎の病理
    　4．大型血管炎
    　5．中型血管炎
    　6．小型血管炎
    　7．多彩な血管を侵襲する血管炎
    　8．単一臓器血管炎
    　9．全身性疾患関連血管炎

    VIII. 動脈・静脈疾患の基礎研究動向
    　1．動脈・静脈血栓症の病理
    　2．動脈・静脈疾患と炎症
    　3．活性酸素と動脈硬化
    　4．血液凝固とその制御機構
    　5．血小板機能と抗血小板薬
    　6．線溶系因子の活性制御
    　7．アディポネクチンと血管疾患
    　8．血管病変における血管外膜の意義
    　9．血管老化の分子機序
    　10．Klotho遺伝子と老化

    IX．特論
    　1．疾患エクソソームとmicroRNA
    　2．腸内細菌叢と心血管病
    　3．脳梗塞と免疫
    　4．細胞膜機能異常と微小循環障害
    　5．血管石灰化と血管病
    　6．DDSによる急性心筋梗塞治療
    　7．ESUSの概念と治療
    　8．Polyvascular diseaseの概念と治療戦略
    　9．時計遺伝子と血管病
    　10．インクレチン関連薬の抗動脈硬化作用

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

VI 動脈・静脈の疾患 ( 臓器別 )

P.558 掲載の参考文献
1) Libby P, et al : Progress and challenges in translating the biology of atherosclerosis. Nature 473 : 317-325, 2011.
PubMed
2) Castelli WP, et al : Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 2 : 23-28, 1992.
PubMed
3) Levy D, et al : Stratifying the patient at risk from coronary disease : new insights from the Framingham Heart Study. Am Heart J 119 : 712-717 ; discussion 717, 1990.
PubMed
4) Kannel WB et al : Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 258 : 1183-1186, 1987.
PubMed
5) Gordon T, et al : Drinking habits and cardiovascular disease : the Framingham Study. Am Heart J 105 : 667-673, 1983.
PubMed
6) Kubo M, et al : Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community : the Hisayama study. Stroke 34 : 2349-2354, 2003.
 
7) Austen WG, et al : A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 51 : 5-40, 1975.
 
8) Gotlld KL, et al : Physiologic basis for assessing critical coronary stenosis. Instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve. Am J Cardiol 33 : 87-94, 1974.
 
9) Pijls NH, et al : Measurement of fractional flow reserve to assess the functional severity of coronaryartery stenoses. N Engl J Med 334 : 1703-1708, 1996.
PubMed
10) Tonino P A, et al : Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 360 : 213-224, 2009.
PubMed
11) Kugiyama K, et al : Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation 94 : 266-271, 1996.
PubMed
12) Masumoto A, et al : Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 105 : 1545-1547, 2002.
PubMed
P.564 掲載の参考文献
1) Gibbons RJ, et al : ACC/AHA 2002 guideline update for exercise testing : sulnmary article : a report of the i Xmerican College of Cardiology, American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 106 : 1883-1892, 2002.
PubMed
2) Lang RM, et al : Recom Inendations for cardiac chamber quantification by echocardiography in adults : an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28 : 1-39. e14, 2015.
 
3) 小谷敦志, 平野豊 : ドブタミン負荷心エコー法. 心臓超音波テキスト第2版 (日本超音波検査学会監修, 増田喜一・遠田栄一編集), p263, 医歯薬出版, 2009年.
 
4) Fine JJ, et al : Comparison of accuracy of 64-slice cardiovascular computed tomography with coronary angiography in patients with suspected coronary artery disease. Am J Cardiol 97 : 173-174, 2006.
PubMed
5) Ehara M, et al : Diagnostic accuracy of 64-slice computed tomography for detecting angiographically significant coronary artery stenosis in an unselected consecutive patient population : comparison with conventional invasive angiography. Circ J 70 : 564-571, 2006.
 
6) Klocke FJ, et al : ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging-executive summary : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). J Am Coll Cardiol 42 : 1318-1333, 2003.
 
7) Ebeling Barbier C, et al : Clinically unrecognized myocardial infarction detected at MR imaging may not be associated with atherosclerosis. Radiology 245 : 103-110, 2007.
 
8) 循環器病の診断と治療に関するガイドライン (2009年度合同研究班報告) 慢性虚血性心疾患の診断と病態把握のための検査法の選択基準に関するガイドライン (2010年改訂版).
 
9) Sakuma H, et al : Detection of coronary artery stenosis with whole-heart coronary magnetic resonance angiography. J Am Coll Cardiol 48 : 1946-1950, 2006.
PubMed
10) Gaemperli O, et al : Validation of a new cardiac image fusion software for three-dimensional integration of myocardial perfusion S P E CT and stand-alone 64-slice CT angiography. Eur J Nucl Med Mol Imaging 34 : 1097-1106, 2007.
 
11) Nakaura T, et al : Three-dimensional cardiac image fusion using new CT angiography and SPECT methods. AJR Am J Roentgenol 185 : 1554-1557, 2005.
PubMed
12) Tonino PA, et al : Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 360 : 213-224, 2009.
PubMed
P.569 掲載の参考文献
1) 高血圧治療ガイドライン 2014 (日本高血圧学会編), p64-65, 2014.
 
2) Balady GJ, et al : Core components of cardiac rehabilitation/secondary prevention programs : 2007 update : a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology ; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism ; and the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation 115 : 2675-2682, 2007.
 
3) Kinjo K et al : Impact of smoking status on long-term mortality in patients with acute myocardial infarction. Circ J 69 : 7-12, 2005.
PubMed
4) Yasue H, et al : Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators. Am J Cardiol 83 : 1308-1313, 1999.
PubMed
5) Dargie HJ : Effect of carvedilol on outcome after myocardial infarction in patients with leftventricular dysfunction : the CAPRICORN randomised trial. Lancet 357 : 1385-1390, 2001.
PubMed
6) Sakamoto T, et al : Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol 97 : 1165-1171, 2006.
PubMed
7) Okazaki S, et al : Early statin treatment in patients with acute coronary syndrome : demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event : the ESTABLISH Study. Circulation 110 : 1061-1068, 2004.
PubMed
8) Cannon CP, et al : Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 372 : 2387-2397, 2015.
PubMed
9) Nicholls SJ, et al : Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients : The GLAGOV Randomized Clinical Trial. JAMA 316 : 2373-2384, 2016.
 
10) Yokoyama M, et al : Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS) : a randomised open-label, blinded endpoint analysis. Lancet 369 : 1090-1098, 2007.
PubMed
11) Japanese beta-Blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators : Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardiol 93 : 969-973, 2004.
PubMed
12) IONA Study Group : Impact of nicorandil in angina : subgroup analyses. Heart 90 : 1427-1430, 2004.
 
13) Takii T, et al : Trends in acute myocardial infarction incidence and mortality over 30 years in Japan : report from the MIYAGI-AMI Registry Study. Circ J 74 : 93-100, 2010.
PubMed
14) De Bruyne B, et al : Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med 371 : 1208-1217, 2014.
PubMed
P.579 掲載の参考文献
1) Fuster V, et al : The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 326 : 310-318, 1992.
PubMed
2) Thygesen K, et al : Third universal definition of myocardial infarction. Circulation 126 : 2020-2035, 2012.
PubMed
3) Alpert JS, et al : Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36 : 959-969, 2000.
 
4) Canto JG, et al : Prevalence, clinical characteristics, and mortality among Patients with myocardial infarction presenting without chest pain, JAMA 283 : 3223-3229, 2000.
PubMed
5) Damman P, et al : Usefulness of the admission electrocardiogram to predict long-term outcomes after non-ST-elevation acute coronary syndrome (from the FRISC II, ICTUS, and RITA-3 [FIR] Trials). Am J Cardiol 109 : 6-12, 2012.
PubMed
6) Kosuge M, et al : An early and simple predictor of severe left main and/or three-vessel disease in patients with non-ST-segment elevation acute coronary syndrome. Am J Cardiol 107 : 495-500, 2011.
PubMed
7) Morrow DA, et al : National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines : Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 115 : e356-375, 2007.
PubMed
8) Than M, et al : A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT) : a prospective observational validation study. Lancet 377 : 1077-1084, 2011.
 
9) 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告). ST上昇型急性心筋梗塞の診療に関するガイドライン (2013年改訂版), 2013.
 
10) Amsterdam EA, et al : 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 64 : e139-228, 2014.
 
11) Authors/Task Force members, et al : 2014 ESC/EACTS Guidelines on myocardial revascularization : The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35 : 2541-2619, 2014.
 
12) Gersh BJ, et al : Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction : is the slope of the curve the shape of the future? JAMA 293 : 979-986, 2005.
PubMed
13) American College of Emergency Physicians, et al : 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61 : e78-140, 2013.
 
14) Fox KA, et al : Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol 55 : 2435-2445, 2010.
 
15) Antman EM, et al : The TIMI risk score for unstable angina/non-ST elevation MI : A method for prognostication and therapeutic decision making. JAMA 284 : 835-842, 2000.
 
16) Eagle KA, et al : A validated prediction model for all forms of acute coronary syndrome : estimating the risk of 6-month postdischarge death in an international registry. JAMA 291 : 2727-2733, 2004.
 
17) Serruys PW, et al : Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360 : 961-972, 2009.
PubMed
P.584 掲載の参考文献
1) 平成27年 (2015) 人口動態統計 (確定数) の概況, 厚生労働省 [http://www.mhiw.go.jp/toukei/saikin/hw/jinkou/kakuteil5/index.html] (2017年6月閲覧)
 
2) Webb JG, et al : Implications of the timing of onset of cardiogenic shock after acute myocardial infarction : a report from the SHOCK Trial Registry. Should we emergently revascularize Occluded Coronaries for cardiogenic shock? J Am Coll Cardiol 36 (3 Suppl A) : 1084-1090, 2000.
 
3) Thiele H, et al : Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 367 : 1287-1296, 2012.
PubMed
4) Cheng JM, et al : Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock : a meta-analysis of controlled trials. Eur Heart J 30 : 2102-2108, 2009.
PubMed
5) Schmidt M, et al : Predicting survival after ECMO for refractory cardiogenic shock : the survival after veno-arterial-ECMO (SAVE) -score. Eur Heart J 36 : 2246-2256, 2015.
PubMed
6) Fox KA, et al : Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome : prospective multinational observational study (GRACE). BMJ 333 : 1091, 2006.
PubMed
7) Morrow DA, et al : TIMI risk score for ST-elevation myocardial infarction : A convenient, bedside, clinical score for risk assessment at presentation : An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 102 : 2031-2037, 2000.
PubMed
8) Halkin A, et al : Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction : the CADILLAC risk score. J Am Coll Cardiol 45 : 1397-1405, 2005.
PubMed
9) Hamm C W, et al : A classification of unstable angina revisited. Circulation 102 : 118-122, 2000.
PubMed
10) Saito M, et al : Long-term prognosis of patients with acute myocardial infarction : is mortality and morbidity as low as the incidence of ischemic heart disease in Japan. Am Heart J 113 : 891-897, 1987.
 
11) Nakatani D, et al : Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. Circ J 77 : 439-446, 2013.
PubMed
12) Masuda M, et al : Clinical Impact of Ventricular Tachycardia and/or Fibrillation During the Acute Phase of Acute Myocardial Infarction on In-Hospital and 5-Year Mortality Rates in the Percutaneous Coronary Intervention Era Circ J 80 : 1539-1547, 2016.
PubMed
13) 心筋梗塞二次予防に関するガイドライン (2011年改訂版) [http://www.j-circ.or.jp/guideline/pdf/JCS2011_ogawah_h.pdf] (2017年6月閲覧)
 
14) Sakata R, et al : Thoracic and cardiovascular surgery in Japan during 2008 : annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 58 : 356-383, 2010.
PubMed
15) Shroyer AL, et al : On-pump versus off-pump coronary-artery bypass surgery. N Engl J Med 361 : 1827-1837, 2009.
PubMed
16) Motomura N, et al : First report on 30-day and operative mortality in risk model of isolated coronary artery bypass grafting in Japan. Ann Thorac Surg 86 : 1866-1872, 2008.
PubMed
17) Tashiro H, et al : Clinical characteristics of patients with spontaneous remission of variant angina. Jpn Circ J 57 : 117-122, 1993.
PubMed
P.590 掲載の参考文献
1) Easton J D, et al : Definition and evaluation of transient ischemic attack : a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke council ; Council on Cardiovascular Nursing ; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirrns the value of this statement as an educational tool for neurologists. Stroke 40 : 2276-2293, 2009.
PubMed
2) Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke 21 : 637-676, 1990.
PubMed
3) Adams HP, et al : Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24 : 35-41, 1993.
 
4) Caplan LR : Intracranial branch atheromatous disease : a neglected, understudied, and underused concept. Neurology 39 : 1246-1250, 1989.
PubMed
5) Amarenco P, et al : Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 331 : 1474-1479, 1994.
PubMed
6) Mohr JP : Cryptogenic stroke. N Engl J Med 318 : 1197-1198, 1988.
PubMed
7) Hart RG, et al : Embolic strokes of undetermined source : the case for a new clinical construct. Lancet Neurol 13 : 429-438, 2014.
PubMed
P.595 掲載の参考文献
1) Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke 21 : 637-676, 1990.
PubMed
2) Adams HP, et al : Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24 : 35-41, 1993.
 
3) Amarenco P, et al : The ASCOD phenotyping of ischemic stroke (Updated ASCO Phenotyping). Cerebrovasc Dis 36 : 1-5, 2013.
PubMed
4) Kimura K, et al : A case of paradoxical cerebral embolism through a patent foramen ovale diagnosed by necropsy. Rinsho Shinkeigaku 34 : 56-60, 1994.
 
5) Hecaen H, et al : Cerebral organization in left-handers. Brain Lang 12 : 261-284, 1981.
PubMed
6) Barber PA, et al : Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet 355 : 1670-1674, 2000.
 
7) Flacke S, et al : Middle cerebral artery (MCA) susceptibility sign at susceptibility-based perfusion MR imaging : clinical importance and comparison with hyperdense MCA sign at CT. Radiology 215 : 476-482, 2000.
PubMed
8) Barber PA, et al : Hyperdense sylvian fissure MCA "dot" sign : A CT marker of acute ischemia. Stroke 32 : 84-88, 2001.
 
9) Azizyan A, et al : Fluid-attenuated inversion recovery vascular hyperintensities : an important imaging marker for cerebrovascular disease. AJNR Am J Neuroradiol 32 : 1771-1775, 2011.
PubMed
P.600 掲載の参考文献
1) Campbell BC, et al : Twenty-Year History of the Evolution of Stroke Thrombolysis With Intravenous Alteplase to Reduce Long-Term Disability. Stroke 46 : 2341-2346, 2015.
PubMed
2) Emberson J, et al : Effect of treatment delay, age, and stroke severity on the cffccts of intravenous thrombolysis with alteplase for acute ischaemic stroke : a meta-analysis of individual patient data from randomised trials. Lancet 384 : 1929-1935, 2014.
PubMed
3) 日本脳卒中学会 脳卒中医療向上・社会保険委員会 : rt-PA (アルテプラーゼ) 静注療法適正治療指針第二版. 脳卒中 34 : 443-480, 2012.
 
4) Koga M, et al : THrombolysis for Acute Wake-up and unclear-onset Strokes with alteplase at 0.6 mg/kg (THAWS) Trial. Int J Stroke 9 : 1117-1124, 2014.
 
5) Chen ZM, et al : Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 31 : 1240-1249, 2000.
 
6) Antithrombotic Trialists' Collaboration : Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 : 71-86, 2002.
PubMed
7) 大友英一, ほか : 脳血栓症急性期におけるOKY-046の臨床的有用性プラセボを対象とした多施設二重盲検試験. 臨床医薬 7 : 353-388, 1991.
 
8) Merwick A, et al : Addition of brain and carotid imaging to the ABCD2 score to identify patients at early risk of stroke after transient ischaemic attack : a multicentre observational study. Lancet Neurol 9 : 1060-1069, 2010.
 
9) Wang Y, et al : Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 369 : 11-19, 2013.
 
10) Wong KS, et al : Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack : an updated systematic review and meta-analysis. Circulation 128 : 1656-1666, 2013.
 
11) Diener H C, et al : Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH) : randomised, double-blind, placebo-controlled trial. Lancet 364 : 331-337, 2004.
PubMed
12) Toyoda K, et al : Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan : the SAMURAI-NVAF study. Int J Stroke 10 : 836-842, 2015.
PubMed
13) Hart RG, et al : Embolic strokes of undetermined source : the case for a new clinical construct. Lancet Neurol 13 : 429-438, 2014.
PubMed
14) Sacco RL, et al : Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death : subgroup analyses from the Warfarin-Aspirin Recurrent Stroke Study. Cerebrovasc Dis 22 : 4-12, 2006.
PubMed
P.607 掲載の参考文献
1) 桑山直也 : 脳動脈瘤・頸動脈狭窄症に対する脳血管内治療. 脳神経外科ジャーナル 19 : 41-46, 2010.
 
2) Kageyama H, et al : Juvenile Cerebral Infarction Caused by Bow Hunter's Syndrome during Sport : Two Case Reports. Neurol Med Chir (Tokyo) 56 : 580-583, 2016.
PubMed
3) Kaku Y, et al : Factors predictive of cerebral hyperperfusion after carotid angioplasty and stent placement. AJNR Am J Neuroradiol 25 : 1403-1408, 2004.
PubMed
4) Yoshimura S, et al : High-intensity signal on time-of-flight magnetic resonance angiography indicates carotid plaques at high risk for cerebral embolism during stenting. Stroke 42 : 3132-3137, 2011.
PubMed
5) Yuan C, et al : MRI of atherosclerosis in clinical trials. NMR Biomed 19 : 636-654, 2006.
 
6) 吉村紳一. ほか : 脳血管内治療診療指針 7 : 頸動脈狭窄症. JNET 3 (Suppl 1) : 56-65, 2009.
 
7) Bijuklic K, et al : The PROFI study (Prevention of Cerebral Embolization by Proximal Balloon Occlusion Compared to Filter Protection During Carotid Artery Stenting) : a prospective randomized trial. J Am Coll Cardiol 59 : 1383-1389, 2012.
 
8) Yoshimura S, et al : Efficacy of endovascular treatment for acute cerebral large-vessel occlusion : analysis of nationwide prospective registry. J Stroke Cerebrovasc Dis 23 : 1183-1190, 2014.
PubMed
9) Broderick JP, et al : Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 368 : 893-903, 2013.
PubMed
10) Kidwell CS, et al : A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 368 : 914-923, 2013.
PubMed
11) Ciccone A, et al : Endovascular treatment for acute ischemic stroke. N Engl J Med 368 : 904-913, 2013.
PubMed
12) Yoshimura S. et al : Endovascular treatment of acute ischemic stroke : Honolulu shock and thereafter. J Stroke Cerebrovasc Dis 23 : e295-298, 2014.
PubMed
13) Berkhemer OA, et al : A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 372 : 11-20, 2015.
PubMed
14) Goyal M, et al : Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 372 : 1019-1030, 2015.
PubMed
15) Campbell BC, et al : Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 372 : 1009-1018, 2015.
PubMed
16) Saver JL, et al : Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med 372 : 2285-2295, 2015.
PubMed
17) Jovin TG, et al : Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 372 : 2296-2306, 2015.
PubMed
18) Prabhakaran S, et al : Acute stroke intervention : a systematic review. JAMA 313 : 1451-1462, 2015.
PubMed
19) Powers WJ, et al : 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment : A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 46 : 3020-3035, 2015.
PubMed
P.611 掲載の参考文献
1) 荒木信夫, ほか : 病型別・年代別頻度. 脳卒中データバンク 2015 (小林祥泰編), p18-19, 中山書店, 2015.
 
2) van Swieten JC, et al : Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19 : 604-607, 1988.
 
3) Kimura K et al : Analysis of 16,922 patients with acute ischemic stroke and transient ischemic attack in Japan. A hospital-based prospective registration study. Cerebrovasc Dis 18 : 47-56, 2004.
PubMed
4) Hata J, et al : Ten year recurrence after first ever stroke in a Japanese community : the Hisayama study. J Neurol Neurosurg Psychiatr 76 : 368-372, 2005.
 
5) 佐伯覚, ほか : 脳卒中の復職-近年の研究の国際動向について. 総合リハビリテーション 39 : 385-390, 2011.
 
6) 竹川英宏, ほか : 病型別にみた人院時重症度と退院時予後の関係. 脳卒中データバンク 2015 (小林祥泰編), p28-29, 中山書店, 2015.
 
7) 鐙谷武雄 : 入院後進行と再発における病型別の頻度と予後 (脳梗塞, 脳出血). 脳卒中データバンク 2015 (小林祥泰編), p40-41, 中山書店, 2015.
 
8) Johnston KC, et al : Medical and neurological complications of ischemic stroke : experience from the RANTTAS trial. RANTTAS Investigators. Stroke 29 : 447-453, 1998.
PubMed
9) Westendorp WF, et al : Post-stroke infection : a systematic review and meta-analysis. BMC Neurol 11 : 110, 2011.
PubMed
10) Nakamori M, et al : Prediction of Pneumonia in Acute Stroke Patients Using Tongue Pressure Measurements. PLoS ONE 11 : e0165837, 2016.
PubMed
11) Aoki S, et al : The Multidisciplinary Swallowing Team Approach Decreases Pneumonia Onset in Acute Stroke Patients. PLoS ONE 11 : e0154608, 2016.
PubMed
12) Nakagawara J, et al : Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice : the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 41 : 1984-1989, 2010.
 
13) Toyoda K, et al : Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients : general outcomes and prognostic factors from the SAMURAI register. Stroke 40 : 3591-3595, 2009.
PubMed
14) 日本脳卒中学会, 日本脳神経学会, 日本脳神経. 血管内治療学会 : 経皮経管的脳血栓回収用機器 適正使用指針 (第2版), 脳卒中 37 : 259-279, 2015.
 
15) Ottenbacher KJ, et al : The results of clinical trials in stroke rehabilitation research. Arch Neurol 50 : 37-44, 1993.
PubMed
16) Bernhardt J, et al : A very early rehabilitation trial for stroke (AVERT) : phase II safety and feasibility. Stroke 39 : 390-396, 2008.
 
17) Yagi M, et al : Impact of rehabilitation on outcomes in patients with ischemic stroke : A nationwide retrospective cohort study in japan. Stroke 48 : 740-746, 2017.
PubMed
P.617 掲載の参考文献
1) A classification and outline of cerebrovascular diseases. Neurology 8 : 395-434, 1958.
PubMed
2) Acheson J, et al : Observations on the natural history of transient cerebral ischaemia. Lancet 2 : 871-874, 1964.
PubMed
3) Marshall J : The natural history of transient ischaemic cerebro-vascular attacks. Q J Med 33 : 309-324, 1964.
PubMed
4) A classification and outline of cerebrovascular diseases. II. Stroke 6 : 564-616, 1975.
PubMed
5) Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke 21 : 637-676, 1990.
PubMed
6) Albers GW, et al : Transient ischemic attack-proposal for a new definition. N Engl J Med 347 : 1713-1716, 2002.
PubMed
7) Easton JD, et al : Definition and evaluation of transient ischemic attack : ascientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council ; Council on Cardiovascular Surgery and Anesthesia ; Council on Cardiovascular Radiology and Intervention ; Council on Cardiovascular Nursing ; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke 40 : 2276-2293, 2009.
 
8) 平成21～23年度 厚生労働科学研究費補助金による「一過性脳虚血発作 (TIA) の診断基準の再検討, ならびに我が国の医療環境に即した適切な診断・治療システムの確立に関する研究」班 : TIA診療マニュアル, 共進社, 2012.
 
9) 上原敏志, ほか : 日本脳卒中学会認定研修教育病院を対象とした一過性脳虚血発作 (TIA) の診療に関するアンケート調査. 脳卒中 32 : 710-718, 2010.
Medical*Online
10) Miyagi T, et al : Examination timing and lesion patterns in diffusion-weighted magnetic resonance imaging of patients with classically defined transient ischemic attack. J Stroke Cerebrovasc Dis 22 : e310-316, 2013.
PubMed
11) Morita N, et al : Frequency of emerging positive diffusion-weighted imaging in early repeat examinations at least 24 h after transient ischemic attacks. Neuroradiology 55 : 399-403, 2013.
PubMed
12) 内山真一郎 : TIAの新しい定義と概念. 臨床神経 50 : 904-906, 2010.
 
13) Wu CM, et al : Early risk of stroke after transient ischemic attack : a systematic review and metaanalysis. Arch Intern Med 167 : 2417-2422, 2007.
PubMed
14) Chandratheva A, et al : Population-based study of risk and predictors of stroke in the first few hours after a TIA. Neurology 72 : 1941-1947, 2009.
PubMed
15) Kiyohara T, et al : ABCD3 and ABCD3-I scores are superior to ABCD2 score in the prediction of short-and long-term risks of stroke after transient ischemic attack. Stroke 45 : 418-425, 2014.
 
16) 上原敏志, ほか : わが国におけるTIAレジストリーの現況. 脳卒中 37 : 197-201, 2015.
Medical*Online
17) Amarenco P, et al : One-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke. N Engl J Med 374 : 1533-1542, 2016.
 
18) Rothwell PM, et al : Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study) : a prospective population-based sequential comparison. Lancet 370 : 1432-1442, 2007.
PubMed
19) Lavallee P C, et al : A transient ischaemic attack clinic with round-the-clock access (SOS-TIA) : feasibility and effects. Lancet Neurol 6 : 953-960, 2007.
PubMed
20) 尾原知行, ほか : 一過性脳虚血発作 (TIA) の病型分類-ラクナTIAの臨床的重要性-. 臨床神経 51 : 406-411, 2011
 
21) Sempere AP, et al : Etiopathogenesis of transient ischemic attacks and minor ischemic strokes : a community-based study in Segovia, Spain. Stroke 29 : 40-45, 1998.
PubMed
22) Weimar C, et al : Etiology, duration, and prognosis of transient ischemic attacks : an analysis from the German Stroke Data Bank. Arch Neurol 59 : 1584-1588, 2002.
PubMed
23) Purroy F, et al : Patterns and predictors of early risk of recurrence after transient ischemic attack with respect to etiologic subtypes. Stroke 38 : 3225-3229, 2007.
PubMed
24) Adams HP, et al : Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24 : 35-41, 1993.
 
P.623 掲載の参考文献
1) Johnston SC, et al : Global variation in stroke burden and mortality : estimates from monitoring, surveillance, and modelling. Lancet Neurol 8 : 345-354, 2009.
PubMed
2) Hand PJ, et al : Distinguishing between stroke and mimic at the bedside : the brain attack study. Stroke 37 : 769-775, 2006.
PubMed
3) Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke 21 : 637-676, 1990.
PubMed
4) Kearney PM, et al : Globai burden of hypertension : analysis of worldwide data. Lancet 365 : 217-223, 2005.
 
5) Hankey GJ : Smoking and risk of stroke. J Cardiovasc Risk 6 : 207-211, 1999.
PubMed
6) Tuomilehto J, et al : Diabetes and glucose intolerance as risk factors for stroke. J Cardiovasc Risk 6 : 241-249, 1999.
PubMed
7) Gage BF, et al : Validation of clinical classification schemes for predicting stroke : results from the National Registry of Atrial Fibrillation. JAMA 285 : 2864-2870, 2001.
 
8) Wyse DG, et al : A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 : 1825-1833, 2002.
PubMed
9) Pendlebury ST, et al : Oxford Case Histories in TIA and Stroke. Oxford University Press, Oxford, 2012.
 
10) Gallmetzer P, et al : Postictal paresis in focal epilepsies-incidence, duration, and causes : a video-EEG monitoring study. Neurology 62 : 2160-2164, 2004.
PubMed
11) Hodges JR, et al : Syndromes of transient amnesia : towards a classification. A study of 153 cases. J Neurol Neurosurg Psychiatr 53 : 834-843, 1990.
 
12) Kerber KA, et al : Stroke among patients with dizziness, vertigo, and imbalance in the emergency department : a population-based study. Stroke 37 : 2484-2487, 2006.
PubMed
P.629 掲載の参考文献
1) Easton JD, et al : Definition and evaluation of transient ischemic attack : ascientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council ; Council on Cardiovascular Surgery and Anesthesia ; Cotlncil on Cardiovascular Radiology and Intervention : Council on Cardiovascular Nursing : and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke 40 : 2276-2293, 2009.
 
2) Johnston SC, et al : Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 369 : 283-292, 2007.
PubMed
3) Gage BF, et al : Validation of clinical classification schemes for predicting stroke : results from the National Registry of Atrial Fibrillation. JAMA 285 : 2864-2870, 2001.
 
4) Diener HC, et al : Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke : a subgroup analysis of the RE-LY tria L Lancet Neurol 9 : 1157-1163, 2010.
 
5) Hankey GJ, et al : Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack : a subgroup analysis of ROCKETAF. Lancet Neurol11 : 315-322, 2012.
 
6) Easton JD, et al : Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack : a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 11 : 503-511, 2012.
 
7) Giugliano RP, et al : Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 : 2093-2104, 2013.
PubMed
8) Giugliano RP, et al : Cerebrovascular events in 21105 patients with atrial fibrillation randomized to edoxaban versus warfarin : Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48. Stroke 45 : 2372-2378, 2014.
 
9) Wang Y, et al : Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 369 : 11-19, 2013.
 
10) Diener HC, et al : Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH) : randomised, double-blind, placebo-controlled trial. Lancet 364 : 331-337, 2004.
PubMed
11) Kamal AK, et al : Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database Syst Rev (1) : CD008076, 2011.
PubMed
12) Inzitari D, et al : The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 342 : 1693-1700, 2000.
 
13) Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 273 : 1421-1428, 1995.
PubMed
14) Yadav JS, et al : Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 351 : 1493-1501, 2004.
PubMed
P.633 掲載の参考文献
1) 小林祥泰 : 脳卒中データバンク 2015, p18-19, p130-151, 中山書店, 2015.
 
2) Lammie GA : Hypertensive cerebral small vessel disease and stroke. Brain Pathol 12 : 358-370, 2002.
PubMed
3) Fukuhara M, et al : Impact of lower range of prehypertension on cardiovascular events in a general population : the Hisayama Study. J Hypertens 30 : 893-900, 2012.
 
4) O'Donnell MJ, et al : Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study) : a case-control study. Lancet 376 : 112-123, 2010.
PubMed
5) 日本脳卒中学会 脳卒中ガイドライン作成委員会 小川彰, ほか : 脳卒中治療ガイドライン 2015, p138-180, 協和企画, 2015.
 
6) Hata J, et al : Secular trends in cardiovascular disease and its risk factors in Japanese : half-century data from the Hisayama Study (1961-2009). Circulation 128 : 1198-1205, 2013.
PubMed
7) Charidimou A, et al : Sporadic cerebral amyloid angiopathy revisited : recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatr 83 : 124-137, 2012.
 
8) Yamada M, et al : Cerebral amyloid angiopathy. Prog Mol Biol Transl Sci 107 : 41-78, 2012.
PubMed
9) Wattendorff AR, et al : Hereditary cerebral haemorrhage with amyloidosis, Dutch type (HCHWA-D) : clinicopathological studies. J Neurol Neurosurg Psychiatr 58 : 699-705, 1995.
 
10) Palsdottir A, et al : Hereditary cystatin C amyloid angiopathy : genetic, clinical, and pathological aspects. Brain Pathol 16 : 55-59, 2006.
PubMed
11) Toyoda K, et al : Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease : a prospective, multicenter, observational study. Stroke 39 : 1740-1745, 2008.
PubMed
12) Shen AY, et al : Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 50 : 309-315, 2007.
PubMed
13) Pisters R, et al : A novel user-friendly score (HAS-BLED) to assess l-year risk of major bleeding in patients with atrial fibrillation : the Euro Heart Survey. Chest 138 : 1093-1100, 2010.
PubMed
14) Okumura K, et al : Validation of CHA2 DS2-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation : an analysis of the J-RHYTHM Registry. Circ J 78 : 1593-1599, 2014.
 
15) Pollack CV, et al : Idarucizumab for Dabigatran Reversal. N Engl J Med 373 : 511-520, 2015.
PubMed
P.640 掲載の参考文献
1) Gervaise A, et al : CT image quality improvement using Adaptive Iterative Dose Reduction with wide-volume acquisition on 320-detector CT. Eur Radiol 22 : 295-301, 2012.
PubMed
2) Hori M, et al : Time-resolved three-dimensional magnetic resonance digital subtraction angiography without contrast material in the brain : Initial investigation. J Magn Reson Imaging 30 : 214-218, 2009.
PubMed
3) Kamran M, et al : Whole brain C-arm computed tomography parenchymal blood volume measurements. Interv Neuroradiol 22 : 165-175, 2016.
 
4) Braun T, et al : Near-infrared spectroscopy for the detection of traumatic intracranial hemorrhage : Feasibility study in a German army field hospital in Afghanistan. Unfallchirurg 118 : 693-700, 2015.
 
5) Dammann P, et al : The venous angioarchitecture of sporadic cerebral cavernous malformations : a susceptibility weighted imaging study at 7 T MRI. J Neurol Neurosurg Psychiatr 84 : 194-200, 2013.
 
6) Nakagawa I, et al : The use of susceptibility-weighted imaging as an indicator of retrograde leptomeningeal venous drainage and venous congestion with dural arteriovenous fistula : diagnosis and follow-up after treatment. Neurosurgery 72 : 47-54, 2013.
PubMed
P.644 掲載の参考文献
1) Mendelow AD, et al : Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II) : a randomised trial. Lancet 382 : 397-408, 2013.
 
2) Gould B, et al : Acute blood pressure reduction in patients with intracerebral hemorrhage does not result in borderzone region hypoperfusion. Stroke 45 : 2894-2899, 2014.
 
3) Butcher KS, et al : The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial. Stroke 44 : 620-626, 2013.
PubMed
4) 脳卒中学会 脳卒中ガイドライン委員会 : 脳卒中治療ガイドライン 2015, p1-337, 2015.
 
5) Anderson CS, et al : Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 368 : 2355-2365, 2013.
PubMed
6) de Oliveira Manoel AL, et al : The critical care management of spontaneous intracranial hemorrhage : a contemporary review. Crit Care 20 : 272, 2016.
PubMed
7) Mendelow AD, et al : Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH) : a randomised trial. Lancet 365 : 387-397, 2005.
 
8) Li Y, et al : Neuroendoscopic surgery versus external ventricular drainage alone or with intraventricular fibrinolysis for intraventricular hemorrhage secondary to spontaneous supratentorial hemorrhage : a systematic review and meta-analysis. PLoS ONE 8 : e80599, 2013.
PubMed
P.646 掲載の参考文献
1) 脳卒中データバンク 2015 (小林祥泰編), p130-151, 中山書店, 2015.
 
2) Mendelow AD, et al : Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH) : a randomised trial. Lancet 365 : 387-397, 2005.
 
3) Manabe Y, et al : High blood pressure in acute ischemic stroke and clinical outcome. Neurol Int 1 : e1, 2009.
PubMed
4) Amarenco P, et al : Statins in stroke prevention and carotid atherosclerosis : systematic review and up-to-date meta-analysis. Stroke 35 : 2902-2909, 2004.
PubMed
5) Schmidt LB, et al : Recurrent Intracerebral Hemorrhage : Associations with Comorbidities and Medicine with Antithrombotic Effects. PLoS ONE 11 : e0166223, 2016.
PubMed
6) Poon MT, et al : Long-term prognosis after intracerebral haemorrhage : systematic review and meta-analysis. J Neurol Neurosurg Psychiatr 85 : 660-667, 2014.
 
7) 荒川修治, ほか : 再発性脳内出血. 日本臨牀 (増刊号 : CT, MRI時代の脳卒中学) 51 : 276-281, 1993.
 
8) Biffi A, et al : Association Between Blood Pressure Control and Risk of Recurrent Intracerebral Hemorrhage. JAMA 314 : 904-912, 2015.
PubMed
P.651 掲載の参考文献
1) van Gijn J, et al : Subarachnoid haemorrhage diagnosis, causes and management. Brain 124 : 249-78, 2001.
PubMed
2) Stehbens WE : Etiology of intracranial berry aneurysm. J Neurosurg 70 : 823-831, 1989.
PubMed
3) Harrigan MR : Cerebral salt wasting syndrome a review. Neurosurgery 38 : 152-160, 1996.
PubMed
4) Ingall T, et al : A multinational comparision of subarachnoid hemorrhage epidemiology in the WHO MONICA stroke study. Stroke 31 : 1054-1061, 2000.
 
5) Aoki T, et al : Simvastatin suppresses the progression of experimentally induced cerebral aneurysms in rats. Stroke 39 : 1276-1285, 2008.
PubMed
6) 片岡大 : 脳動脈瘤の発生要因・自然歴・スタチンの可能性. 脳神経外科ジャーナル 23 : 702-709, 2014.
 
7) Ronkainen A, et al : Special features of familial intracranial aneurysms report of 215 familial aneurysm. Neurosurgery 35 : 43-46 (discussion 46-47), 1995.
 
8) Hussain I, et al : Genome-wide association studies of intracranial aneurysms : An update. Stroke 44 : 2670-2675, 2013.
PubMed
9) Morita A, et al : The natural course of unruptured cerebral aneurysms in a japanese cohort. The New England journal of medicine 366 : 2474-2482, 2012.
 
10) Wiebers DO, et al : Unruptured intracranial aneurysms Natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 362 : 103-110, 2003.
PubMed
11) 脳ドックのガイドライン 2014 (日本脳ドッグ学会脳ドッグの新ガイドライン作成委員会編), 響文社, 2014.
 
12) Kataoka K, et al : Structural fragility and inflammatory response of ruptured cerebral aneurysms. A comparative study between ruptured and unruptured cerebral aneurysms. Stroke 30 : 1396-1401, 1999.
PubMed
13) Wiebers DO, et al : Unruptured intracranial aneurysms : Natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 362 : 103-110, 2003.
PubMed
14) Yonekura M : Importance of prospective studies for deciding on a therapeutic guideline for unruptured cerebral aneurysm. Acta neurochir Suppl 82 : 21-25, 2002.
PubMed
15) Roos YB, et al : Complications and outcome in patients with aneurysmal subarachnoid haemorrhage ; a prospective hospital based cohort study in the Netherlands. J Neurol Neurosurg Psychiatry 68 : 337-341, 2000.
PubMed
P.655 掲載の参考文献
1) Nieuwkamp DJ, et al : Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region : ameta-analysis. Lancet Neurol 8 : 635-642, 2009.
 
2) Perry JJ, et al : Clinical decision rules to rule out subarachnoid hemorrhage for acute headache. JAMA 310 : 1248-1255, 2013.
PubMed
3) Hunt WE, et al : Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg 28 : 14-20, 1968.
PubMed
4) Hunt WE, et al : Timing and perioperative care in intracranial aneurysm surgery. Clin Neurosurg 21 : 79-89, 1974.
PubMed
5) Report of World Federation of Neurological Surgeons Committee on a Universal Subarachnoid Hemorrhage Grading Scale. J Neurosurg 68 : 985-986, 1988.
PubMed
6) Kowalski RG, et al : Initial misdiagnosis and outcome after subarachnoid hemorrhage. JAMA 291 : 866-869, 2004.
PubMed
7) Fisher CM, et al : Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 6 : 1-9, 1980.
PubMed
8) Frontera JA, et al : Prediction of symptomatic vasospasm after subarachnoid hemorrhage : the modified fisher scale. Neurosurgery 59 : 21-27 ; discussion 21-27, 2006.
 
9) Komiyama M, et al : Aneurysmal rupture during angiography. Neurosurgery 33 : 798-803, 1993.
PubMed
10) Ishihara H, et al : Angiogram-negative subarachnoid hemorrhage in the era of three dimensional rotational angiography. J Clin Neurosci 14 : 252-255, 2007.
PubMed
11) Andaluz N, et al : Yield of further diagnostic work-up of cryptogenic subarachnoid hemorrhage based on bleeding patterns on computed tomographic scans. Neurosurgery 62 : 1040-1046 ; discussion 1047, 2008.
PubMed
P.659 掲載の参考文献
1) van Gijn J, et al : Subarachnoid haemorrhage : diagnosis, causes and management. Brain 124 : 249-278, 2001.
PubMed
2) 日本脳卒中学会 脳卒中ガイドライン委員会 : IV. くも膜下出血. 脳卒中治療ガイドライン 2015 (小川彰編), p184-208, 協和企画, 2015.
 
3) Tanno Y, et al : Rebleeding from ruptured intracranial aneurysms in North Eastern Province of Japan. A cooperative study. J Neurol Sci 258 : 11-16, 2007.
PubMed
4) Mayberg MR, et al : Guidelines for the management of aneurysmal subarachnoid hemorrhage. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 25 : 2315-2328. 1994.
PubMed
5) Molyneux A. et al : International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms : a randomised trial. Lancet 360 : 1267-1274, 2002.
PubMed
6) Li H, et al : Clipping versus coiling for ruptured intracranial aneurysms : asystematic review and meta-analysis. Stroke 44 : 29-37, 2013.
 
7) Molyneux AJ, et al : The durability of endovascular coiling versus neurosurgical clipping of ruptured cerebral aneurysms : 18 year follow-up of the U K cohort of the International Subarachnoid Aneurysm Trial (ISAT). Lancet 385 : 691-697, 2015.
 
8) Johnston SC, et al : Predictors of rehemorrhage after treatment of ruptured intracranial aneurysms : the Cerebral Aneurysm Rerupture After Treatment (CARAT) study. Stroke 39 : 120-125, 2008.
PubMed
9) 古谷一英 : 第1章 脳血管障害. EBMに基づく脳神経疾患の基本治療指針, 改訂第3版 (川村晃編), p2-9, メジカルビュー社, 2016.
 
10) Kwon OY, et al : The Utility and Benefits of External Lumbar CSF Drainage after Endovascular Coiling on Aneurysmal Subarachnoid Hemorrhage. J Korean Neurosurg Soc 43 : 281-287, 2008.
PubMed
11) Shibuya M, et al : Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 76 : 571-577, 1992.
 
12) Tokiyoshi K, et al : Efficacy and toxicity of thromboxane synthetase inhibitor for cerebral vasospasm after subarachnoid hemorrhage. Surg Neurol 36 : 112-118, 1991.
PubMed
13) Dorhout Mees SM, et al : Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Databese Syst Rev (3) : CD000277, 2007.
 
14) Sawada M, et al : Effectiveness of intra-arterially infused papaverine solutions of various concentrations for the treatment of cerebral vasospasm. Acta Neurochir (Wien) 139 : 706-711, 1997.
PubMed
15) Elliott Jp, et al : Comparison of balloon angioplasty and papaverine infusion for the treatment of vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg 88 : 277-284, 1998.
PubMed
P.664 掲載の参考文献
1) Inagawa T, et al : Study of aneurysmal subarachnoid hemorrhage in Izumo City, Japan. Stroke 26 : 761-766, 1995.
PubMed
2) Broderick JP, et al : Initial and recurrent bleeding are the major causes of death following subarachnoid hemorrhage. Stroke 25 : 1342-1347, 1994.
PubMed
3) Edner G, et al : Total overall management and surgical outcome after aneurysmal subarachnoid haemorrhage in a defined population. Br J Neurosurg 6 : 409-420, 1992.
 
4) Mitsuma W, et al : Clinical and cardiac features of patients with subarachnoid haemorrhage presenting with out-of-hospital cardiac arrest. Resuscitation 82 : 1294-1297, 2011.
PubMed
5) Larsen CC, et al : Rebleeding after aneurysmal subarachnoid hemorrhage : a literature review. World Neurosurg 79 : 307-312, 2013.
PubMed
6) Molyneux A, et al : International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms : a randomised trial. Lancet 360 : 1267-1274, 2002.
PubMed
7) Molyneux AJ, et al : Risk of recurrent subarachnoid haemorrhage, death, or dependence and standardised mortality ratios after clipping or coiling of an intracranial aneurysm in the International Subarachnoid Aneurysm Trial (ISAT) : long-term follow-up. Lancet Neurol 8 : 427-433, 2009.
 
8) Molyneux AJ, et al : The durability of endovascular coiling versus neurosurgical clip Ping of ruptured cerebral aneurysms : 18 year follow-up of the U K cohort of the International Subarachnoid Aneurysm Trial (ISAT). Lancet 385 : 691-697, 2015.
 
9) Qureshi AI, et al : Impact of International Subarachnoid Aneurysm Trial results on treatment of ruptured intracranial aneurysms in the United States. Clinical article. J Neurosurg 114 : 834-841, 2011.
PubMed
10) Nieuwkamp DJ, et al : Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region : a meta-analysis. Lancet Neurol 8 : 635-642, 2009,
PubMed
11) Iihara K, et al : The impact of comprehensive stroke care capacity on the hospital volume of stroke interventions : a nationwide study in Japan : J-ASPECT study. J Stroke Cerebrovasc Dis 23 : 1001-1018, 2014.
 
12) Iihara K, et al : Effects of comprehensive stroke care capabilities on in-hospital mortality of patients with ischemic and hemorrhagic stroke : J-ASPECT study. PLoS ONE 9 : e96819, 2014.
PubMed
13) Kurogi R, et al : Effect of treatment modality on in-hospital outcome in patients with subarachnoid hemorrhage : a nationwide study in Japan (J-ASPECT Study). J Neurosurg. (in press)
 
14) Mc Donald JS, et al : Comparative effectiveness of ruptured cerebral aneurysm therapies : propensity score analysis of clip Ping versus coiling. AJNR Am J Ncuroradiol 35 : 164-169, 2014.
 
P.669 掲載の参考文献
1) Stam J : Thrombosis of the cerebral veins and sinuses. N Engl J Med 352 : 1791-1798, 2005.
PubMed
2) Bousser MG, et al : Cerebral venous thrombosis : an update. Lancet Neurol 6 : 162-170, 2007.
PubMed
3) Ferro JM, et al : Cerebral venous sinus thrombosis : update on diagnosis and management. Curr Cardiol Rep 16 : 523, 2014.
PubMed
4) Coutinho JM : Cerebral venous thrombosis. J Thromb Haemost 13 (Suppl l) : S238-244, 2015.
 
5) Ferro JM, et al : Prognosis of cerebral vein and dural sinus thrombosis : results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 35 : 664-670, 2004.
 
6) Saposnik G, et al : Diagnosis and management of cerebral venous thrombosis : a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42 : 1158-1192, 2011.
PubMed
7) Kinoshita Y, et al : Cerebral venous sinus thrombosis associated with iron deficiency : two case reports, Neurol Med Chir (Tokyo) 46 : 589-593, 2006.
PubMed
8) Alons IM, et al : D-dimer for the exclusion of cerebral venous thrombosis : ameta-analysis of low risk patients with isolated headache. BMC Neurol 15 : 118, 2015.
 
9) Siudut J, et al : Altered Fibrin Clot Properties in Patients With Cerebral Venous Sinus Thrombosis : Association With the Risk of Recurrence. Stroke 46 : 2665-2668, 2015.
PubMed
10) Nakase H, et al : Local cerebral blood fiow in a rat cortical vein occlusion model. J Cereb Blood Flow Metab 16 : 720-728, 1996.
 
11) Shinohara Y, et al : Influence of cerebral venous obstruction on cerebral circulation in humans. Arch Neurol 39 : 479-481, 1982.
PubMed
12) Keller E, et al : Diffusion-and perfusion-weighted magnetic resonance imaging in deep cerebral venous thrombosis. Stroke 30 : 1144-1146, 1999.
PubMed
13) Srivastava AK, et al : Studies of free radical generation by neurons in a rat model of cerebral venous sinus thrombosis. Neurosci Lett 450 : 127-131, 2009.
 
14) Tiwari HS, et al : A study of ER stress in rat model of cerebral venous sinus thrombosis. Neurosci Lett 589 : 121-125, 2015.
PubMed
15) Tiwari HS, et al : Oxidative stress and glutamate excitotoxicity contribute to apoptosis in cerebral venous sinus thrombosis. Neurochem Int 100 : 91-96, 2016.
PubMed
P.675 掲載の参考文献
1) Stam J : Thrombosis of the cerebral veins and sinuses. N Engl J Med 352 : 1791-1798, 2005.
PubMed
2) Saposnik G, et al : Diagnosis and management of cerebral venous thrombosis : a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42 : 1158-ll92, 2011.
PubMed
3) Canhao P, et al : Causes and predictors of death in cerebral venous thrombosis. Stroke 36 : 1720-1725, 2005.
PubMed
4) Bousser MG, et al : Cerebral venous thrombosis : an update. Lancet Neurol 6 : 162-170, 2007.
PubMed
5) Palazzo P, et al : Venous Thrombotic Recurrence After Cerebral Venous Thrombosis : A Long-Term Follow-Up Study. Stroke 48 : 321-326, 2017.
PubMed
6) Gulati D, et al : Cerebral venous thrombosis : diagnosis and management. Stroke 45 : e16-18, 2014.
PubMed
7) Bombeli T, et al : Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol 70 : 126-132, 2002.
PubMed
8) Passamonti S M, et al : The JAK2 V617F mutation in patients with cerebral venous thrombosis. J Thromb Haemost 10 : 998-1003, 2012.
PubMed
9) Ferro JM, et al : Prognosis of cerebral vein and dural sinus thrombosis : results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 35 : 664-670, 2004.
 
10) Crassard I, et al : Anegative D-dimer assay does not rule out cerebral venous thrombosis : a series of seventy-three patients. Stroke 36 : 1716-1719, 2005.
 
11) Idbaih A, et al : MRI of clot in cerebral venous thrombosis : high diagnostic value of susceptibilityweighted images. Stroke 37 : 991-995, 2006.
PubMed
P.680 掲載の参考文献
1) Einhaupl KM, et al : Heparin treatment in sinus venous thrombosis. Lancet 338 : 597-600, 1991.
PubMed
2) de Bruijn SF, et al : Randomized, placebo-controlled trial of anticoagulant treatment with lowmolecular-weight heparin for cerebral sinus thrombosis. Stroke 30 : 484-488, 1999.
 
3) Coutinho J, et al : Anticoagulation for cerebral venous sinus thrombosis. Cochrane Database Syst Rev (8) : CD002005, 2011.
PubMed
4) Misra UK, et al : Low molecular weight heparin versus unfractionated heparin in cerebral venous sinus thrombosis : a randomized controlled trial. Eur J Neurol 19 : 1030-1036, 2012.
 
5) Saposnik G, et al : Diagnosis and management of cerebral venous thrombosis : a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42 : 1158-1192, 2011.
PubMed
6) Einhaupl K, et al : EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol 17 : 1229-1235, 2010.
PubMed
7) Ageno W, et al : Guidance for the management of venous thrombosis in unusual sites. J Thromb Thrombolysis 41 : 129-143, 2016.
 
8) Mendonca MD, et al : Oral direct thrombin inhibitor as an alternative in the management of cerebral venous thrombosis : a series of 15 patients. Int J Stroke 10 : 1115-1118, 2015.
PubMed
9) Mohammadian R, et al : Treatment of progressive cerebral sinuses thrombosis with local thrombolysis. Interv Neuroradiol 18 : 89-96, 2012.
PubMed
10) Siddiqui FM, et al : Mechanical thrombectomy in cerebral venous thrombosis : systematic review of 185 cases. Stroke 46 : 1263-1268, 2015.
PubMed
11) Siddiqui FM, et al : Mechanical thrombectomy versus intrasinus thrombolysis for cerebral venous sinus thrombosis : a non-randomized comparison. Interv Neuroradiol 20 : 336-344, 2014.
PubMed
12) Ferro JM, et al : Decompressive surgery in cerebrovenous thrombosis : a multicenter registry and a systematic review of individual patient data. Stroke 42 : 2825-2831, 2011.
 
13) Kwan J, et al : Antiepileptic drugs for the primary and secondary prevention of seizures after intracranial venous thrombosis. Cochrane Database Syst Rev 4 : CD005501, 2016.
PubMed
P.685 掲載の参考文献
1) Bousser MG, et al : Cerebral venous thrombosis : an update. Lancet Neurol 6 : 162-170, 2007.
PubMed
2) Bushnell C, et al : Evaluation and management of cerebral venous thrombosis. Continuum (Minneap Minn) 20 : 335-351, 2014.
PubMed
3) Stam J : Thrombosis of the cerebral veins and sinuses. N Engl J Med 352 : 1791-1798, 2005.
PubMed
4) Coutinho J, et al : Anticoagulation for cerebral venous sinus thrombosis. Cochrane Database Syst Rev (8) : CD002005, 2011.
PubMed
5) Diaz JM, et al : Superior sagittal sinus thrombosis and pulmonary embolism : a syndrome rediscovered. Acta Neuro Scand 86 : 390-396, 1992.
 
6) Putaala J, et al : Recanalization and its correlation to outcome after cerebral venous thrombosis. J Neurol Sci 292 : 11-15, 2010.
PubMed
7) de Bruijn SF, et al : Clinical features and prognostic factors of cerebral venous sinus thrombosis in a prospective series of 59 patients. For The Cerebral Venous Sinus Thrombosis Study Group. J Neurol Neurosurg Psychiatry 70 : 105-108, 2001.
 
8) Barinagarrementeria F, et al : Aseptic cerebral venous thrombosis : proposed prognostic scale. J of Stroke and Cerebrovasc Dis 2 : 34-39, 1992.
PubMed
9) Breteau G, et al : Cerebral venous thrombosis 3-year clinical outcome in 55 consecutive patients. J Neurol 250 : 29-35, 2003.
PubMed
10) Stolz E, et al : Cerebral venous thrombosis : an all or nothing disease? Prognostic factors and longterm outcome. Clin Neurol Neurosurg 107 : 99-107, 2005.
 
11) Ferro J M, et al : Prognosis of cerebral vein and dural sinus thrombosis : results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 35 : 664-670, 2004.
 
12) Biousse V, et al : Isolated intracranial hypertension as the only sign of cerebral venous thrombosis. Neurology 53 : 1537-1542, 1999.
PubMed
13) Saposnik G, et al : Diagnosis and management of cerebral venous thrombosis : a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42 : 1158-1192, 2011.
PubMed
14) Stam J : Cerebral venous and sinus thrombosis : incidence and causes. Adv Neurol 92 : 225-232, 2003.
PubMed
15) Ferro JM : Causes, predictors of death, and antithrombotic treatment in cerebral venous thrombosis. Clin Adv Hematol Oncol 4 : 732-733, 2006.
PubMed
16) Aguiar de Sousa D, et al : Safety of Pregnancy After Cerebral Venous Thrombosis : A Systematic Review. Stroke 47 : 713-718, 2016.
PubMed
17) Hiltunen S, et al : Long-term outcome after cerebral venous thrombosis : analysis of functional and vocational outcome, residual symptoms, and adversc cvents in 161 patients. J Neurol 263 : 477-484, 2016.
PubMed
18) Bugnicourt JM, et al : Cognitive impairment after cerebral venous thrombosis : a two-center study. J Neurol 260 : 1324-1331, 2013.
PubMed
P.690 掲載の参考文献
1) Suzuki J, et al : Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 20 : 288-299, 1969.
PubMed
2) Kuroda S, et al : Moyamoya disease : current concepts and future perspectives. Lancet Neuroi 7 : 1056-1066, 2008.
 
3) Kuroda S, et al : Specific shrinkage of carotid forks in moyamoya disease : Anovel key finding for diagnosis. Neurol Med Chir (Tokyo) 55 : 796-804, 2015.
 
4) Kaku Y, et al : Outer-diameter narrowing of the internal carotid and middle cerebral arteries in moyamoya disease detected on 3D constructive interference in steady-state MR image : is arterial constrictive remodeling a major pathogenesis? Acta Neurochir (Wien) 154 : 2151-2157, 2012.
 
5) Yamamoto S, et al : Is Quasi-moyamoya Disease a Uniform Disease Entity? A Three-Dimensional Constructive Interference in Steady State Imaging Study. J Stroke Cerebrovasc Dis 25 : 1509-1516, 2016.
PubMed
6) Yoshihara T, et al : Increase in circulating CD34-positive cells in patients with angiographic evidence of moyamoya-like vessels. J Cereb Blood Flow Metab 28 : 1086-1089, 2008.
 
7) Sugiyama T, et al : Bone marrow-derived endothelial progenitor cells participate in the initiation of moyamoya disease. Neurol Med Chir (Tokyo) 51 : 767-773, 2011.
PubMed
8) Nanba R, et al : Increased expression of hepatocyte growth factor in cerebrospinal fluid and intracranial artery in moyamoya disease. Stroke 35 : 2837-2842, 2004.
PubMed
9) Yoshimoto T, et al : Angiogenic factors in moyamoya disease. Stroke 27 : 2160-2165, 1996.
PubMed
10) Nanba R, et al : Clinical features of familial moyamoya disease. Childs Nerv Syst 22 : 258-262, 2006.
PubMed
11) Yamauchi T, et al : Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25. Stroke 31 : 930-935, 2000.
PubMed
12) Nanba R, et al : Sequence analysis and bioinformatics analysis of chromosome 17q25 in familial moyamoya disease. Childs Nerv Syst 21 : 62-68, 2005.
PubMed
13) Liu W, et al : Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS ONE 6 : e22542, 2011.
PubMed
14) Kamada F, et al : A genome-wide association study identifies RNF213 a Sthe first Moyamoya disease gene. J Hum Genet 56 : 34-40, 2011.
 
15) Sonobe S, et al : Temporal profile of the vascular anatomy evaluated by 9.4-T magnetic resonance angiography and histopathological analysis in mice lacking R N F213 : a susceptibility gene for moyamoya disease. Brain Res 1552 : 64-71, 2014.
 
P.697 掲載の参考文献
1) Takeuchi K, et al : Hypogenesis of bilateral internal carotid arteries. No To Shinkei 9 : 37-43, 1957.
 
2) Kudo T : Occlusion of the internal carotid artery and the type of recovery of cerebral blood circulation. Rin-sho Shinkeigaku 1 : 199-200, 1960.
 
3) Kudo T : Spontaneous occlusion of the circle of Willis. A disease apparently confined to Japanese. Neurology 18 : 485-496, 1968.
PubMed
4) Nishimoto A, et al : Abnormal cerebrovascular network related to the internal cartoid arteries. J Neurosurg 29 : 255-260, 1968.
 
5) Suzuki J, et al : Cerebrovascular' "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 20 : 288-299, 1969.
PubMed
6) 鈴木二郎, ほか : 日本人に多発する脳底部網状異常血管像を示す疾患, 群の検討. 脳と神経 17 : 767-776, 1965.
 
7) Suzuki J, et al : Cerebrovascular "Moyamoya" disease. 2. Collateral routes to forebrain via ethmoid sinus and superior nasal meatus. Angiology 22 : 223-236, 1971.
PubMed
8) 厚生労働科学研究費補助金 難治性疾患克服事業 ウイリス動脈輪閉塞症における病態・治療に関する研究班 : もやもや病 (ウイリス動脈輪閉塞症) 診断・治療ガイドライン. 脳卒巾の外科 37 : 321-337, 2009.
 
9) Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, et al : Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo) 52 : 245-266, 2012.
PubMed
10) 林健太郎, ほか : もやもや病, 片側型もやもや病, 類もやもや病に関する企国調査. 脳卒中の外科 40 : 179-182, 2012.
 
11) Hayashi K, et al : An epidemiological survey of moyamoya disease, unilateral moyamoya disease and quasi-moyamoya disease in Japan. Clin Neurol Neurosurg 115 : 930-933, 2013.
PubMed
12) 指定難病テキスト (第1次実施分) 概要から診断基準まで110の疾病, 22. もやもや病, 社会保険出版社, 2015.
 
13) Mikami T, et al : Diagnosis of moyamoya disease on magnetic resonance imaging : are flow voids in the basal ganglia an essential criterion for definitive diagnosis? J Stroke Cerebrovasc Dis 22 : 862-868, 2013.
PubMed
14) Sawada T, et al : Diagnosis of moyamoya disease using 3-T MRI and MRA : value of cisternal moyamoya vessels. Neuroradiology 54 : 1089-1097, 2012.
PubMed
15) Hosoda Y, et al : Histopathological studies on spontaneous occlusion of the circle of Willis (cerebrovascular moyamoya disease). Clin Neurol Neurosurg 99 (Suppl 2) : S203-208, 1997.
 
16) Sugiyama T, et al : Bone marrow-derived endothelial progenitor cells participate in the initiation of moyamoya disease. Neurol Med Chir (Tokyo) 51 : 767-773, 2011.
PubMed
17) Houkin K, et al : Review of past research and current concepts on the etiology of moyamoya disease. Neurol Med Chir (Tokyo) 52 : 267-277, 2012.
PubMed
18) Ikezaki K, et al : Cerebral circulation and oxygen metabolism in childhood moyamoya disease : a perioperative positron emission tomography study. J Neurosurg 81 : 843-850, 1994.
PubMed
19) Kuwabara Y, et al : Cerebral hemodynamics and metabolism in moyamoya disease-a positron emission tomography study. Clin Neurol Neurosurg 99 (Suppl 2) : S74-78, 1997.
 
20) Morimoto M, et al : Efficacy of direct revascularization in adult Moyamoya disease : haemodynamic evaluation by positron emission tomography. Acta Neurochir (Wien) 141 : 377-384, 1999.
PubMed
21) Piao R, et al : Cerebral hemodynamics and metabolism in adult moyamoya disease : comparison of angiographic collateral circulation. Ann Nucl Med 18 : 115-121, 2004.
PubMed
22) Saito N, et al : Assessment of cerebral hemodynamics in childhood moyamoya disease using a quantitative and a semiquantitative IMP-SPECT study. Ann Nucl Med 18 : 323-331, 2004.
 
23) 日本脳卒中学会, ほか : アセタゾラミド (ダイアモックス注射用) 適正使用指針 2015年4月. [http://www.jsts.gr.jp/img/acetazolamide.pdf]
 
24) Kuroda S, et al : Incidence and clinical features of disease progression in adult moyamoya disease. Stroke 36 : 2148-2153, 2005.
PubMed
25) Nagata S, et al : Unilaterally symptomatic moyamoya disease in children : long-term follow-up of 20 patients. Neurosurgery 59 : 830-836 : discussion 836-837, 2006.
 
26) Miyamoto S, et al : Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease : results of the Japan Adult Moyamoya Trial. Stroke 45 : 1415-1421, 2014.
PubMed
27) Takahashi JC, et al : Significance of the Hemorrhagic Site for Recurrent Bleeding : Prespecified Analysis in the Japan Adult Moyamoya Trial. Stroke 47 : 37-43, 2016.
PubMed
28) Fujimura M, et al : Temporary neurologic deterioration due to cerebral hyperperfusion after superficial temporal artery-middle cerebral artery anastomosis in patients with adult-onset moyamoya disease. Surg Neurol 67 : 273-282, 2007.
PubMed
29) Fujimura M, et al : Incidence and risk factors for symptomatic cerebral hyperperfusion after superficial temporal artery-middle cerebral artery anastomosis in patients with moyamoya disease. Surg Neurol 71 : 442-447, 2009.
PubMed
30) Uchino H, et al : Predictors and clinicai features of postoperative hyperperfusion after surgical revascularization for moyamoya disease : a serial single photon emission CT/positron emission tomography study. Stroke 43 : 2610-2616, 2012.
 
31) Kaku Y, et al : Cerebral blood flow and metabolism of hyperperfusion after cerebral revascularization in patients with moyamoya disease. J Cereb Blood Flow Metab 32 : 2066-2075, 2012.
PubMed
32) Fujimura M, et al : Efficacy of superficial temporal artery-middle cerebral artery anastomosis with routine postoperative cerebral blood flow measurement during the acute stage in childhood moyamoya disease. Childs Nerv Syst 24 : 827-832, 2008.
PubMed
33) So Y, et al : Prediction of the clinical outcome of pediatric moyamoya disease with postoperative basal/acetazolamide stress brain perfusion SPECT after revascularization surgery. Stroke 36 : 1485-1489, 2005.
PubMed
34) Han JS, et al : Impact of extracranial-intracranial bypass on cerebrovascular reactivity and clinical outcome in patients with symptomatic moyamoya vasculopathy. Stroke 42 : 3047-3054, 2011.
PubMed
35) Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, et al : Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo) 52 : 245-266, 2012.
PubMed
36) Houkin K, et al : Novel magnetic resonance angiography stage grading for moyamoya disease. Cerebrovasc Dis 20 : 347-354, 2005.
PubMed
37) Houkin K, et al : How does angiogenesis develop in pediatric moyamoya disease after surgery? A prospective study with MR angiography. Childs Nerv Syst 20 : 734-741, 2004.
PubMed
38) Uchino H, et al : Synergistic interactions between direct and indirect bypasses in combined procedures : the significance of indirect bypasses in moyamoya disease. Neurosurgery 80 (2) : 201-209. 2017.
PubMed
39) Noguchi T, et al : Arterial spin-labeling MR imaging in moyamoya disease compared with SPECT imaging. Eur J Radiol 80 : e557-562, 2011.
PubMed
40) Uchino H, et al : Anovel application of four-dimensional magnetic resonance angiography using an arterial spin labeling technique for noninvasive diagnosis of Moyamoya disease. Clin Neurol Neurosurg 137 : 105-111, 2015.
 
P.701 掲載の参考文献
1) Cho WS, et al : Long-term outcomes after combined revascularization surgery in adult moyamoya disease. Stroke 45 : 3025-3031, 2014.
PubMed
2) Fujimura M, et al : Incidence and risk factors for symptomatic cerebral hyperperfusion after superficial temporal artery-middle cerebral artery anastomosis in patients with moyamoya disease. Surg Neurol 71 : 442-447, 2009.
PubMed
3) Fujimura M, et al : Minocycline prevents focal neurological deterioration due to cerebral hyperperfusion after extracranial-intracranial bypass for moyamoya disease. Neurosurgery 74 : 163-170 ; discussion 170, 2014.
PubMed
4) Fujimura M, et al : Significance of focal cerebral hyperperfusion as a cause of transient neurologic deterioration after extracranial-intracranial bypass for moyamoya disease : comparative study with non-moyamoya patients using N-isopropyl-p-[(123) I] iodoamphetamine single-photon emission computed tomography. Neurosurgery 68 : 957-964 ; discussion 964-965, 2011.
 
5) Fujimura M, et al : Lessons learned from moyamoya disease : outcome of direct/indirect revascularization surgery for 150 affected hemispheres. Neurol Med Chir (Tokyo) 52 : 327-332, 2012.
PubMed
6) Hayashi T, et al : Postoperative neurological deterioration in pediatric moyamoya disease : watershed shift and hyperperfusion. J Neurosurg Pediatr 6 : 73-81, 2010.
PubMed
7) Kim J E, et al : Transient hyperperfusion after superficial temporal artery/middle cerebral artery bypass surgery as a possible cause of postoperatlve translent neurological deterioration. Cerebrovasc Dis 25 : 580-586, 2008.
 
8) 厚生労働省 ウイリス動脈輪閉塞症における病態・治療に関する研究班 もやもや病 (ウイリス動脈輪閉塞症) 診断・治療ガイドライン 脳卒中の外科 37 : 321-337, 2009.
 
9) Miyamoto S, et al : Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease : results of the Japan Adult Moyamoya Trial. Stroke 45 : 1415-1421, 2014.
PubMed
10) Rashad S, et al : Long-term follow-up of pediatric moyamoya disease treated by combined direct-indirect revascularization surgery : single institute experience with surgical and perioperative management. Neurosurg Rev 39 : 615-623, 2016.
PubMed
11) Suzuki J, et al : Cerebrovascular ' moyamoya"disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 20 : 288-299, 1969.
PubMed
12) Takahashi JC, et al : Significance of the Hemorrhagic Site for Recurrent Bleeding : Prespecified Analysis in the Japan Adult Moyamoya Trial. Stroke 47 : 37-43, 2016.
PubMed
13) Uchino H, et al : Predictors and clinical features of postoperative hyperperfusion after surgical revascularization for moyamoya disease : aserial single photon emission CT/positron emission tomography study. Stroke 43 : 2610-2616, 2012.
PubMed
P.704 掲載の参考文献
1) Bulsara KR, et al : De novo cerebral arteriovenous malformation : case report. Neurosurgery 50 : 1137-1140 ; discussion 1140-1141, 2002.
 
2) Shovlin CL, et al : Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 91 : 66-67, 2000.
PubMed
3) Mikhak B, et al : Angiopoietin-like 4 (ANGPTL4) gene polymorphisms and risk of brain arteriovenous malformations. Cerebrovasc Dis 31 : 338-345, 2011.
PubMed
4) Inoue S, et al : Combination of linkage and association studies for brain arteriovenous malformation. Stroke 38 : 1368-1370, 2007.
PubMed
5) Sturiale CL, et al : Single nucleotide polymorphisms associated with sporadic brain arteriovenous malformations : where do we stand? Brain 136 : 665-681, 2013.
PubMed
6) Weinsheimer S, et al : Genome-wide association study of sporadic brain arteriovenous malformations. J Neurol Neurosurg Psychiatr 87 : 916-923, 2016.
 
7) Moftakhar P, et al : Cerebral arteriovenous malformations. Part 1 : cellular and molecular biology. Neurosurg Focus 26 : EIO, 2009.
 
8) Ferreira R, et al : Micro RNA-18a improves human cerebral arteriovenous malformation endothelial cell function. Stroke 45 : 293-297, 2014.
PubMed
9) Thomas JM, et al : Genetic and epigenetic mechanisms in the development of arteriovenous malformations in the brain. Clin Epigenetics 8 : 78, 2016.
PubMed
10) Gross BA, et al : Natural history of cerebral arteriovenous malformations : a meta-analysis. J Neurosurg 118 : 437-443, 2013.
PubMed
11) Moftakhar P, et al : Cerebral arteriovenous malformations. Part 2 : physiology. Neurosurg Focus 26 : E11, 2009.
PubMed
12) Josephson CB, et al : Seizure risk with AVM treatment or conservative management : prospective, population-based study. Neurology 79 : 500-507, 2012.
 
13) Brown RD, et al : Frequency of intracranial hemorrhage as a presenting symptom and subtype analysis : a population-based study of intracranial vascular malformations in Olmsted Country, Minnesota. J Neurosurg 85 : 29-32, 1996.
PubMed
14) Mohr JP, et al : Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA) : a multicentre, non-blinded, randomised trial. Lancet 383 : 614-621, 2014.
 
P.710 掲載の参考文献
1) Hillman J : Population-based analysis of arteriovenous malformation treatment. J Neurosurg 95 : 633-637, 2001.
PubMed
2) Mohr JP, et al : Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA) : a multicentre, non-blinded, randomised trial. Lancet 383 : 614-621, 2014.
 
3) Mikami T, et al : Presurgical planning for arteriovenous malformations using multidetector row CT. Neurosurg Rev 35 : 393-399 ; discussion 399-400, 2012.
 
4) Willems PW, et al : The use of 4D-CTA in the diagnostic work-up of brain arteriovenous malformations. Neuroradiology 54 : 123-131, 2012.
PubMed
5) Tsui YK, et al : Susceptibility-weighted imaging for differential diagnosis of cerebral vascular pathology : a pictorial review. J Neurol Sci 287 : 7-16, 2009.
 
6) Heidenreich JO, et al : Assessment of 3D-TOF-MRA at 3.0 Tesla in the characterization of the angioarchitecture of cerebral arteriovenous malformations : a preliminary study. Acta Radiol 48 : 678-686, 2007.
 
7) Kikuta K, et al : Introduction to tractography-guided navigation : using 3-tesla magnetic resonance tractography in surgery for cerebral arteriovenous malformations. Acta Neurochir Suppl 103 : 11-14, 2008.
 
8) Maruyama K et al : Arcuate fasciculus tractography integrated into Gamma Knife surgery. J Neurosurg 111 : 520-526, 2009.
PubMed
9) Iwama T, et al : Cerebral hemodynamics and metabolism in patients with cerebral arteriovenous malformations : an evaluation using Positron emission tomography scanning. J Neurosurg 97 : 1314-1321, 2002,
PubMed
10) Spetzler RF, et al : A proposed grading system for arteriovenous malformations. J Neurosurg 65 : 476-483, 1986.
PubMed
11) Hamilton MG, et al : The prospective application of a grading system for arteriovenous malformations, Neurosurgery 34 : 2-6 : discussion 6-7, 1994.
 
12) Hartmann A, et al : Determinants of neurological outcome after surgery for brain arteriovenous malformation. Stroke 31 : 2361-2364, 2000.
PubMed
13) Elhammady MS, et al : Early elective surgical exploration of spontaneous intracerebral hematomas of unknown origin. J Neurosurg 109 : 1005-1011, 2008.
PubMed
14) Willinsky RA, et al : Delayed angiography in the investigation of intracerebral hematomas caused by small arteriovenous malformations. Neuroradiology 35 : 307-311, 1993.
PubMed
15) Ogilvy CS, et al : Angiographically occult arteriovenous malformations. J Neurosurg 69 : 350-355, 1988.
PubMed
P.714 掲載の参考文献
1) Spetzler RF, et al : A proposed grading system for arteriovenous malformations. J Neurosurg 65 : 476-483, 1986.
PubMed
2) Spetzler RF, et al : Normal perfusion pressure breakthrough theory. Clin Neurosurg 25 : 651-672, 1978.
PubMed
P.718 掲載の参考文献
1) 桑山直也, ほか : わが国における硬膜動静脈棲の治療の現状. 脳神経外科ジャーナル 20 : 12-19, 2011.
 
2) Piippo A, et al : Characteristics and long-term outcome of 251 patients with dural arteriovenous fistulas in a defined population. J Neurosurg 118 : 923-934, 2013.
 
3) Brown RD, et al : Incidence and prevalence of intracranial vascular malformations in Olmsted County, Minnesota, 1965 to 1992. Neurology 46 : 949-952, 1996.
PubMed
4) Hiramatsu M, et al : Epidemiology of dural arteriovenous fistula in Japan : Analysis of Japanese Registry of Neuroendovascular Therapy (JR-NET2). Neurol Med Chir (Tokyo) 54 : 63-71, 2014.
 
5) Lalwani AK, et al : Grading venous restrictive disease in patients with dural arteriovenous fistulas of the transverse/sigmoid sinus. J Neurosurg 79 : 11-15, 1993.
PubMed
6) Cognard C, et al : Cerebral dural arteriovenous fistulas : clinical and angiographic correlation with a revised classification of venous drainage. Radiology 194 : 671-680, 1995.
PubMed
7) Borden JA, et al : A proposed classification for spinal and cranial dural arteriovenous fistulous malformations and implications for treatment. J Neurosurg 82 : 166-179, 1995.
PubMed
8) Barrow DL, et al : Classification and treatment of spontaneous carotid-cavernous sinus fistulas. J Neurosurg 62 : 248-256, 1985.
PubMed
9) Zipfel GJ, et al : Cranial dural arteriovenous fistulas : modification of angiographic classification scales based on new natural history data. Neurosurg Focus 26 : E14, 2009.
PubMed
10) Tanaka M : Embryological Consideration of Dural Arteriovenous Fistulas. Neurol Med Chir (Tokyo) 56 : 544-551, 2016.
PubMed
11) Satomi J, et al : Benign cranial dural arteriovenous fistulas : outcome of conservative management based on the natural history of the iesion. J Neurosurg 97 : 767-770, 2002.
 
12) Lin Y H, et al : Diagnostic performance of CT and MRI on the detection of symptomatic intracranial dural arteriovenous fistula : a meta-analysis with indirect comparison. Neuroradiology 58 : 753-763, 2016.
PubMed
13) Noguchi K, et al : Intracranial dural arteriovenous fistula with retrograde cortical venous drainage : use of susceptibility-weighted imaging in combination with dynamic susceptibility contrast imaging. AJNR Am J Neuroradiol 31 : 1903-1910, 2010.
PubMed
14) Noguchi T, et al : Hemodynamic studies of intracranial dural arteriovenous fistulas using arterial spin-labeling MR imaging. Interv Neuroradiol 16 : 409-419, 2010.
PubMed
15) Chandra RV, et al : Transarterial onyx embolization of cranial dural arteriovenous fistulas : long-term follow-up. AJNR Am J Neuroradiol 35 : 1793-1797, 2014.
PubMed
16) 杉生憲志, ほか : 頭蓋内硬膜動静脈瘻の分類と治療. 脳神経外科ジャーナル 22 : 37-43, 2013.
 
P.725 掲載の参考文献
1) Cardenas JF, et al : Pediatric stroke. Childs Nerv Syst 27 : 1375-1390, 2011.
PubMed
2) de Veber G, et al : Cerebral sinovenous thrombosis in children. N Engl J Med 345 : 417-423, 2001.
PubMed
3) Bernard TJ, et al : Towards a consensus-based classification of childhood arterial ischemic stroke. Stroke 43 : 371-377, 2012.
PubMed
4) Simma B, et al : Therapy in pediatric stroke. Eur J Pediatr 172 : 867-875, 2013.
PubMed
5) Fernindez-Lopez D, et al : Mechanisms of perinatal arterial ischemic stroke. J Cereb Blood Flow Metab 34 : 9. 21-932, 2014.
 
6) Chabrier S, et al : New insights (and new interrogations) in perinatal arterial ischemic stroke. Thromb Rea 127 : 13-22, 2011.
 
7) Ibrahim SH : Cerebral venous sinus thrombosis in neonates. J Pak Med Assoc 56 : 535-537, 2006.
PubMed
8) Gupta SN, et al : Intracranial hemorrhage in term newborns : management and outcomes. Pediatr Neurol 40 : 1-12, 2009.
PubMed
9) Armstrong-Wells J, et al : Prevalence and predictors of perinatal hemorrhagic stroke : results from the kaiser pediatric stroke study. Pediatrics 123 : 823-828. 2009.
PubMed
10) Lee JY, et al : Risk factors for periventricular-intraventricular hemorrhage in premature infants. J Korean Med Sci 25 : 418-424. 2010.
PubMed
11) Robinson S : Neonatal posthemorrhagic hydrocephalus from prematurity : pathophysiology and current treatment concepts. J Neurosurg Pediatr 9 : 242-258, 2012.
PubMed
12) Lasjaunias P, et al : Surgical N euroangiography, Vol. 3, p789-850. Springer-Verlag, Berlin. 2006.
 
13) Sorteberg A, et al : Intracranial Non-traumatic Aneurysms in Children and Adolescents. Curr Pediatr Rev 9 : 343-352, 2013.
PubMed
14) Lasjaunias P, et al : Surgical Neuroangiography, Vol. 3, p27-453, Springer-Verlag, Berlin, 2006.
 
15) Ishiguro T, et al : Required knowledge for neuroendovascular surgeon (12) pediatric neurointervention. No Shinkei Geka 41 : 731-742, 2013.
PubMed
P.729 掲載の参考文献
1) 太田覚史, ほか : 肺血栓塞栓症・深部静脈血栓症 全国調査研究. 厚生労働科学研究費補助金 血液凝固異常症に関する調査研究 平成25年度 総括・分担研究報告書, p163-169, 2014.
 
2) 安藤太三 : 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告) 肺血栓塞栓症および深部静脈血栓症の診断治療予防に関するガイドライン (2009年改訂版), 2009.
 
3) Konstantinides SV, et al : 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 35 : 3033-3069, 3069a-3069k, 2014.
 
4) Douketis JD : The 2016 American College of Chest Physicians treatment guidelines for venous thromboembolism : a review and critical appraisa L Intern Emerg Med 11 : 1031-1035, 2016.
 
5) 山本剛, ほか : 広範型急性肺塞栓症の治療. 日本集中治療医学会雑誌 18 : 567-574, 2011.
 
6) 應儀成二, ほか : 肺塞栓症-第一報-本邦における静脈疾患に関するSurvey IV. 静脈学 11 : 59-65, 2000.
 
7) 高松純樹, ほか : 確定した深部静脈血栓症における先天性凝固線溶因子欠乏-異常症. 日本血栓止血学会誌 2 : 384, 1991.
 
8) Rosendaal FR : Venous thrombosis : am ulticausal disease. Lancet 353 : 1167-1173, 1999.
 
9) 阪田敏幸, ほか : 日本人における凝固制御因子の異常と静脈血栓症との関連. 静脈学 14 : 339-345, 2003.
 
10) Nakamura M, et al : Clinical characteristics of acute pulmonary thromboembolism in Japan : results of a multicenter registry in the Japanese Society of Pulmonary Embolism Research. Clin Cardiol 24 : 132-138, 2001.
PubMed
11) Nakamura M, et al : Current venous thromboembolism management and outcomes in Japan. Circ J 78 : 708-717, 2014.
PubMed
P.737 掲載の参考文献
1) JCS Joint Working Group : Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis OCS 2009). Circ J 75 : 1258-1281, 2011.
 
2) Nakamura M. et al : Current management of venous thromboembolism in Japan : Current epidemiology and advances in anticoagulant therapy. J Cardiol 66 : 451-459, 2015.
PubMed
3) Tanabe Y, et al : Predictive value of biomarkers for the prognosis of acute pulmonary embolism in Japanese patients : Results of the Tokyo C C U Network registry. J Cardiol 66 : 460-465, 2015.
 
4) Konstantinides SV, et al : 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 35 : 3033-3069, 3069a-3069k, 2014.
 
5) Stein PD, et al : Clinical characteristics of patients with acute pulmonary embolism : data from PIOPED II. Am J Med 120 : 871-879, 2007.
PubMed
6) Kosuge M, et al : Electrocardiographic differentiation between acute pulmonary embolism and acute coronary syndromes on the basis of negative T waves. Am J Cardiol 99 : 817-821. 2007.
PubMed
7) Righini M, et al : Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism : the ADJUST-PE study. JAMA 311 : 1117-ll24, 2014.
PubMed
8) Kucher N, et al : Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 107 : 2545-2547, 2003.
PubMed
9) Konstantinides S, et al : Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation 106 : 1263-1268, 2002.
 
10) Roach p J, et al : V/Q scanning using SPECT and SPECT/CT. J Nucl Med 54 : 1588-1596, 2013.
PubMed
11) Kurzyna M, et al : Disturbed right ventricular ejection pattern as a new Doppler echocardiographic sign of acute pulmonary embolism. Am J Cardiol go : 507-511, 2002.
 
P.741 掲載の参考文献
1) Konstantinides SV, et al : 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 35 : 3033-3069, 2014.
PubMed
2) 福田幾夫 : 急性肺血栓塞栓症に対する血栓除去術. 静脈学 22 : 281-288, 2011.
Medical*Online
3) Kasper W, et al : Management strategies and determinants of outcome in acute major pulmonary embolism : results of a multicenter registry. J Am Coll Cardiol 30 : 1165-1171, 1997.
PubMed
4) Kucher N, et al : Massive pulmonary embolism. Circulation 113 : 577-582, 2006.
PubMed
5) 福田幾夫 : 臨床医のための静脈血栓塞栓症 (深部静脈血栓症・急性肺塞栓症) 診断・治療マニュアル, 医薬ジャーナル社, 2015.
 
6) Kawahito K, et al : Resuscitation and circulatory support using extracorporeal membrane oxygenation for fulminant pulmonary embolism. Artif Organs 24 : 427-430, 2000.
PubMed
7) Hori D, et al : Successful usage of extracorporeal membrane oxygenation as a bridge therapy for acute pulmonary embolism between hospitals. Gen Thorac Cardiovasc Surg 58 : 283-286. 2010.
PubMed
8) 佐戸川弘之, ほか : 深部静脈血栓症に対する抗凝固療法. 血管外科 35 : 13-19, 2016.
 
9) Hokusai-VTE Investigators, et al : Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369 : 1406-1415, 2013.
PubMed
10) 田島廣之, ほか : 急性肺血栓塞栓症の IVR (画像下治療). 血管外科 35 : 24-30, 2016.
 
11) Kearon C, et al : Antithrombotic Therapy for VTE Disease : CHEST Guideline and Expert Panel Report. Chest 149 : 315-352, 2016.
 
12) JCS Joint Working Group : Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009). Circ J 75 : 1258-1281, 2011.
 
13) Fukuda I, et al : Improved outcome of surgical pulmonary embolectomy by aggressive intervention for critically ill patients. Ann Thorac Surg 91 : 728-732, 2011.
PubMed
14) 大徳和之, ほか : 急性肺血栓塞栓症の外科的治療. ICUとCCU 39 : 175-181, 2015.
Medical*Online
P.748 掲載の参考文献
1) Kumasaka N, et al : Incidence of pulmonary thromboembolism in Japan. J Pn Circ J 63 : 439-441, 1999.
 
2) Sakuma M, et al : Venous thromboembolism : deep vein thrombosis with pulmonary embolism, deep vein thrombosis alone, and pulmonary embolism alone. Circ J 73 : 305-309, 2009.
PubMed
3) Silverstein MD, et al : Trends in the incidence of deep vein thrombosis and pulmonary embolism : a 25-year population-based study. Arch Intern Med 158 : 585-593, 1998.
PubMed
4) Tanabe N, et al : Association of clinical features with HLA in chronic pulmonary thromboembolism. Eur Respir J 25 : 131-138, 2005.
PubMed
5) Kato F, et al : Association of plasma fibrinogen and plasminogen with prognosis of inoperable chronic thromboembolic pulmonary hypertension. Circ J 78 : 1754-1761, 2014.
PubMed
6) Rijken DC, et al : New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 7 : 4-13, 2009.
PubMed
7) Chibana H, et al : Optical frequency-domain imaging and pulmonary angioscopy in chronic thromboembolic pulmonary hypertension. Eur Heart J 37 : 1296-1304, 2016.
PubMed
8) Yaoita N, et al : Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary Hypertension. Arterioscler Thromb Vasc Biol 36 : 1293-1301, 2016.
PubMed
9) Hoeper MM. et al : Chronic thromboembolic pulmonary hypertension. Circulation 113 : 2011-2020, 2006.
PubMed
10) Moser KM, et al : Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 103 : 685-692, 1993.
PubMed
11) Galie N, et al : Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 3 : 571-576, 2006.
PubMed
12) Sacks RS, et al : Molecular biology of chronic thromboembolic pulmonary hypertension. Semin Thorac Cardiovasc Surg 18 : 265-276, 2006.
PubMed
13) Christman BW, et al : An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327 : 70-75, 1992.
PubMed
14) Giaid A. et al : Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328 : 1732-1739, 1993.
PubMed
15) Giaid A, et al : Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333 : 214-221, 1995.
PubMed
16) Tuder RM, et al : Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159 : 1925-1932, 1999.
PubMed
17) Bauer M, et al : Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 105 : 1034-1036, 2002.
PubMed
18) Budhiraja R, et al : Endothelial dysfunction in pulmonary hypertension. Circulation 109 : 159-165, 2004.
PubMed
P.757 掲載の参考文献
1) Tanabe N, et al : Recent progress in the diagnosis and management of chronic thromboembolic pulmonary hypertension. Respir Investig 51 : 134-146, 2013.
PubMed
2) Pengo V, et al : Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350 : 2257-2264, 2004.
PubMed
3) Jenkins D, et al : State-of-the-art chronic thromboembolic pulmonary hypertension diagnosis and management. Eur Respir Rev 21 : 32-39, 2012.
PubMed
4) D'Armini AM : Diagnostic advances and opportunities in chronic thromboembolic pulmonary hypertension. Eur Respir Rev 24 : 253-262, 2015.
PubMed
5) Galie N, et al : 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension : The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) : Endorsed by : Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 46 : 903-975, 2015.
 
6) Sugiura T, et al : Role of 320-slice CT imaging in the diagnostic workup of patients with chronic thromboembolic pulmonary hypertension. Chest 143 : 1070-1077, 2013.
PubMed
7) Riedel M, et al : Longterm follow-up of patients with pulmonary thromboernbolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest 81 : 151-158, 1982.
PubMed
8) Taboada D, et al : Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease. Eur Respir J 44 : 1635-1645, 2014.
PubMed
9) Mussot S, et al : Retrospective institutional study of 31 patients treated for pulmonary artery sarcoma. Eur J Cardiothorac Surg 43 : 787-793, 2013.
PubMed
10) Dartevelle P, et al : Chronic thromboembolic pulmonary hypertension. Eur Respir J 23 : 637-648, 2004.
PubMed
P.763 掲載の参考文献
1) 2011年度合同研究班 : 肺高血圧症治療ガイドライン (2012年改訂版). 循環器病の診断と診療に関するガイドライン, p1-69, 2012.
 
2) Kim NH, et al : Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 62 (25 Suppl) : D92-99, 2013.
 
3) 合同研究班参加学会 (日本循環器学会, 日本胸部外科学会, 日本呼吸器学会, 日本心臓病学会) : 慢性肺動脈血栓塞栓症に対するballoon pulmonary angioplastyの適応と実施法に関するステートメント (2014年度版), 2014.
 
4) Galie N, et al : 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension : The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) : Endorsed by : Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37 : 67-119, 2016.
 
5) Klok FA, et al : Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Haematologica 95 : 970-975, 2010.
PubMed
6) Dentali F, et al : Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism. Thromb Res 124 : 256-258, 2009.
PubMed
7) Kim NH, et al : Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir Rev 21 : 27-31, 2012.
PubMed
8) Klok FA, et al : Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. J Thromb Haemost 14 : 121-128, 2016.
PubMed
9) Jamieson SW, et al : Pulmonary endarterectomy : experience and lessons learned in 1,500 cases. Ann Thorac Surg 76 : 1457-1462 : discussion 1462-1464, 2003.
 
10) Mayer E, et al : Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension : results from an international prospective registry. J Thorac Cardiovasc Surg 141 : 702-710, 2011.
PubMed
11) Feinstein J A, et al : Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension. Circulation 103 : 10-13, 2001.
PubMed
12) Kinutani H, et al : High perfusion pressure as a predictor of reperfusion pulmonary injury after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. IJC Heart & Vasculature 11 : 1-6, 2016.
PubMed
13) Ehlken N, et al : Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension : a prospective, randomized, controlled trial. Eur Heart J 37 : 35-44, 2016.
PubMed
14) Fukui S, et al : Efficacy of cardiac rehabilitation after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Heart 102 : 1403-1409, 2016.
PubMed
15) Kawakami T, et al : Novel Angiographic Classification of Each Vascular Lesion in Chronic Thromboembolic Pulmonary Hypertension Based on Selective Angiogram and Results of Balloon Pulmonary Angioplasty. Circ Cardiovasc Interv 9 : pii : e003318, 2016.
 
16) Ogino H : Recent advances of pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension including Japanese experiences. Gen Thorac Cardiovasc Surg 62 : 9-18, 2014.
PubMed
17) Taniguchi Y, et al : Balloon pulmonary angioplasty : an additional treatment option to improve the prognosis of patients with chronic thromboembolic pulmonary hypertension. Euro Intervention 10 : 518-525, 2014.
PubMed
18) Aoki T, et al : Effects of Balloon Pulmonary Angioplasty on Oxygenation in Patients With Chronic Thromboembolic Pulmonary Hypertension-lmportance of Intrapulmonary Shunt. Circ J 80 : 2227-2234, 2016.
PubMed
19) Ogo T : Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension. Curr Opin Pulm Med 21 : 425-431, 2015.
PubMed
P.768 掲載の参考文献
1) Galie N, et al : 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 46 : 903-975, 2015.
PubMed
2) Dclcroix M, et al : Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension : Results From an International Prospective Registry. Circulation 133 : 859-871, 2016.
PubMed
3) Inami T, et al : Pressure-wire-guided percutaneous transluminal pulmonary angioplasty : a breakthrough in catheter-interventional therapy for chronic thromboembolic pulmonary hypertension. JACC Cardiovasc Interv 7 : 1297-1306, 2014.
PubMed
4) Jais X, et al : Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension : BENEFiT (Bosentan Effects in iNop Erable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 52 : 2127-2134, 2008.
 
5) Nagaya N, et al : Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest 123 : 338-343, 2003.
PubMed
6) Olschewski H, et al : Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 : 322-329, 2002.
PubMed
7) Reichenberger F, et al : Long-term treatment with sildenafil in chronic thromboembolic pulmonary ypertension. Eur Respir J 30 : 922-927, 2007.
 
8) Ghofrani HA, et al : Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 369 : 319-329, 2013.
PubMed
9) Simonneau G, et al : Riociguat for the treatment of chronic thromboembolic pulmonary hypertension : a long-term extension study (CHEST-2). Eur Respir J 45 : 1293-1302, 2015.
PubMed
10) Sitbon O, et al : Upfront triple combination therapy in pulmonary arterial hypertension : a pilot study. Eur Respir J 43 : 1691-1697, 2014.
PubMed
11) 斎藤俊一, ほか : 在宅酸素実施症例の全国調査結果について. 厚生省特定疾患呼吸不全調査研究班平成7年度研究報告書, p5-7, 1995.
 
12) Mereles D, et al : Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 114 : 1482-1489, 2006.
PubMed
13) de Perrot M, et al : Outcome of patients with pulmonary arterial hypertension referred for lung transplantation : a 14-year single-center experience. J Thorac Cardiovasc Surg 143 : 910-918, 2012.
PubMed
14) Sato M, et al : Registry of the Japanese Society of Lung and Heart-Lung Transplantation : official Japanese lung transplantation report, 2014. Gen Thorac Cardiovasc Surg 62 : 594-601, 2014.
PubMed
15) Urushibara T, et al : Effects of Surgical and Medical Treatment on Quality of Life for Patients With Chronic Thromboembolic Pulmonary Hypertension. Circ J 79 : 2696-2702, 2015.
PubMed
P.773 掲載の参考文献
1) 佐々木了, ほか : 血管腫・血管奇形診療ガイドライン 2013, 2013.
 
2) Kawata H, et al : Pulmonary and systemic arteriovenous fistulas in patients with left isomerism. Cardiol Young 8 : 290-294, 1998.
PubMed
3) Black H, et al : Anomalous inferior vena cava draining into the left atrium associated with intact interatrial septum and multiple pulmonary arteriovenous fistulae. Circulation 29 : 258-267, 1964.
PubMed
4) Trusler GA, et al : William Glenn lecture. The cavopulmonary shunt. Evolution of a concept. Circulation 82 : IVI31-138, 1990.
 
5) Kim SJ, et al : Development of pulmonary arteriovenous fistulas after bidirectional cavopulmonary shunt. Ann Thorac Surg 70 : 1918-1922, 2000.
PubMed
6) Brown JW, et al : Pulmonary arteriovenous malformations in children after the Kawashima operation. Ann Thorac Surg 80 : 1592-1596, 2005.
PubMed
7) Rodriguez-Roisin R, et al : Hepatopulmonary syndrome : the paradigm of liver-induced hypoxaemia. Baillieres Clin Gastroenterol 11 : 387-406, 1997.
PubMed
8) Cremona G, et al : Elevated exhaled nitric oxide in patients with hepatopulmonary syndrome. Eur Respir J 8 : 1883-1885, 1995.
PubMed
9) Schenk P, et al : Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med 133 : 701-706, 2000.
PubMed
10) Arguedas MR, et al : Carboxyhemoglobin levels in cirrhotic patients with and without hepatopulmonary syndrome. Gastroenterology 128 : 328-333, 2005.
PubMed
11) Thenappan T, et al : Acentral role for CD68 (+) macrophages in hepatopulmonary syndrome. Reversal by macrophage depletion. Am J Respir Crit Care Med 183 : 1080-1091, 2011.
 
12) Zhang J, et al : Pulmonary anglogenesis in a rat model of hepatopulmonary syndrome. Gastroenterology 136 : 1070-1080, 2009.
 
13) Mc Allister KA, et al : Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8 : 345-351, 1994.
PubMed
14) Berg JN, et al : The activin receptor-like kinase 1 gene : genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2. Am J Hum Genet 61 : 60-67, 1997.
PubMed
P.778 掲載の参考文献
1) Gossage JR, et al : Pulmonary arteriovenous malformations. A state of the art review. Am J Respir Crit Care Med 158 : 643-661, 1998.
PubMed
2) van Gent MW, et al : Screening for pulmonary arteriovenous malformations using transthoracic contrast echocardiography : a prospective study. Eur Respir J 33 : 85-9. 1, 2009.
PubMed
3) Trerotola SO, et al : PAVM embolization : an update. AJR Am J Roentgenol 195 : 837-845, 2010.
PubMed
4) Vogt FM, et al : HASTE MRI versus chest radiography in the detection of pulmonary nodules : comparison with MDCT. AJR Am J Roentgeno 183 : 71-78, 2004.
 
5) Kawai T, et al : Feasibility of time-resolved MR angiography for detecting recanalization of pulmonary arteriovenous malformations treated with embolization with platinum coils. J Vasc Interv Radiol 25 : 1339-1347, 2014.
PubMed
6) White RI, et al : Angioarchitecture of pulmonary arteriovenous malformations : an important consideration before embolotherapy. AJR Am J Roentgenol 140 : 681-686, 1983.
PubMed
7) Faughnan ME, et al : International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 48 : 73-87, 2011.
PubMed
8) 塩谷隆信 (編著) : 遺伝性出血性末梢血管拡張症 (HHT) の診療マニュアル, 163-170, 中外医学社, 2011.
 
9) オスラー病 (指走難病 227). 難病情報センター [http://www.nanbyou.or.jp/entry/4352] (2017年5月閲覧)
 
P.782 掲載の参考文献
1) Faughnan ME, et al : International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 48 : 73-87, 2011.
PubMed
2) Cartin-Ceba R, et al : Pulmonary arteriovenous malformations. Chest 144 : 1033-1044, 2013.
PubMed
3) Trerotola SO, et al : PAVM embolization : an update. AJR Am J Roentgenol 195 : 837-845, 2010.
PubMed
4) Shovlin CL, et al : Primary determinants of ischaemic stroke/brain abscess risks are independent of severity of pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia. Thorax 63 : 259-266, 2008.
PubMed
5) Hsu CC, et al : Embolisation for pulmonary arteriovenous malformation. Cochrane Database Syst Rev 1 : CD008017, 2015.
PubMed
6) Hayashi S, et al : Efficacy of venous sac embolization for pulmonary arteriovenous malformations : comparison with feeding artery embolization. J Vasc Interv Radiol 23 : 1566-1577, 2012.
PubMed
7) Kajiwara K, et al : Venous sac embolization of pulmonary arteriovenous malformation : safety and effectiveness at mid-term follow-up. Acta Radiol 55 : 1093-1098, 2014.
PubMed
8) Hart JL, et al : Embolization of pulmonary arteriovenous malformations using the Amplatzer vascular plug : successful treatment of 69 consecutive patients. Eur Radiol 20 : 2663-2670, 2010.
PubMed
9) Mager JJ, et al : Embolotherapy of pulmonary arteriovenous malformations : long-term results in 112 patients. J Vasc Interv Radiol 15 : 451-456. 2004.
PubMed
10) Pollak JS, et al : Clinical and anatomic outcomes after embolotherapy of pulmonary arteriovenous maiformations. J Vasc Interv Radiol 17 : 35-44, 2006.
 
11) Milic A, et al : Reperfusion of pulmonary arteriovenous malformations after embolotherapy. J Vasc Interv Radiol 16 : 1675-1683, 2005.
PubMed
12) Makimoto S, et al : Association between reperfusion and shrinkage percentage of the aneurysmal sac after embolization of pulmonary arteriovenous malformation : evaluation based on contrastenhanced thin-section CT images. Jpn J Radiol 32 : 266-273, 2014.
PubMed
13) Kawai T, et al : Feasibility of time-resolved MR angiography for detecting recanalization of pulmonary arteriovenous malformations treated with embolization with platinum coils. J Vasc Interv Radiol 25 : 1339-1347, 2014.
PubMed
14) Gossage JR, et al : Pulmonary arteriovenous malformations. A state of the art review. Am J Respir Crit Care Med 158 : 643-661, 1998.
PubMed
15) Reynaud-Gaubert M, et al : Pulmonary arteriovenous malformations : lung transplantation as a therapeutic option. Eur Respir J 14 : 1425-1428, 1999.
PubMed
P.788 掲載の参考文献
1) Updates in Pulmonary Hypertension. J Am Coll Cardiol 62 (25 Suppl) : A-8, D-128, 2013.
 
2) Galie N, et al : 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension : The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) : Endorsed by : Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 46 : 903-975, 2015.
 
3) 中西宣文, ほか : 肺高血圧症治療ガイドライン. 日本循環器学会2012年改訂版, 2012.
 
4) 肺高血圧症. 診断と治療のABC (最新医学別冊) (企画 : 巽浩一郎), 最新医学社, 2015.
 
P.794 掲載の参考文献
1) Galie N, et al : 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension : The Joint Task Force for the Diagnosis and Trcatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) : Endorsed by : Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 46 : 903-975, 2015.
 
2) Simonneau G, et al : Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62 : D34-41, 2013.
PubMed
3) Hurdman J, et al : ASPIRE registry : assessing the Spectrum of Pulmonary hypertension ldentified at a REferral centre. Eur Respir J 39 : 945-955, 2012.
 
4) 吉田俊治, ほか : 膠原病性肺高血圧症の頻度と病態の解析. 厚生労働科学研究費補助金 免疫アレルギー疾患予防・治療研究事業 全身性自己免疫疾患における難治性自己免疫疾患の診断と治療に関する研究. 平成15年総括・分担研究報告書, p40-43, 2004.
 
5) Montani D, et al : Pulmonary veno-occlusive disease. Eur Respir J 47 : 1518-1534, 2016.
PubMed
6) Pengo V, et al : Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350 : 2257-2264, 2004.
PubMed
7) 田邉信宏, ほか : 慢性肺血栓塞栓性肺高血圧症臨床個人調査票による解析. 厚生労働省特定疾患呼吸不全調査研究班平成17年度報告書, p171-173, 2006.
 
P.798 掲載の参考文献
1) Pulido T, et al : Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369 : 809-818, 2013.
PubMed
2) Ghofrani HA, et al : Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 369 : 319-329, 2013.
PubMed
3) Ghofrani HA, et al : Riociguat for the treatrnent of pulrnonary arterial hypertension. N Engl J Med 369 : 330-340, 2013.
 
4) Olschewski H, et al : Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 : 322-329, 2002.
PubMed
5) Saji T, et al : Efficacy and Safety of lnhaled lloprost in Japanese Patients With Pulmonary Arterial Hypertension-Insights From the IBUKI and AIR Studies. Circ J 80 : 835-842, 2016.
 
6) Sitbon O, et al : Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 373 : 2522-2533, 2015.
PubMed
7) Mizoguchi H, et al : Refined balloon pulmonary angioplasty for inoperablc paticnts with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 5 : 748-755, 2012.
 
8) Ehlken N, et al : Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension : a prospective, randomized, controlled trial. Eur Heart J 37 : 35-44, 2016.
PubMed
9) McLaughlin VV, et al : Pulmonary arterial hypertension. Circulation 114 : 1417-1431, 2006.
PubMed
P.804 掲載の参考文献
1) Hirsch AT, et al : ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic) : a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of lnterventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) : endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation ; National Heart, Lung, and Blood Institute : Society for Vascular Nursing ; Trans Atlantic Inter-Society Consensus ; and Vascular Disease Foundation. Circulation 113 : e463-654, 2006.
 
2) 高本眞一, ほか : 大動脈瘤・大動脈解離診療ガイドライン (2011年改訂版). 循環器病の診断と治療に関するガイドライン, 2011.
 
3) Chaikof EL, et al : The care of patients with an abdominal aortic aneurysm : the Society for Vascular Surgery practice guidelines. J Vasc Surg 50 : S2-49, 2009.
 
4) Singh K, et al : Prevalence of and risk factors for abdominal aortic aneurysms in a population-based study : The Tromso Study. Am J Epidemiol 154 : 236-244, 2001.
 
5) Wang S, et al : Activation of AMP-activated protein kinase α2 by nicotine instigates formation of abdominal aortic aneurysms in mice in vivo. Nat Med 18 : 902-910, 2012.
 
6) Tang W, et al : Lifetime Risk and Risk Factors for Abdominal Aortic Aneurysm in a 24-Year Prospective Study : The ARIC Study (Atherosclerosis Risk in Communities). Arterioscler Thromb Vasc Biol 36 : 2468-2477, 2016.
 
7) McCaul KA, et al : Long-term Outcomes of the Western Australian Trial of Screening for Abdominal Aortic Aneurysms : Secondary Analysis of a Randomized Clinical Trial. JAMA Intern Med 176 : 1761-1767, 2016.
PubMed
8) RESCAN Collaborators, et al : Surveillance intervals for small abdominal aortic aneurysms : a metaanalysis. JAMA 309 : 806-813, 2013.
PubMed
9) Ouriel K, et al : Endovascular repair compared with surveillance for patients with small abdominal aortic aneurysms. J Vasc Surg 51 : 1081-1087, 2010.
PubMed
10) Cao P, et al : Comparison of surveillance versus aortic endografting for small aneurysm repair (CAESAR) : results from a randomised trial. Eur J Vasc Endovasc Surg 41 : 13-25, 2011.
PubMed
11) Prinssen M, et al : A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. N Engl J Med 351 : 1607-1618, 2004.
PubMed
12) 2011 WRITING GROUP MEMBERS, et al : 2011 ACCF/AHA Focused Update of the Guideline for the Managcment of patients with peripheral artery disease (Updating the 2005 Guideline) : a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 124 : 2020-2045, 2011.
 
13) Patel R, et al : Endovascular versus open repair of abdominal aortic aneurysm in 15-years' follow-up of the UK endovascular aneurysm repair trial 1 (EVAR trial 1) : a randomised controlled trial. Lancet 388 : 2366-2374, 2016.
PubMed
14) de Bruin JL, et al : Quality of life from a randomized trial of open and endovascular repair for abdominal aortic aneurysm. Br J Surg lo3 : 995-1002, 2016.
 
15) IMPROVE Trial Investigators : Endovascular strategy or open repair for ruptured abdominal aortic aneurysm : one-year outcomes from the IMPROVE randomized trial. Eur Heart J 36 : 2061-2069, 2015.
 
P.810 掲載の参考文献
1) 佐藤雅人, ほか : 大動脈 (大動脈瘤, 大動脈解離) : 外科的治療, 血管無侵襲診断テキスト. p208-211, 南江堂, 2007.
 
2) 大城孟 : 図説血管外科. 日本アクセル・シュプリンガー出版, メディカルトリビューン, 1992.
 
3) NEW BED SIDE MEMO (外科) 実地医家のためのノーハウ (杉町上蔵監), 南山堂, 1993.
 
4) 臨床脈管学 (三島好雄, ほか編), 文光堂, 1992.
 
5) 脈管専門医のための臨床脈管学 (日本脈管学編), メディカルトリビューン. 2010.
 
P.814 掲載の参考文献
1) Panayiotopoulos YP, et al : Aneurysms of the visceral and renal arteries. Ann R Coll Surg Engl 78 : 412-419, 1996.
PubMed
2) Hossain A, et al : Visceral artery aneurysms : experience in a tertiary-care center. Am Surg 67 : 432-437, 2001.
 
3) Deterling RA : Aneurysm of the visceral arteries. J Cardiovasc Surg (Torino) 12 : 309-322, 1971.
PubMed
4) Stanley JC, et al : Splanchnic artery aneurysms. Arch Surg 101 : 689-697, 1970.
PubMed
5) Stanley JC, et al : Clinical importance and management of splanchnic artery aneurysms. J Vasc Surg 3 : 836-840, 1986.
PubMed
6) Zelenock GB, et al : Splanchnic artery aneurysms. In : Vascular Surgery, 5th ed (ed by Rutherford RB), p1369-1382, Saunders, Philadelphia, 2003.
 
7) Shanley CJ, et al : Uncommon splanchnic artery aneurysms : pancreaticoduodenal, gastroduodenal, superior mesenteric, inferior mesenteric, and colic. Ann Vasc Surg 10 : 506-515, 1996.
PubMed
8) Slavin RE, et al : Segmental mediolytic arteritis : a clinical pathologic study. Lab Invest 35 : 23-29, 1976.
PubMed
9) 稲田潔, ほか : 腹部内臓動脈の多発動脈瘤を伴うsegmental arterial mediolysis (SAM) の20例. 日本臨床外科学会雑誌 69 : 3101-3106, 2008.
 
10) Anderson JL, et al : Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations) : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 127 : 1425-1443, 2013.
 
11) Rokke O, et al : The diagnosis and management of splanchnic artery aneurysms. Scand J Gastroenterol 31 : 737-743, 1996.
PubMed
12) 高橋直子, ほか : 腹部内臓動脈瘤の治療検討. 日本血管外科学会雑誌 19 : 487-493, 2010.
Medical*Online
13) 高橋英雄, ほか : 当院における腹部内臓動脈瘤破裂9例の検討. 日本臨床外科学会雑誌 70 : 2303-2308, 2009.
 
14) Tsugawa K, et al : Laparoscopic splenectomy for splenic artery aneurysm. Hepatogastroenterology 46 : 2631-2634, 1999.
PubMed
P.819 掲載の参考文献
1) Leriche R, et al : The syndrome of thrombotic obliteration of the aortic bifurcation. Ann Surg 127 : 193-206, 1948.
PubMed
2) TASCII Working Group (日本脈管学会訳) : 下肢閉塞性動脈硬化症の診断・治療指針 (日本脈管学会編), p1-109, メディカルトリビューン社, 2007.
 
3) 白石学, ほか : 虚血性心疾患を伴う Leriche症候群に対する治療経験. 日本心臓血管外科学会雑誌 40 : 86-88, 2011.
 
4) 高島範之, ほか : 重症虚血性心疾患とLeriche症候群に対するOPCABと上行大動脈-両側大腿動脈バイパスの同時手術例. 日本心臓血管外科学会雑誌 41 : 152-155, 2012.
 
5) 正木久男, ほか : 閉塞性動脈硬化症1000例の検討. 日本臨床外科学会雑誌 61 : 873-876, 2000.
 
6) De Vries SO, et al : Results of aortic bifurcation grafts for aortoiliac occlusive disease : a meta-analysis. J Vasc Surg 26 : 558-569, 1997.
PubMed
7) Brewster DC : Current controversies in the management of aortoiliac occlusive disease. J Vasc Surg 25 : 365-379, 1997.
 
8) Lorenzi G, et al : Role of bypass, endarterectomy, extra-anatomic bypass and endovascular surgery in unilateral iliac occlusive disease : a review of 1257 cases. Cardiovasc Surg 2 : 370-373, 1994.
PubMed
9) Ng RL, et al : iliofemoral versus femorofemoral bypass : a 6-year audit. Br J Surg 79 : 1011-1013, 1992.
PubMed
10) Ascer E, et al : Comparison of axillounifemoral and axillobifemoral bypass operations. Surgery 97 : 169-175, 1985.
PubMed
11) Passmann MA, et al : Comparison of axillofemoral and aortofemoral bypass for aortoiliac occlusive disease. J Vasc Surg 23 : 263-269 ; discussion 269-271, 1996.
 
12) Dohi T, et al : Mid-term clinical outcome following endovascular therapy in patients with chronic aortic occlusion. Cardiovasc Interv Ther 28 : 327-332, 2013.
PubMed
P.822 掲載の参考文献
1) Jabbari M, et al : Gastric antral vascular ectasia : the watermelon stomach. Gastroenterology 87 : 1165-1170, 1984.
PubMed
2) Gostout CJ, et al : The clinical and endoscopic spectrum of the watermelon stomach. J Clin Gastroenterol 15 : 256-263, 1992.
PubMed
3) Lowes JR, et al : Neuroendocrine cell proliferations in gastric antral vascular ectasia. Gastroenterology 97 : 207-212, 1989.
PubMed
4) Charneau J, et al : Antral motility in patients with cirrhosis with or without gastric antral vascular ectasia. Gut 37 : 488-492, 1995.
PubMed
6) 佐藤隆啓, ほか : 肝硬変, 門脈圧亢進症に伴う胃前庭部・毛細血管拡張症. 日本門脈圧亢進症学会雑誌 18 : 145-148, 2012.
 
7) Spahr L, et al : Gastric antral vascular ectasia in cirrhotic patients : absence of relation with portal hypertension. Gut 44 : 739-742, 1999.
PubMed
8) Lee FI, et al : Diffuse antral vascular ectasia. Gastrointest Endosc 30 : 87-90, 1984.
PubMed
9) Grund KE, et al : Endoscopic argon plasma coagulation (APC) : First clinical experiences in flexible endoscopy. Endosc Surg Allied Technol 2 : 42-46, 1994.
PubMed
10) Roman S, et al : Tolerance and efficacy of argon plasma coagulation for controlling bleeding in patients with typical and atypical manifestations of watermelon stomach. Endoscopy 35 : 1024-1028, 2003.
PubMed
11) Nakamura S, et al : Long-term follow up of gastric antral vascular ectasia treated by argon plasma coagulation. Dig Endosc 18 : 128-133, 2006.
 
12) Sinha SK, et al : Watermelon stomach treated with endoscopic band ligation. Gastrointest Endosc 64 : 1028-1031, 2006.
PubMed
13) Kumar R, et al : Endoscopic band ligation : a novel therapy for bleedinggastric antral vascular ectasia. Endoscopy 39 (Suppl 1) : E56-57, 2007.
 
14) Wells CD, et al : Treatment of gastric antral vascular ectasia (watermelon stomach) with endoscopic band ligation. Gastrointest Endosc 68 : 231-236, 2008.
PubMed
15) Sato T, et al : Endoscopic band ligation versus argon plasma coagulation for gastric antral vascular ectasia associated with liver diseases, Dig Endosc 24 : 237-242, 2012.
PubMed
P.828 掲載の参考文献
1) 小宮山雅樹 : 遺伝性出血性毛細血管拡張症. 脳卒中外科 43 : 193-200, 2015.
 
2) Shovlin CL, et al : Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 91 : 66-67, 2000.
PubMed
3) Shovlin CL, et al : A gene for hereditary haemorrhagic telangiectasia maps to chromosome 9q3. Nat Genet 6 : 205-209, 1994.
PubMed
4) Johnson DW, et al : A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12. Genome Res 5 : 21-28, 1995.
PubMed
5) Gallione CJ, et al : A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 363 : 852-859, 2004.
PubMed
5) Ikeda M et al : An endoscopic follow-up study of the development of diffuse antral vascular ectasia. Endoscopy 28 : 390-393, 1996.
PubMed
6) Komiyama M, et al : Hereditary hemorrhagic telangiectasia in Japanese patients. J Hum Genet 59 : 37-41, 2014.
PubMed
7) Dakeishi M et al : Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Hum Mutat 19 : 140-148, 2002.
 
8) 市村恵一 : オスラー病 (遺伝性出血性末梢血管拡張症) の鼻出血. 基礎と臨床. 耳鼻咽喉科展望 3 : 138-152, 2009.
 
9) Longacre AV, et al : Diagnosis and management of gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Am J Gastroenterol 98 : 59-65, 2003.
PubMed
10) White RI : Pulmonary arteriovenous malformations : how do I embolize? Tech Vasc Interv Radiol 10 : 283-290, 2007.
PubMed
11) Krings T, et al : Hereditary haemorrhagic telangiectasia in children. Endovascular treatment of neurovascular malformations. Results in 31 patients. Interv Neuroradiol 11 : 13-23, 2005.
PubMed
12) Krings T, et al : Neurovascular manifestations in hereditary hemorrhagic telangiectasia : imaging features and genotype-phenotype correlations. AJNR Am J Neuroradiol 36 : 863-870, 2015.
PubMed
13) Garcia-Tsao G, et al : Liver disease in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 343 : 931-936, 2000.
PubMed
14) Baba Y, et al : Hyperintense basal ganglia lesions on Tl-weighted images in hereditary hemorrhagic telangiectasia with hepatic involvement. J Comput Assist Tomogr 22 : 976-979, 1998.
 
15) Shovlin CL, et al : Estimates of maternal risks of pregnancy for women with hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome) : suggested approach for obstetric services. BJOG 115 : 1108-1115, 2008.
PubMed
P.833 掲載の参考文献
1) Dieulafoy G : Exulceratio simplex. L'intervention chirllrgicale dans les hematemeses foudroyantes consecutives a rexulceratioll simple de restomac. Bull Acad Med 39 : 49-84, 1898.
 
2) Norton ID, et al : Management and long-term prognosis of Dieulafoy lesion. Gastrointest Endosc 50 : 762-767, 1999.
PubMed
3) 並木正義 : Dieulafoy潰瘍の概念と病態をめぐって. 胃と腸 22 : 1109-1112, 1979.
 
4) 田中昌宏, ほか : 統計を主としたDieulafoy潰瘍93症例 (本邦報告例) の臨床的分析. 胃と腸 22 : 1125-1133, 1987.
 
5) Lara LF, et al : Dieulafoy lesions of the GI tract : localization and therapeutic outcomes. Dig Dis Sci 55 : 3436-3441, 2010.
PubMed
6) Gimeno-Garcia A Z, et al : Management of colonic Dieulafoy lesions with endoscopic mechanical techniques : report of two cases. Dis Colon Rectum 47 : 1539-1543, 2004.
PubMed
7) 林俊治, ほか : 胆嚢体部に発生したDieulafoy潰瘍が原因となった出血性胆嚢炎の1例. 日本臨床外科学会雑誌 75 : 2280-2283, 2014.
 
8) Dulic-Lakovic E, et al : Bleeding Dieulafoy lesions of the small bowel : asystematic study on the epidemiology and efficacy of enteroscopic treatment. Gastrointest Endosc 74 : 573-580, 2011.
 
9) 平尾雅紀, ほか : 臨床からみた Dieulafoy潰瘍治療を中心として. 胃と腸 22 : 1143-1151, 1987.
 
10) Yano T, et al : Endoscopic classification of vascular lesions of the small intestine (with videos). Gastrointest Endosc 67 : 169-172, 2008.
PubMed
11) Chung IK, et al : Bleeding Dieulafoy's lesions and the choice of endoscopic method : comparing the hemostatic efficacy of mechanical and injection methods. Gastrointest Endosc 52 : 721-724, 2000.
PubMed
12) Park CH, et al : The usefulness of endoscopic hemoclipping for bleeding Dieulafoy lesions. Endoscopy 35 : 388-392, 2003.
PubMed
13) Park CH, et al : A prospective, randomized trial of endoscopic band ligation versus endoscopic hemoclip placement for bleeding gastric Dieulafoy's lesions. Endoscopy 36 : 677-681, 2004.
PubMed
14) Baxter M, et al : Dieulafoy's lesion : current trends in diagnosis and management Ann R Coll Surg Engl 92 : 548-554, 2010.
PubMed
P.839 掲載の参考文献
1) Rutter AG : Submucous telangiectasis of the colon. Lancet 271 : 1077-1079, 1956.
PubMed
2) Margulis AR, et al : Operative mesenteric arteriography in the search for the site of bleeding in unexplained gastrointestinal hemorrhage : a preliminary report. Surgery 48 : 534-539, 1960.
PubMed
3) Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 36-1974. N Engl J Med 291 : 569-575, 1974.
PubMed
4) Moore JD, et al : Arteriovenous malformations of the gastrointestinal tract. Arch Surg 111 : 381-389, 1976.
PubMed
5) Lee FI, et al : Diffuse antral vasctllar ectasia. Gastrointest Endosc 30 : 87-90, 1984.
PubMed
6) Lewin KJ, et al : Gastrointestinal Pathology and Its Clinical Implications. p72-85, Igaku Shoin, New York/Tokyo, 1992.
 
7) Baum S : Angiodysplasia of the right colon : acause of gastrointestinal bleeding AJR Am J Roentgenol 129 : 789-794, 1977.
 
8) 古賀秀樹, ほか : 最近10年間の本邦報告からみた消化管の血管性病変. 胃と腸 35 : 797-802, 2000.
 
9) Meyer CT, et al : Arteriovenous malformations of the bowel : an analysis of 22 cases and a review of the literature. Medicine (Baltimore) 60 : 36-48, 1981.
 
10) 小林清典, ほか : 腸管動静脈奇形-自験12例と本邦報告例の解析. 胃と, 35 : 758-761, 2000
 
11) 岩下明徳, ほか : 腸管の血管性病変の病理学的鑑別診断. 胃と腸 35 : 771-784, 2000.
 
12) 辻井正, ほか : Dieulafoy潰瘍 (exulceratio simplex). 別冊日本臨牀 消化管症候群 (上巻), p244-246, 日本臨牀社, 1994.
 
13) Fuchizaki U, et al: Hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease). Lancet 362 : 1490-1494, 2003.
PubMed
P.844 掲載の参考文献
1) 遠城寺宗知, ほか : 血管の腫瘍および腫瘍状病変. 外科病理学 (石川栄世, ほか編), p1226-1235, 文光堂, 1999.
 
2) 岩下明徳, ほか : 腸管の血管性病変の病理学的鑑別診断. 胃と腸 35 : 771-784, 2000.
 
3) 古賀秀樹, ほか : 消化管脈管系腫瘍 (血管腫・リンパ管腫) の診断と治療. 胃と腸 39 : 612-627, 2004.
 
4) 大平周作, ほか : 術前に部位診断し得た小腸血管腫の1例. 日本消化器病学会雑誌 100 : 166-169, 2003.
 
5) 中村厚夫, ほか : 直腸びまん性海綿状血管腫の1例. 胃と腸 35 : 819-822, 2000.
 
6) 矢野智則, ほか : 小腸血管腫 別冊n本臨床 消化管症候群 (下), p107-109, 日本臨林社, 2009.
 
7) Kawasaki K, et al : Pyogenic granuloma of the ileum depicted by small-bowel radiography, capsule endoscopy and double balloon endoscopy. Dig Liver Dis 47 : 436, 2015.
PubMed
8) 真栄城剛, ほか : 直腸・ S状結腸血管腫の1例. Gastroenterological Endoscopy 41 (Suppl 1) : 713, 1999.
 
9) Nishiyama N, et al : Bleeding duodenal hemangioma : morphological changes and endoscopic mucosal resection. World J Gastroenterol 18 : 2872-2876, 2012.
PubMed
10) Kimura S, et al : Cavernous hemangioma in the ascending colon treated by endoscopic mucosal resection. J Gastroenterol Hepatol 22 : 280-281, 2007.
PubMed
11) 水沢悠子, ほか : ダブルバルーン内視鏡で治療した小腸毛細血管腫の2例. Progress of Digestive Endoscopy 82 : 168-169, 2013.
Medical*Online
12) Ng EK, et al : Blue rubber bleb nevus syndrome : treatment of multiple gastrointestinal hemangiomas with argon plasma coagulator. Dig Endosc 21 : 40-42, 2009.
PubMed
13) Jin J, et al : Therapy for hemangiomas of blue rubber bleb nevus syndrome in the small intestine with single balloon endoscopy. Dig Endosc 27 : 780, 2015.
PubMed
14) 遠藤豪一, ほか : Blue rubber bleb nevus syndromeによる多発性小腸血管腫に対し術中内視鏡下硬化療法が有効であった1例. 日本臨床外科学会雑誌 70 : 761-765, 2009.
 
P.848 掲載の参考文献
1) Acosta S, et al : Clinical implications for the management of acute thromboembolic occlusion of the superior mesenteric artery : autopsy findings in 213 patients. Ann Surg 241 : 516-522, 2005.
PubMed
2) Sise MJ : Acute mesenteric ischemia. Surg Clin North Am 94 : 165-181, 2014.
PubMed
3) 錦織直人, ほか : 上腸間膜動脈閉塞症・上腸間膜静脈閉塞症. 今日の臨床サポート (杉原健一監). [https://clinicalsup.jp/contentlist/1537.html] (2017年5月閲覧)
 
4) 鈴木彰, ほか : 急性上腸間膜動脈閉塞症に対する外科治療. 日本臨床外科学会雑誌 75 : 337-343, 2014.
 
5) 大原みずほ, ほか : 上腸間膜動脈閉塞症20例の検討. 日本腹部救急医学会雑誌 36 : 705-709, 2009.
 
6) Walker TG : Mesenteric ischemia. Semin Intervent Radiol 26 : 175-183, 2009.
PubMed
7) 光吉明, ほか : 上腸間膜動脈血栓症に非閉塞性腸間膜梗塞症を合併した症例. 消化器外科 34 : 1395-1399, 2011.
 
8) Hirsch AT, et al : ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic) : a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of lnterventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) : endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation ; National Heart, Lung, and Blood Institute ; Society for Vascular Nursing ; Trans Atlantic Inter-Society Consensus ; and Vascular Disease Foundation. Circulation 113 : e463-654, 2006.
 
9) 宮田哲郎, ほか : 急性腸間膜動脈閉塞. 2014年度合同研究班報告. 末梢閉塞性動脈疾患の治療ガイドライン (2015年改訂版), p50-51, 2015.
 
10) 松原健太郎, ほか : 腹部大動脈, 上腸間膜動脈の血栓・塞栓症の診断と治療. 日本臨牀 72 : 1289-1293, 2014.
Medical*Online
11) 谷達夫, ほか : 腸間膜動脈閉塞症. 別冊日本臨牀 消化管症候群 (下巻) (第2版), p365-368, 日本臨牀社, 2009.
 
12) Nishigori N, et al : Visualization of Lymph/Blood Flow in Laparoscopic Colorectal Cancer Surgery by ICGF Iuorescence Imaging (Lap-IGFI). Ann Surg Oncol 23 (Suppl 2) : S266-274, 2016.
 
13) Alemanno G, ct al : Combination of diagnostic laparoscopy and intraoperative indocyanine green fluorescence angiography for the early detection of intestinal ischemia not detectable at CT scan. Int J Surg Case Rep 26 : 77-80, 2016.
 
14) Beaulieu RJ, et al : Comparison of open and endovascular treatment of acute mesenteric ischemia. J Vasc Surg 59 : 159-164, 2014.
PubMed
15) 柚原正直 : ハイブリッド手術室の現状と今後の動向. 医療機器学 81 : 290-296, 2011.
Medical*Online
P.854 掲載の参考文献
1) Thomas JH, et al : The clinical course of asymptomatic mesenteric arterial stenosis. J Vasc Surg 27 : 840-844, 1998.
PubMed
2) Park WM, et al : Contemporary management of acute mesenteric ischemia : Factors associated with survival. J Vasc Surg 35 : 445-452, 2002.
PubMed
3) Shaw RS, et al : Acute and chronic thrombosis of the mesenteric arteries associated with malabsorption ; Report of two cases successfully treated by thromboendarterectomy. N Engl J Med 258 : 874-878, 1958.
PubMed
4) Morris GC Jr, et al : Abdominal angina. Surg Clin North Am 46 : 919-930, 1966.
PubMed
5) Stoney RJ, et al : Revascularization methods in chronic visceral ischemia caused by atherosclerosis. Ann Surg 186 : 468-476, 1977.
PubMed
6) Foley MI, et al : Revascularization of the superior mesenteric artery alone for treatment of intestinal ischemia. J Vasc Surg 32 : 37-47, 2000.
PubMed
7) Inoue Y, et al : Long-term results of aorta-superior mesenteric artery bypass using a new route. Surg Today 34 : 658-661, 2004.
PubMed
8) Furrer J, et al : Treatment of abdominal angina with percutaneous dilatation of an arteria mesenterica superior stenosis. Preliminary communication. Cardiovasc Intervent Radiol 3 : 43-44, 1980.
PubMed
9) Wang LL, et al : Extra-Anatomic Axillo-Mesenteric Reconstruction for Chronic Mesenteric Ischemia. Ann Vasc Surg 31 : 206. e5-8, 2016.
 
10) Sullivan TM, et al : Open and endovascular revascularization for chronic mesenteric ischemia : tabular review of the literature. Ann Vasc Surg 23 : 700-712, 2009.
 
11) Cai W, et al : Comparison of clinical outcomes of endovascular versus open revascularization for chronic mesenteric ischemia : a meta-analysis. Ann Vasc Surg 29 : 934-940, 2015.
PubMed
12) Zacharias N, et al : Chronic mesenteric ischemia outcome analysis and predictors of endovascular failure. J Vasc Surg 63 : 1582-1587, 2016.
PubMed
P.860 掲載の参考文献
1) Lipshutz B : A composite study of the coeliac axis artery. Ann Surg 65 : 159-169, 1917.
PubMed
2) Harjola PT : A rare obstruction of the coeliac artery. Report of a case. Ann Chir Gynaecol Fenn 52 : 547-550, 1963.
 
3) 原田岳, ほか : 正中弓状靱帯圧迫による腹腔動脈閉塞を伴った膵頭部癌に膵頭十二指腸切除を施行した1例. 日本臨床外科学会雑誌 67 : 2941-2945, 2006.
 
4) Park CM, et al : Celiac axis stenosis : incidence and etiologies in asymptomatic individuals. Korean J Radiol 2 : 8-13, 2001.
PubMed
5) Scholbach T : Celiac artery compression syndrome in children, adolescents, and young adults : clinical and color duplex sonographic features in a series of 59 cases. J Ultrasound Med 25 : 299-305, 2006.
 
6) 楠裕明, ほか : 知ってそうで知らない消化器疾患, 腹腔動脈圧迫症候群 (CACS). G. 1. Research 22 : 544-553, 2014.
 
7) Horton K M, et al : Median arcuate ligament syndrome : evaluation with CT angiography. Radiographics 25 : 1177-1182, 2005.
PubMed
8) Bech FR : Celiac artery compression syndromes. Surg Clin North Am 77 : 409-424, 1997.
PubMed
9) Ducasse E, et al : Aneurysm of the pancreaticoduodenal arteries with a celiac trunk lesion : current management. J Vasc Surg 39 : 906-911, 2004.
PubMed
10) Kim EN, et al : Median Arcuate Ligament Syndrome-Review of This Rare Disease. JAMA Surg 151 : 471-477, 2016.
PubMed
11) Gruber H, et al : Ultrasound of the median arcuate ligament syndrome : anew approach to diagnosis. Med Ultrason 14 : 5-9, 2012.
 
12) Grotemeyer D, et al : Median arcuate ligament syndrome : vascular surgical therapy and follow-up of 18 patients. Langenbecks Arch Surg 394 : 1085-1092, 2009.
PubMed
13) Roseborough GS : Laparoscopic management of celiac artery compression syndrome. J Vasc Surg 50 : 124-133, 2009.
PubMed
14) Reilly LM, et al : Late results following operative repair for celiac artery compression syndrome. J Vasc Surg 2 : 79-91, 1985.
PubMed
15) Takach TJ, et al : Celiac compression syndrome : tailored therapy based on intraoperative findings. J Am Coll Surg 183 : 606-610, 1996.
PubMed
P.864 掲載の参考文献
1) 小原勝敏ほか : 食道・胃静脈瘤, p21-26, 日本メディカルセンター, 2012.
 
2) Koyanagi N, et al : Decreased arteriovenous flow resistance in the left gastric venous area in cirrhotic patients. Eur J Clin Invest 11 : 355-359, 1981.
PubMed
3) Cales P, et al : Gastroesophageal endoscopic features in cirrhosis. Observer variability, interassociations, and relationship to hepatic dysfunction. Gastroenterology 98 : 156-162, 1990.
PubMed
4) 小俣政男 : "シャーロック" 肝臓病学. 食道静脈瘤出血, p146-148, 西村書店, 2004.
 
5) 日本門脈圧亢進症学会 (編) : 門脈圧亢進症取り扱い規約 第3版, 金原出版, 2013.
 
6) 於保和彦 : 食道・胃静脈瘤出血の危険因子. 門脈圧亢進症診療マニュアル (日本門脈圧亢進症学会編), p19-22, 南江堂, 2015.
 
7) 中村真一, ほか : 食道・胃静脈瘤に対する治療, 消化器内視鏡ハンドブック (日本消化器内視鏡学会監), p199-209, 日本メディカルセンター, 2012.
 
8) Kanagawa H, et al : Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol 11 : 51-58, 1996.
PubMed
9) 太田正之 : バルーンタンポナーデ法. 門脈圧亢進症診療マニュアル (日本門脈圧亢進症学会編), p138-141, 南江堂, 2015.
 
10) 太田正之, ほか : 門脈圧亢進症に対する外科治療の歩み. 日本門脈圧亢進症学会雑誌 22 : 18-22, 2016.
 
P.868 掲載の参考文献
1) Thomson WHF : The nature of haemorrhoids. Br J Surg 62 : 542-552, 1975.
 
2) Goligher JC : Surgery of the Anus, Rectum and Colon, 5th ed, p101, Billiere Yindall, London, 1984.
 
3) Banov L Jr, et al : Managementoh hemorrhoidal disease. J S C Med Assoc 81 : 398-401, 1985.
 
4) 高村寿雄, ほか : 新規硬化剤OC-108の内痔核患者における有効性. 安全性および薬物動態の臨床研究 : 前期第II相試験. 薬理と治療 32 : 355-365, 2004.
 
5) 三枝純一, ほか : 痔核治療の歴史的変遷. 日本大腸肛門病学会雑誌 63 : 813-818, 2010.
 
6) Longo A : Stapled anopexy and stapled hemorrhoidectomy : two opposite concepts and procedures. Dis Colon Rectum 45 : 571-572 ; author reply 572, 2002.
PubMed
P.873 掲載の参考文献
1) Minegishi S, et al : An isoform of Nedd4-2 is critically involved in the renal adaptation to high salt intake in mice. Sci Rep 6 : 27137, 2016.
PubMed
2) Bax L, et al : Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function : a randomized trial. Ann Intern Med 150 : 840-848, W150-151, 2009.
 
3) ASTRAL Investigators ; Wheatly K, et al : Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 361 : 1953-1962, 2009.
 
4) Cooper CJ, et al : Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 370 : 13-22, 2014.
PubMed
5) Morgan DJ, et al : Update on Medical Practices That Should Be Questioned in 2015. JAMA Intern Med 175 : 1960-1964, 2015.
PubMed
6) Derkx FH, et al : Renal artery stenosis and hypertension. Lancet 344 : 237-239, 1994.
PubMed
7) Hansen KJ, et al : Prevalence of renovascular disease in the elderly : apopulation-based study. J Vasc Surg 36 : 443-451, 2002.
 
8) Sawicki PT, et al : Prevalence of renal artery stenosis in diabetes mellitus-an autopsy study. J Intern Med 229 : 489-492, 1991.
PubMed
9) de Mast Q, et al : The prevalence of atherosclerotic renal artery stenosis in risk groups : a systematic literature review. J Hypertens 27 : 1333-1340, 2009.
PubMed
10) Hirsch AT, et al : ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic) : a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) : endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation ; National Heart, Lung, and Blood Institute ; Society for Vascular Nursing ; Trans Atlantic Inter-Society Consensus ; and Vascular Disease Foundation. Circulation 113 : e463-654, 2006.
 
11) 日本腎臓学会 (編) : エビデンスに基づくCKD診療ガイドライン 2013. 東京医学社, 2013.
 
12) 重永豊一郎, ほか : 腎動脈狭窄の頻度. 血圧 18 : 449-451, 2011.
Medical*Online
13) Preston RA, et al : Ischemic renal disease : an emerging cause of chronic renal failure and end-stage renal disease. J Hypertens 15 : 1365-1377, 1997.
PubMed
14) Losito A, et al : Long-term follow-up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition. Nephrol Dial Transplant 20 : 1604-1609, 2005.
PubMed
15) Moloo J : Renal Artery Stenting Receives the Death Knell. NEJM Journal Watch : General Medicine. December 31, 2013.
 
P.878 掲載の参考文献
1) Hoxie HJ, et al : Renal infarction ; statistical study of 205 cases and detailed report of an unusual case. Arch Intern Med 65 : 587-594, 1940.
 
2) Huang CC, et al : ED presentations of acute renal infarction. Am J Emerg Med 25 : 164-169, 2007.
PubMed
3) Nagasawa T, et al : A case series of acute renal infarction at a single center in Japan. Clin Exp Nephrol 20 : 411-415, 2016.
 
4) Oh YK, et al : Clinical Characteristics and Outcomes of Renal Infarction. Am J Kidney Dis 67 : 243-250, 2016.
PubMed
5) Filip Pone EJ, et al : Segmental arterial mediolysis : report of 2 cases and review of the literature. Am J Kidney Dis 58 : 981-987, 2011.
 
6) Bemanian S, et al : Cocaine-induced renal infarction : report of a case and review of the literature. BMC Nephrol 6 : 10, 2005.
PubMed
7) Bourgault M, et al : Acute renal infarction : acase series. Clin J Am Soc Nephrol 8 : 392-398, 2013.
 
8) Paris B, et al : Blood pressure and renal outcomes in patients with kidney infarction and hypertension. J Hypertens 24 : 1649-1654, 2006.
PubMed
9) Antopolsky M, et al : Renal infarction in the ED : 10-year experience and review of the literature. Am J Emerg Med 30 : 1055-1060, 2012.
PubMed
10) Gault MH, et al : Clinical significance of urinary LDH, alkaline phosphatase and other enzymes. Can Med Assoc J 101 : 208-215, 1969.
PubMed
11) Bae E J, et al : A retrospective study of short-and long-term effects on renal function after acute renal infarction. Ren Fail 36 : 1385-1389, 2014.
 
12) Hazanov N, et al : Acute renal embolism. Forty-four cases of renal infarction in patients with atrial fibrillation. Medicine (Baltimore) 83 : 292-299, 2004.
PubMed
13) Hsiao PJ, et al : Cortical rim sign and acute renal infarction. CMAJ 182 : E313, 2010.
PubMed
14) Salam TA, et al : Local infusion of fibrinolytic agents for acute renal artery thromboembolism : report of ten cases. Ann Vasc Surg 7 : 21-26, 1993.
PubMed
15) Blum U, et al : Effect of local low-dose thrombolysis on clinical outcome in acute embolic renal artery occlusion. Radiology 189 : 549-554, 1993.
PubMed
16) Pellerin O, et al : Spontaneous renal artery dissection : long-term outcomes after endovascular stent placement. J Vasc Interv Radiol 20 : 1024-1030, 2009.
PubMed
17) Nicholas GG, et al : Treatment of renal artery embolism. Arch Surg 119 : 278-281, 1984.
PubMed
P.882 掲載の参考文献
1) Stanley JC, et al : Renal artery aneurysms. Significance of macroaneurysms exclusive of dissections and fibrodysplastic mural dilations. Arch Surg 110 : 1327-1333, 1975.
PubMed
2) McCarron Jp, et al : Indications for surgery on renal artery aneurysms. J Urol 114 : 177-180, 1975.
PubMed
3) Tham G, et al : Renal artery aneurysms. Natural history and prognosis. Ann Surg l97 : 348-352, 1983.
 
4) Henriksson C, et al : Angiographically discovered, non-operated renal artery aneurysms. Scand J Urol Nephrol 18 : 59-62, 1984.
PubMed
5) Zhang LJ, et al : Renal artery aneurysm : diagnosis and surveillance with multidetector-row computed tomography. Acta Radiol 48 : 274-279, 2007.
PubMed
6) Klausner JQ, et al : Current treatment of renal artery aneurysms may be too aggressive. J Vasc Surg 59 : 1356-1361, 2014.
PubMed
7) Klausner JQ, et al : The contemporary management of renal artery aneurysms. J Vasc Surg 61 : 978-984, 2015.
PubMed
8) Wayne EJ, et al : Anatomic characteristics and natural history of renal artery aneurysms during longitudinal imaging surveillance. J Vasc Surg 60 : 448-452, 2014.
PubMed
9) Robinson WP, et al : Favorable outcomes with in situ techniques for surgical repair of complex renal artery aneurysms. J Vasc Surg 53 : 684-691, 2011.
PubMed
10) Pfeiffer T, et al : Reconstruction for renal artery aneurysm : operative techniques and long-term results. J Vasc Surg 37 : 293-300, 2003.
PubMed
11) Hislop SJ, et al : Therapy of renal artery aneurysms in New York State : outcomes of patients undergoing open and endovascular repair. Ann Vasc Surg 23 : 194-200, 2009.
PubMed
12) Tsilimparis N, et al : Endovascular vs open repair of renal artery aneurysms : outcomes of repair and long-term renal function. J Am Coll Surg 217 : 263-269, 2013.
PubMed
13) Poutasse E F : Renal artery aneurysms. J Urol 113 : 443-449, 1975.
PubMed
P.887 掲載の参考文献
1) 日本腎臓学会 (編) : CKD診療ガイド 2012, 日本腎臓学会, 東京医学社, 2012.
 
2) 日本腎臓学会 (編) : エビデンスに基づくCKD診療ガイドライン 2013, 日本腎臓学会, 東京医学社, 2013.
 
3) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン 2014 (JSH 2014). 日本高血圧学会, 2014.
 
4) Hirsch AT, et al : ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric. and abdominal aortic) : a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) : endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation ; National Heart, Lung, and Blood Institute ; Society for Vascular Nursing : Trans Atlantic Inter-Society Consensus ; and Vascular Disease Foundation. Circulation 113 : e463-654, 2006.
 
5) Olin JW, et al : The utility of duplex ultrasound scanning of the renal arteries for diagnosing significant renal artery stenosis. Ann Intern Med 122 : 833-838, 1995.
PubMed
6) Williams GJ, et al : Comparative accuracy of renal duplex sonographic parameters in the diagnosis of renal artery stenosis : paired and unpaired analysis. AJR Am J Roentgenol 188 : 798-811, 2007.
PubMed
7) Vasbinder GB, et al : Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension : a meta-analysis. Ann Intern Med 135 : 401-411, 2001.
PubMed
8) Khoo M M, et al : Renal artery stenosis : comparative assessment by unenhanced renal artery MRA versus contrast-enhanced MRA. Eur Radiol 21 : 1470-1476, 2011.
PubMed
9) Vasbinder GB, et al : Accuracy of computed tomographic angiography and magnetic resonance angiography for diagnosing renal artery stenosis. Ann Intern Med 141 : 674-682 ; discussion 682, 2004.
PubMed
10) van de Ven PJ, et al : Angiotensin converting enzyme inhibitor-induced renal dysfunction in atherosclerotic renovascular disease. Kidney Int 53 : 986-993, 1998.
PubMed
11) Cooper CJ, et al : Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 370 : 13-22, 2014.
PubMed
P.892 掲載の参考文献
1) Saric M, et al : Aortic atherosclerosis and embolic events. Curr Cardiol Rep 14 : 342-349, 2012.
PubMed
2) Scolari F, et al : Atheroembolic renal disease. Lancet 375 : 1650-1660, 2010.
PubMed
3) French Study of Aortic Plaques in Stroke Group ; Amarenco P, et al : Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. N Engl J Med 334 : 1216-1221, 1996.
PubMed
4) Haqqie SS, et al : Nephrotic-range proteinuria in renal atheroembolic disease : report of four cases. Am J Kidney Dis 28 : 493-501, 1996.
PubMed
5) Belenfant X, et al : Supportive treatment improves survival in multivisceral cholesterol crystal embolism. Am J Kidney Dis 33 : 840-850, 1999.
PubMed
6) Moolenaar W, et al : Cholesterol crystal embolization in the Netherlands. Arch Intern Med 156 : 653-657, 1996.
PubMed
7) Saklayen MG, et al : Incidence of atheroembolic renal failure after coronary angiography. A prospective study. Angiology 48 : 609-613, 1997.
PubMed
8) Fukumoto Y, et al : The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization : aprospective study. J Am Coll Cardiol 42 : 211-216, 2003.
 
9) Blauth CI, et al : Atheroembolism from the ascending aorta. An emerging problem in cardiac surgery. J Thorac Cardiovasc Surg 103 : 1104-1111 ; discussion 1111-1112, 1992.
 
10) Blackshear JL, et al : Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation. SPAFTEE Investigators. Stroke Prevention and Atrial Fibrillation. Transesophageal echocardiography. Am J Cardiol 83 : 453-455, A9, 1999.
PubMed
11) Fine MJ, et al : Cholesterol crystal embolization : a review of 221 cases in the English literature. Angiology 38 : 769-784, 1987.
PubMed
12) Scolari F, et al : The challenge of diagnosing atheroembolic renal disease : clinical features and prognostic factors. Circulation 116 : 298-304, 2007.
PubMed
13) Frock J, et al : Atheroembolic renal disease : experience with 22 patients. Nebr Med J 79 : 317-321, 1994.
PubMed
14) Lye WC, et al : Renal cholesterol embolic disease. Case report and review of the literature. Am J Nephrol 13 : 489-493, 1993.
PubMed
15) Dalakos TG, et al : "Malignant" hypertension resulting from atheromatous embolization predominantly of one kidney. Am J Med 57 : 135-138, 1974.
PubMed
16) Kasinath BS, et al : Eosinophilia in the diagnosis of atheroembolic renal disease. Am J Nephrol 7 : 173-177, 1987.
PubMed
17) Cosio FG, et al : Atheroembolic renal disease causes hypocomplementaemia. Lancet 2 : 118-121, 1985.
PubMed
18) Sugimoto T, et al : Systemic cholesterol embolization syndrome associated with myeloperoxidase-anti-neutrophil cytoplasmic antibody. Intern Med 45 : 557-561, 2006.
PubMed
19) Elinav E, et al : Improvement in cholesterol emboli syndrome after iloprost therapy. BMJ 324 : 268-269, 2002.
PubMed
20) Tsunoda S, et al : LDL apheresis as intensive lipid-lowering therapy for cholesterol embolism. Nephrol Dial Transplant 14 : 1041-1042, 1999.
PubMed
21) Scolari F, et al : Predictors of renal and patient outcomes in atheroembolic renal disease : a prospective study. J Am Soc Ncphrol 14 : 1584-1590, 2003.
PubMed
22) Tunick PA, et al : Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol 90 : 1320-1325, 2002,
PubMed
23) Nakayama M, et al : Low-dose prednisolone ameliorates acute renal failure caused by cholesterol crystal embolism. Clin Nephrol 66 : 232-239, 2006.
PubMed
24) Gutierrez Solis E, et al : Atheroembolic renal disease : analysis of clinical and therapeutic factors that influence its progression. Nefrologia 30 : 317-323, 2010.
PubMed
25) Carroccio A, et al : The role of aortic stent grafting in the treatment of atheromatous embolization syndrome : results after a mean of 15 months follow-up. J Vasc Surg 40 : 424-429, 2004.
PubMed
26) Heart Outcomes Prevention Evaluation Study lnvestigators ; Yusuf S, et al : effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 : 145-153, 2000.
PubMed
P.897 掲載の参考文献
1) Wysokinski WE, et al : Clinical characteristics and long-term follow-up of patients with renal vein thrombosis. Am J Kidney Dis 51 : 224-232, 2008.
PubMed
2) Mahmoodi BK, et al : High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome : results from a large retrospective cohort study. Circulation 117 : 224-230, 2008.
PubMed
3) Singhal R, et al : Thromboembolic complications in the nephrotic syndrome : pathophysiology and clinical management. Thromb Res 118 : 397-407, 2006.
PubMed
4) Bellomo R, et al : Membranous nephropathy and thromboembolism : is prophylactic anticoagulation warranted? Nephron 63 : 249-254, 1993.
PubMed
5) Jordan ML, et al : Ten years of experience with vascular complications in renal transplantation. J Urol 128 : 689-692, 1982.
PubMed
6) Osman Y, et al : Vascular complications after live donor renal transplantation : study of risk factors and effects on graft and patient survival. J Urol 169 : 859-862, 2003.
PubMed
7) Vanrenterghem Y, et al : Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet 1 : 999-1002, 1985.
PubMed
8) Glassock RJ : Prophylactic anticoagulation in nephrotic syndrome : a clinical conundrum. J Am Soc Nephrol 18 : 2221-2225, 2007.
PubMed
9) Kerlin BA, et al : Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol 7 : 513-520, 2012.
PubMed
10) Loscalzo J : Venous thrombosis in the nephrotic syndrome. N Engl J Med 368 : 956-958, 2013.
PubMed
11) Llach F, et al : The clinical spectrum of renal vein thrombosis : acute and chronic. Am J Med 69 : 819-827, 1980.
PubMed
12) Kanagasundaram NS, et al : The diagnosis of renal vein thrombosis by magnetic resonance angiography. Nephrol Dial Transplant 13 : 200-202, 1998.
PubMed
13) Sarasin FP, et al : Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int 45 : 578-585, 1994.
PubMed
14) 日本腎臓学会 : エビデンスに基づくCKD診療ガイドライン 2013. 日本腎臓学会雑誌 55 : 732-734, 2013.
 
15) Dupree LH, et al : Use of rivaroxaban in a patient with history of nephrotic syndrome and hypercoagulability. Ann Pharmacother 48 : 1655-1658, 2014.
 
16) Markowitz GS, et al : Renal vein thrombosis treated with thrombolytic therapy : case report and brief review. Am J Kidney Dis 25 : 801-806, 1995.
PubMed
17) Wu CH, et al : Successful outpatient treatment of renal vein thrombosis by low-molecular weight heparins in 3 patients with nephrotic syndrome. Clin Nephrol 65 : 433-440, 2006.
PubMed
18) JCS Joint Working Group : Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009). Circ J 75 : 1258-1281, 2011.
 
P.902 掲載の参考文献
1) Sievers HH, et al : A classification system for the bicuspid aortic valve from 304 surgical specimens. J Thorac Cardiovasc Surg 133 : 1226-1233, 2007.
PubMed
2) Otto CM, et al : Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90 : 844-853, 1994.
PubMed
3) Agmon Y, et al : Aortic valve sclerosis and aortic atherosclerosis : different manifestations of the same disease? Insights from a population-based study. J Am Coll Cardiol 38 : 827-834, 2001.
PubMed
4) Nassimiha D, et al : Rate of progression of valvular aortic stenosis in patients > or=60 years of age. Am J Cardiol 87 : 807-809, A9, 2001.
PubMed
5) Kume T, et al : Rapid progression of mild to moderate aortic stenosis in patients older than 80 years. J Am Soc Echocardiogr 20 : 1243-1246, 2007.
PubMed
6) Ross J Jr, et al : Aortic stenosis. Circulation 38 (1 Suppl) : 61-67, 1968.
 
P.910 掲載の参考文献
1) Nishimura RA, et al : 2014 AHA/ACC guideline for the management of patients with valvular heart disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 : e57-185, 2014.
 
2) Owens DS, et al : Incidence and progression of aortic valve calcium in the Multi-ethnic Study of Atherosclerosis (MESA). Am J Cardiol 105 : 701-708, 2010.
 
3) Minners J, et al : Inconsistencies of echocardiographic criteria for the grading of aortic valve stenosis. Eur Heart J 29 : 1043-1048, 2008.
PubMed
4) Clavel MA, et al : Comparison between transcatheter and surgical prosthetic valve implantation in patients with severe aortic stenosis and reduced left ventricular ejection fraction. Circulation 122 : 1928-1936, 2010.
PubMed
5) Ribeiro H, et al. Transcatheter aortic valve implantation in patients with low-flow, low-gradient aortic stenosis. the prospective rnulti-center TOPAS-TAVI registry. Paper presented at : Transcatheter Cardiovascular Therapeutics 2016 ; October 29 to November 2, 2016 ; Washington DC.
 
6) Yamashita E, et al : Prognostic value of paradoxical low-gradient severe aortic stenosis in Japan : Japanese Multicenter Aortic Stenosis Study, Retrospective (JUST-R) Registry. J Cardiol 65 : 360-368, 2015.
 
7) Kataoka A, et al : Prognostic Impact of Low-Flow Severe Aortic Stenosis in Small-Body Patients undergoing TAVR : the OCEAN-TAVI Registry. J ACC Cardiovasc Imaging, 2017 May 11.
 
8) 高橋利之, ほか (監訳) : 心臓カテーテルハンドブック (第2版), p117, メディカル・サイエンス・インターナショナル, 2004.
 
9) Computed tomography (CT) scanners. OECD DATA. [https://data.oecd.org/healtheqt/computed-tomography-ct-scanners.htm] (2017年6月閲覧)
 
P.916 掲載の参考文献
1) 日本循環器学会循環器病の診断と治療に関するガイドライン (2011年度合同研究班報告) 弁膜疾患の非薬物治療に関するガイドライン (2012年改訂版). [http://www.j-circ.or.jp/guideline/pdf/JCS2012_ookita_h.pdf] (2017年5月閲覧).
 
2) Committee for Scientific Affairs, et al : Thoracic and cardiovascular surgery in Japan during 2014 : Annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 64 : 665-697, 2016.
PubMed
3) 鳥飼慶 : 人工弁の現状と今後の展望 人工臓器 45 (3), 2016.
 
4) Sezai A, et al : Selection of prosthetic valve and evidence-need for the development of Japan's own guidelines. Ann Thorac Cardiovasc Surg 21 : 305-313, 2015.
PubMed
5) Beckmann A, et al : German Heart Surgery Report 2015 : The Annual Updated Registry of the German Society for Thoracic and Cardiovascular Surgery. Thorac Cardiovasc Surg 64 : 462-474, 2016.
PubMed
6) Nishimura RA, et al : 2014 AHA/ACC guideline for the management of patients with valvular heart disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 : e57-185, 2014.
 
7) Poterucha TJ, Goldhaber SZ. Warfarin and Vascular Calcification. Am J Med 129 : 635. e1-4, 2016.
 
8) Ozaki S, et al : Atotal of 404 cases of aortic valve reconstruction with glutaraldehyde-treated autologous pericardium. J Thorac Cardiovasc Surg 147 : 301-306, 2014.
 
9) Ozaki S, et al : Aortic Valve Reconstruction Using Autologous Pericardium for Aortic Stenosis. Circ J 79 : 1504-1510, 2015.
PubMed
10) Brown ML, et al : Ministernotomy versus conventional sternotomy for aortic valve replacement : a systematic review and meta-analysis. J Thorac Cardiovasc Surg 137 : 670-679. e5, 2009.
 
11) Glauber M, et al : International Expert Consensus on Sutureless and Rapid Deployment Valves in Aortic Valve Replacement Using Minimally Invasive Approaches. Innovations (Phila) 11 : 165-173, 2016.
PubMed
12) Cribier A, et al : Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis : first human case description. Circulation 106 : 3006-3008, 2002.
PubMed
13) Leon MB, et al : Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 363 : 1597-1607, 2010.
PubMed
14) Smith CR, et al : Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 364 : 2187-2198, 2011.
PubMed
15) Adams DH, et al : Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 370 : 1790-1798, 2014.
PubMed
P.924 掲載の参考文献
1) Laffan M, et al : The diagnosis of von Willebrand disease : a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 10 : 199-217, 2004.
PubMed
2) Tiede A, et al : How I treat the acquired von Willebrand syndrome. Blood 117 : 6777-6785, 2011.
 
3) Federici AB, et al : Acquired von Willebrand syndrome : data from an international registry. Thromb Haemost 84 : 345-349, 2000.
 
4) Pasi KJ, et al : Management of von Willebrand disease : a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 10 : 218-231, 2004.
PubMed
5) Nichols WL, et al : von Willebrand disease (VWD) : evidence-based diagnosis and management guidellnes, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 14 : 171-232, 2008.
 
6) Tiede A, et al : Diagnostic workup of patients with acquired von Willebrand syndrome : a retrospective single-centre cohort study. J Thromb Haemost 6 : 569-576, 2008.
 
7) Lenting PJ, et al : von Willebrand factor biosynthesis, secretion, and clearance : connecting the far ends. Blood 125 : 2019-2028, 2015.
PubMed
8) Yee A, et al : Visualization of an N-terminal fragment of von Willebrand factor in complex with factor VIII. Blood 126 : 939-942, 2015.
 
9) Yago T, et al : Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. J Clin Invest 118 : 3195-3207, 2008.
 
10) Ng C, et al : Diagnostic approach to von Willebrand disease. Blood 125 : 2029-2037, 2015.
PubMed
11) Blackshear JL et al : von Willebrand Factor Abnormalities and Heyde Syndrome in Dysfunctional Heart Valve Prostheses. JAMA Cardiol 1 : 198-204, 2016.
PubMed
12) Van Belle E, et al : Von Willebrand factor as a biological sensor of blood flow to monitor percutaneous aortic valve interventions. Circ Res 116 : 1193-1201, 2015.
PubMed
13) 厚生労働科学研究費補助金 難治性疾患等克服研究事業 (難治性疾患克服研究事業) 「診断困難な (原因不明の) 出血性後天性凝固異常症の総合的診療指針の作成」AVWS診断の参照ガイド作成委員会 (毛利博, 松下正, 家子正裕, 田村俊寛, 一瀬白帝) : 後天性von Willebrand症候群診断の参照ガイド. 最新医学 71 : 883-890, 2016.
 

VII 血管炎

P.932 掲載の参考文献
1) 難病情報センター. 特定医療費 (指定難病) 受給者証所持者数. [http://www.nanbyou.or.jp/entry/5354] (2017年4月閲覧)
 
2) Fujimoto S, et al : Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U. K. Rheumatology (Oxford) 50 : 1916-1920, 2011.
 
3) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
4) Fries JE et al : The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 33 : 1135-1136, 1990.
 
5) Watts R, et al : Development and validation of a consensus methodology for the clag. sification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66 : 222-227, 2007.
 
6) Yates M, et al : EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75 : 1583-1594, 2016.
 
7) Koster M. et al : Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis. Curr Opin Rheumatol 28 : 211-217, 2016.
PubMed
8) Leib ES, et al : Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med 67 : 941-947, 1979.
PubMed
9) Sada KE, et al : Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis : a nationwide prospective inception cohort study. Arthritis Res Ther 17 : 305, 2015.
PubMed
10) Mukhtyar C, et al : EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 68 : 318-323, 2009.
PubMed
11) Mukhtyar C, et al : EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68 : 310-317, 2009.
PubMed
12) Ntatsaki E, et al : BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford) 53 : 2306-2309, 2014.
PubMed
13) JCS Joint Working Group : Guideline for management of vasculitis syndrome (JCS 2008). Japanese Circulation Society. Circ J 75 : 474-503, 2011.
 
14) 難治性血管炎に関する調査研究班, 進行性腎障害に関する調査研究班 : ANCA関連血管炎の診療ガイドライン (2014年改訂版). [http://www.vas-mhlw.org/pdf/results/aav-guideline.pdf] (2017年4月閲覧)
 
P.939 掲載の参考文献
1) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
2) Fries JF, et al : The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 33 : 1135-1136, 1990.
PubMed
3) Sada KE, et al : Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther 16 : R101, 2014.
 
4) Watts R, et al : Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66 : 222-227, 2007.
PubMed
5) ANCA関連血管炎の診療ガイドライン (愼野博史, 松尾清一), p20-621, 2014.
 
6) Sada KE, et al : Issues associated with the Ministry of Health, Labour and Welfare diagnostic criteria for antineutrophil cytoplasmic antibody-associated vasculitides : Reclassification of patients in the prospective cohort study of Remission Induction Therapy in Japanese patients with ANCA-associated vasculitides according to the MHLW criteria. Mod Rheumatol 25 : 657-659, 2015.
 
7) Lyons PA, et al : Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 367 : 214-223, 2012.
PubMed
8) Rahmattulla C, et al : Genetic variants in ANCA-associated vasculitis : a meta-analysis. Ann Rheum Dis 75 : 1687-1692, 2016.
PubMed
9) Craven A, et al : ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). Clin Exp Nephrol 17 : 619-621, 2013.
PubMed
P.945 掲載の参考文献
1) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
2) 宮崎龍彦 : 血管炎症候群の形態学的診断tips. 診断病理 33 : 19-37, 2016.
Medical*Online
3) Berden AE, et al : Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 21 : 1628-1636, 2010.
PubMed
4) Rahmattulla C, et al : Histopathological classification of antineutrophil cytoplasmic antibody-associated glomerulonephritis : an update. Curr Opin Nephrol Hypertens 23 : 224-231, 2014.
PubMed
5) Endo A, et al : Significance of small renal artery lesions in patients with antineutrophil cytoplasmic antibody-associated glomerulonephritis. J Rheumatol 41 : 1140-1146, 2014.
PubMed
6) Jennette JC, et al : Pauci-immune and antineutrophil cytoplasmic autoantibody-mediated crescentic giomerulonephritis and vasculitis. In : Heptinstall's Pathology of the Kidney 7th ed (ed by Jennette JC, et al), p685-709, Wolters Kluwer. Philadelphia, 2015.
 
7) Houghton DC, et al : An abundance of IgG4+plasma cells is not specific for IgG4-related tubulointerstitial nephritis. Mod Pathol 24 : 1480-1487, 2011.
 
8) Pillebout E, et al : Henoch-Schonlein Purpura in adults : outcome and prognostic factors. J Am Soc Nephrol 13 : 1271-1278, 2002.
PubMed
P.951 掲載の参考文献
1) 高安右人 : 奇異なる網膜中心血管の変化の1例. 日本眼科学会雑誌 12 : 554-555, 1908.
 
2) Takamura C, et al : New human leukocyte antigen risk allele in Japanese patients with Takayasu arteritis. Circ J 76 : 1697-1702, 2012.
PubMed
3) Terao C, et al : Two sしisceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population. Am J Hum Genet 93 : 289-297, 2013.
 
4) Matsumura T, et al : A novel susceptibility locus for Takayasu arteritis in the IL12B region can be a genetic marker of disease severity. Heart Vessels 31 : 1016-1019, 2016.
PubMed
5) Ishihara T, et al : Sensitive assessment of activity of Takayasu's arteritis by pentraxin3, a new biomarker. J Am Coll Cardiol 57 : 1712-1713, 2011.
PubMed
6) Ishihara T. et al : Diagnosis and assessment of Takayasu arteritis by multiple biomarkers. Circ J 77 : 477-483, 2013.
PubMed
7) Tezuka D, et al : Role of FDG PET-CT in Takayasu arteritis : sensitive detection of recurrences. JACC Cardiovasc Imaging 5 : 422-429, 2012.
PubMed
8) Ohigashi H, et al : Improved prognosis of Takayasu arteritis over the past decade-comprehensive analysis of 106 patients. Circ J 76 : 1004-1011, 2012.
PubMed
9) Maksimowicz-McKinnon K, et al : Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 56 : 1000-1009, 2007.
 
10) Molloy ES, et al : Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis : long-term follow-up. Ann Rheum Dis 67 : 1567-1569, 2008.
PubMed
11) Miyata T, et al : Long-term survival after surgical treatment of patients with Takayasu' s arteritis. Circulation 108 : 1474-1480, 2003.
PubMed
12) Park MC, et al : Post-interventional immunosuppressive treatment and vascular restenosis in Takayasu's arteritis. Rheumatology (Oxford) 45 : 600-605, 2006.
PubMed
P.956 掲載の参考文献
1) Kobayashi S, et al : Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan : the first government-sup Ported nationwide survey. Arthritis Rheum 49 : 594-598, 2003.
 
2) Weyand CM, et al : Medium-and large-vessel vasculitis. N Engl J Med 349 : 160-169, 2003.
PubMed
3) Imai N, et al : Giant cell arteritis : clinical features of patients visiting a headache clinic in Japan. Intern Med 50 : 1679-1682, 2011.
PubMed
4) Hoffman GS : Giant Cell Arteritis. Ann Intern Med 165 : ITC65-ITC80, 2016.
PubMed
5) Prieto-Gonzalez S, et al : Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis : a prospective, case-control study. Ann Rheum Dis 73 : 1388-1392, 2014.
PubMed
6) Lariviere D, et al : Positron emission tomography and computed tomography angiography for the diagnosis of giant cell arteritis : A real-life prospective study. Medicine (Baltimore) 95 : e4146, 2016.
PubMed
7) Ninan J, et al : Giant cell arteritis. Best Pract Res Clin Rheumatol 30 : 169-188, 2016.
PubMed
8) Breuer GS, et al : Effect of biopsy length on the rate of positive temporal artery biopsies. Clin Exp Rheumatol 27 (1 Suppl 52) : S10-13, 2009.
 
9) Achkar AA, et al : How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 120 : 987-992, 1994.
PubMed
10) Smetana GW, et al : Does this patient have temporal arteritis? JAMA 287 : 92-101, 2002.
PubMed
11) Gonzalez-Gay MA, et al : Permanent visual loss and cerebrovascular accidents in giant cell arteritis : predictors and response to treatment, Arthritis Rheum 41 : 1497-1504, 1998.
PubMed
12) Danesh-Meyer H, et al : Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 112 : 1098-1103, 2005.
PubMed
13) Hayreh SS, et al : Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 110 : 1204-1215, 2003.
PubMed
14) Stone JH, et al : Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis : Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. 2016 ACR/ARHP Annual Meeting, Abstract Number 911.
 
15) Langford CA, et al : A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. Arthritis Rheumatol 69 : 837-845, 2017.
PubMed
16) Baslund B, et al : Mortality in patients with giant cell arteritis. Rheumatology (Oxford) 54 : 139-143, 2015.
PubMed
P.961 掲載の参考文献
1) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
2) Kussmaul A, et al : Uber eine bisher nicht beschriebenen Eigenthumliche arterienerkrankung (periarteritis nodosa) fie mit Morbus Brightii und rapid fortschreitender allgemeiner muskellah-mung Eihhergeht. Dtsch Arch Klin Med l : 484-518, 1866.
 
3) Stone JH : Polyarteritis nodosa. JAMA 288 : 1632-1639, 2002.
PubMed
4) 中林公正, ほか : 結節性多発動脈炎-Polyarteritis Nodosa, PN-厚生科学研究特定疾患対策研究事業 難治性血管炎に関する調査研究班 (班長 橋本博史). 難治性血管炎の診療マニュアル, p19-23, キタ・メディア, 2002.
 
5) Yalginkaya F, et al : Prevalence of the MEFV gene mutations in childhood polyarteritis nodosa. J Pediatr 151 : 675-678, 2007.
 
6) Navon Elkan P, et al : Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 370 : 921-931, 2014.
 
7) Zhou Q, et al : Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 370 : 9. 11-920, 2014.
 
8) Lightfoot RW, et al : The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 33 : 1088-1093, 1990.
PubMed
9) Jennette JC, et al : Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37 : 187-192, 1994.
PubMed
10) Filer AD, et al : Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa. Ann Rheum Dis 62 : 162-167, 2003.
PubMed
11) Guillevin L : Polyarteritis nodosa and microsucopic polyangiitis. In : Vasculitis (ed by Ball GV, et al), p300-320, Oxford University Press, New York, 2002.
 
12) Coll-Vinent B, et al : Circulating soluble adhesion molecules in patients with classical polyarteritis nodosa. Br J Rheumatol 36 : 1178-1183, 1997.
PubMed
13) 厚生労働省指摘難病42結節性多発動脈炎 [http://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-kenkoukyouku/0000157689.docx]
 
14) Lightfoot RW, et al : The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 33 : 1088-1093, 1990.
PubMed
15) Mukhtyar C, et al : EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68 : 310-317, 2009.
PubMed
16) Guillevin L, et al : Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 75 : 17-28, 1996.
PubMed
17) Guillevin L et al : The Five-Factor Score revisited : assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 90 : 19-27, 2011.
 
P.966 掲載の参考文献
1) 川崎富作 : 指趾の特異的落屑を伴う小児の急性熱性皮膚粘膜淋巴症候群. アレルギー 16 : 178-222, 1967.
 
2) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
3) Uehara R, et al : Kawasaki disease in parents and children. Acta Paediatr 92 : 694-697, 2003.
PubMed
4) Ayusawa M, et al : Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int 47 : 232-234, 2005.
PubMed
5) 中村好一, ほか : 第22回川崎病全国調査成績. 小児科診療 77 : 271-290, 2014.
Medical*Online
6) Newburger JW, et al : Diagnosis, treatment, and long-term management of Kawasaki disease : a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 110 : 2747-2771, 2004.
 
7) 吉野篤範, ほか : 発熱なく冠動脈拡張を来した川崎病と思われる2症例の検討. 日本小児科学会雑誌 15 : 674, 2011.
 
8) Tashiro N, et al : Ultrasonographic evaluation of cervical lymph nodes in Kawasaki disease. Pediatrics 109 : E77-7, 2002.
PubMed
9) 小川俊一, ほか : 川崎病心臓血管後遺症の診断と治療に関するガイドライン (2013年改訂版). 日本循環器学会 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告), 2013.
 
10) Onouchi Y, et al : A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet 44 : 517-521, 2012.
PubMed
11) Newburger JW, et al : A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324 : 1633-1639, 1991.
PubMed
12) 佐地勉, ほか : 川崎病急性期治療のガイドライン. 日本小児循環器学会雑誌 28 (Supple 3) : 4997-5028, 2012.
 
13) Shinohara M, et al : Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr 135 : 465-469, 1999.
PubMed
14) Kobayashi T, et al : Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study) : a randomised, open-label, blindedendpoints trial. Lancet 379 : 1613-1620, 2012.
PubMed
15) Burns JC, et al : Infliximab treatment for refractory Kawasaki syndrome. J pediatr 146 : 662-667, 2005.
PubMed
P.971 掲載の参考文献
1) Guillevin L, et al : Microscopic polyangiitis : clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42 : 421-430, 1999.
PubMed
2) Watts RA, et al : Effect of classification on the incidence of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum 39 : 1208-1212, 1996.
PubMed
3) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-I L2013.
 
4) Fujimoto S, et al : Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U. K. Rheumatology (Oxford) 50 : 1916-1920, 2011.
 
5) Mukhtyar C, et al : Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis : a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 67 : 1004-1010, 2008.
PubMed
6) Basu N, et al : EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis 69 : 1744-1750, 2010.
PubMed
7) Mahr A, et al : Brief report : prevalence of antineutrophil cytoplasmic antibodies in infective endocarditis. Arthritis Rheumatol 66 : 1672-1677, 2014.
PubMed
8) Abe Y, et al : Predictive factors for mortality in elderly Japanese patients with severe microscopic polyangiitis : A retrospective single-center study. Mod Rheumatol 27 : 315-319, 2017.
PubMed
9) Ozaki S, et al : Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis : the JMAAV study. Mod Rheumatol 22 : 394-404, 2012.
PubMed
10) Lapraik C, et al : BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 46 : 1615-1616, 2007.
PubMed
11) de Groot K, et al : Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis : a randomized trial. Ann Intern Med 150 : 670-680, 2009.
PubMed
12) Stone JH, et al : Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363 : 221-232, 2010.
PubMed
13) Koldingsnes W, et al : Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis. J Rheumatol 30 : 80-88, 2003.
PubMed
14) Faurschou M, et al : Malignancies in Wegener's granulomatosis : incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35 : 100-105, 2008.
 
15) Pagnoux C, et al : Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older : results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol 67 : 1117-1127, 2015.
PubMed
P.977 掲載の参考文献
1) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
2) Watts RA, et al : ANCA vasculitis : to lump or split? Why we should study MPA and GPA separately. Rheumatology (Oxford) 51 : 2115-2117, 2012.
PubMed
3) Sada KE, et al : Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther 16 : R101, 2014.
 
4) Kessenbrock K, et al : Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 6 : 623-625, 2009.
PubMed
5) Harabuchi Y, et al : Clinical features and treatment outcomes of otitis media with antineutrophil cytoplasmic antibody (ANCA) -associated vasculitis (OMAAV) : A retrospective analysis of 235 patients from a nationwide survey in Japan. Mod Rheumatol 27 : 87-94, 2017.
PubMed
6) Furuta S, et al : Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan. J Rheumatol 41 : 325-333, 2014.
PubMed
7) Watts R, et al : Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66 : 222-227, 2007.
PubMed
8) 愼野博史 : ANCA関連血管炎の診療ガイドライン. 厚生労働省難治性疾患克服研究事業難治性血管炎に関する調査研究班, 2014年改訂版, p21, 2014.
 
9) Mukhtyar C, et al : EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68 : 310-317, 2009.
PubMed
10) Lapraik C, et al : BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 46 : 1615-1616. 2007.
PubMed
11) de Groot K, et al : Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis : a randomized trial. Ann Intern Med 150 : 670-680, 2009.
PubMed
12) Harper L, et al : Pulse versus daily oral cyclophosphamide for induction of remission in ANC Aassociated vasculitis : long-term follow-up. Ann Rheum Dis 71 : 955-960, 2012.
 
13) Guillevin L, et al : A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 40 : 2187-2198, 1997.
 
14) de Groot K, et al : Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis : a randomized trial. Ann Intern Med 150 : 670-680, 2009.
PubMed
15) Popa ER, et al : Staphylococcus aureus and Wegener's granulomatosis. Arthritis Res 4 : 77-79, 2002.
PubMed
P.982 掲載の参考文献
1) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
2) Mohammad AJ, et al : Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford) 48 : 1560-1565, 2009.
PubMed
3) Sada KE, et al : Anationwide survey on the epidemiology and clinical feattlres of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) in Japan. Mod Rheumatol 24 : 640-644, 2014.
 
4) Watts R, et al : Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66 : 222-227, 2007.
PubMed
5) Comarmond C, et al : Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) : clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 65 : 270-281, 2013.
 
6) Groh M, et al : Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 26 : 545-553, 2015.
PubMed
7) Lanham JG, et al : Systemic vasculitis with asthma and eosinophilia : a clinical ap Proach to the Churg-Strauss syndrome. Medicine (Baltimore) 63 : 65-81, 1984.
 
8) 釣木澤尚美 : Churg-Strauss症候群の多発単神経炎に対する治療. リウマチ科 40 : 509-518, 2008.
 
9) Bacciu A, et al : Nasal polyposis in Churg-Strauss syndrome. Laryngoscope 118 : 325-329. 2008.
PubMed
10) Moosig F, et al : A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA) : monocentric experiences in 150 patients. Ann Rheum Dis 72 : 1011-1017, 2013.
PubMed
11) Hattori N, et al : Clinicopathological features of Churg-Strauss syndrome-associated neuropathy. Brain 122 (Pt 3) : 427-439, 1999.
 
12) Santos-Pinheiro F, et al : Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) presenting with polyneuropathy-a case series. J Clin Neuromuscul Dis 16 : 125-130, 2015.
 
13) Neumann T, et al : Cardiac involvement in Churg-Strauss syndrome : impact of endomyocarditis. Medicine (Baltimore) 88 : 236-243, 2009.
PubMed
14) Bourgarit A, et al : Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome : a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 84 : 323-330, 2005.
PubMed
15) Dunogue B, et al : Impact of cardiac magnetic resonance imaging on eosinophilic granulomatosis with polyangiitis outcomes : A long-term retrospective study on 42 patients. Autoimmun Rev 14 : 774-780, 2015.
PubMed
16) Cottin V, et al : Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss) : A study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmunol Rev 16 : 1-9, 2017.
 
17) Pagnoux C, et al : Optimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Expert Rev Clin Immunol 12 : 1059-1067, 2016.
PubMed
18) Guillevin L, et al : Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 75 : 17-28, 1996.
PubMed
19) Ribi C, et al : Treatment of Churg-Strauss syndrome without poor-prognosis factors : a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 58 : 586-594, 2008.
PubMed
20) Gayraud M, et al : Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome : analysis of four prospective trials including 278 patients. Arthritis Rheum 44 : 666-675, 2001.
PubMed
21) Cohen P, et al : Churg-Strauss syndrome with poor-prognosis factors : A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphalnide pulses in forty-eight patients. Arthritis Rheum 57 : 686-693, 2007.
PubMed
22) McGeoch L, et al : Can Vasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitides. J Rheumatol 43 : 97-120, 2016.
 
23) Metzler C, et al : Churg Strauss syndrome-successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 22 : S52-61, 2004.
PubMed
24) Samson M, et al : Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun 43 : 60-69, 2013.
PubMed
25) Koike H, et al : Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) : a multicenter, double-blind trial. J Neurol 262 : 752-759, 2015.
 
26) Fanouriakis A, et al : Rituximab for eosinophilic granulomatosis with polyangiitis with severe vasculitic neuropathy : Case report and review of current clinical evidence. Semin Arthritis Rheum 45 : 60-66, 2015.
PubMed
P.986 掲載の参考文献
1) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
2) Koyama A, et al : A nationwide survey of rapidly progressive giomerulonephritis in Japan : etiology, prognosis and treatment diversity. Clin Exp Nephrol 13 : 633-650, 2009.
 
3) Fisher M, et al : Susceptibility to anti-glomerular basement membrane disease is strongly associated with HLA-DRBI genes. Kidney Int 51 : 222-229, 1997.
 
4) 厚生労働省特定疾患進行性腎障害に関する調査研究班 : 急速進行性腎炎症候群の診療指針 (第2版). 日本腎臓学会誌 53 : 509-555, 2011.
 
5) 松尾清一, ほか : エビデンスに基づく急速進行性腎炎症候群 (RPGN) 診療ガイドライン 2014. 日本腎臓学会誌 57 : 139-232, 2015.
 
6) CKD診療ガイド 2012 (日本腎臓病学会 (編)). 東京医学社, 2012.
 
P.992 掲載の参考文献
1) Brouet J C, et al : Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 57 : 775-788, 1974.
PubMed
2) Lamprecht P, et al : Cryoglobulinemic vasculitis. Arthritis Rheum 42 : 2507-2516, 1999.
PubMed
3) Ferri C, et al : Cryoglobulinemic vasculitis. Curr Opin Rheumatol 18 : 54-63, 2006.
PubMed
4) Santagostino E, et al : High prevalence of serum cryoglobulins in multitransfused hemophilic patients with chronic hepatitis C. Blood 92 : 516-519, 1998.
PubMed
5) Dammacco F, et al : The expanding spectrum of H C V-related cryoglobulinemic vasculitis : anarrative review. Clin Exp Med 16 : 233-242, 2016.
 
6) 吉田健 : 全身性自己免疫疾患 クリオフィブリノーゲン血症. 別冊日本臨牀 免疫症候群 (第2版) -その他の免疫疾患を含めて-, p729-733, 日本臨牀社, 2015.
 
7) C型肝炎治療ガイドライン (第5.1版), 日本肝臓学会肝炎診療ガイドライン作成委員会 (編) t2016.
 
8) De Vita S, et al : Arandomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 64 : 843-853, 2012.
 
9) Sneller MC, et al : A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 64 : 835-842, 2012.
PubMed
10) Cacoub P, et al : Cryoglobulinemia Vasculitis. Am J Med 128 : 950-955, 2015.
PubMed
P.996 掲載の参考文献
1) Trnka P : Henoch-Schonlein purpura in children. J Paediatr Child Health 49 : 995-1003, 2013.
 
2) Jennette J C, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
3) Gonzalez-Gay MA, et al : Implications of upper respiratory tract infections and drugs in the clinical spectrum of Henoch-Schonlein purpura in children. Clin Exp Rheumatol 22 : 781-784, 2004.
PubMed
4) Suzuki H, et al : The pathophysiology of Ig A nephropathy. J Am Soc Nephrol 22 : 1795-1803, 2011.
 
5) Suzuki H, et al : Aberrantly glycosylated IgA1 in Ig A nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 119 : 1668-1677, 2009.
 
6) Rigante D, et al : Is there a crossroad between infections, genetics, and Henoch-Schonlein purpura? Autoimmun Rev 12 : 1016-1021, 2013.
 
7) Saulsbury FT : Clinical update : Henoch-Schonlein purpura. Lancet 369 : 976-978, 2007.
PubMed
8) Audemard-Verger A, et al : IgA vasculitis (Henoch-Shonlein purpura) in adults : Diagnostic and therapeutic aspects. Autoimmun Rev 14 : 579-585, 2015.
PubMed
9) Mills J A, et al : The American College of Rheumatology 1990 criteria for the classification of Henoch-Schonlein purpura. Arthritis Rheum 33 : 1114-1121, 1990.
PubMed
10) Ozen S, et al : EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis : Ankara 2008. Part II : Final dassification criteria. Ann Rheum Dis 69 : 798-806, 2010.
 
11) Tizard EJ, et al : Henoch Schonlein ptlrpura. Arch Dis Child Educ Pract Ed 93 : 1-8, 2008.
PubMed
12) Pillebout E : Adult Henoch-Schonlein purpura. Presse Med 37 : 1773-1778, 2008.
PubMed
13) Garzoni L, et al : Nervous system dysfunction in Henoch-Schonlein syndrome : systematic review of the literature. Rheumatology (Oxford) 48 : 1524-1529, 2009.
PubMed
14) 尾崎承一, ほか : 循環器病の診断と治療に関するガイドライン (2006-2007年度合同研究班報告) 血管炎症候群の診療ガイドライン VI. 小型血管炎 4. ヘノッホ・シェーンライン紫斑病. Circulation Journal 72 (Suppl IV) : 1303-1305, 2008.
 
15) 川上民裕 : 血管炎の診断と治療一新分類CHCC2012に沿ってIgA血管炎 (Henoch-Schonlein). 医学のあゆみ 246 : 72-73, 2013.
 
P.1003 掲載の参考文献
1) 中江公裕 : ベーチェット病患者全国疫学調査成績. 厚生省特定疾患ベーチェット病調. 査研究班. 平成5年度研究業績, p53-54, 1994.
 
2) Hirohata S, et al : Beh Cet' s disease. Arthritis Res Ther 5 : 139-146, 2003.
 
3)Kobayashi M, et al : Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behcet disease. Histopathology 36 : 362-371, 2000.
PubMed
4) Katoh K, et al : Pathologically defined neuro-, vasculo-, entero-Behcet's disease. J Rheumatol 12 : 1186-1190, 1985.
 
5) Hirohata S, et al : Histopathology of the ruptured pulmonary artery aneurysm in a patient with Behget's disease. Clin Exp Rheumatol 27 : S91-95, 2009.
 
6) Shimizu T, et al : Behget disease (Behcet syndrome). Semin Arthritis Rheum 8 : 223-260, 1979.
 
7) Zhu YL, et al : The clinical characteristics and outcome of intracardiac thrombus and aortic valvular involvement in Behcet's disease : an analysis of 20 cases. Clin Exp Rheumatol 30 : S40-45, 2012.
PubMed
8) Ideguchi H, et al : Characteristics of vascular involvement in Behcet's disease in Japan : a retrospective cohort study. Clin Exp Rheumatol 29 : S47-53, 2011.
PubMed
9) Erkan F, et al : Pulmonary vasculitis in Behcet's disease. Am Rev Respir Dis 146 : 232-239, 1992.
PubMed
10) Temizoz O, et al : CT-angiographic demonstration of hepatic collateral pathways due to superior vena cava obstruction in Behget disease. Diagn Interv Radiol 16 : 302-305, 2010.
 
11) Cronstein BN, et al : Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 96 : 994-1002, 1995.
PubMed
12) Desbois AC, et al : Immunosuppressants reduce venous thrombosis relapse in Behcet's disease. Arthritis Rheum 64 : 2753-2760, 2012.
PubMed
13) Hatemi G, et al : EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 67 : 1656-1662, 2008.
PubMed
14) Adler S, et al : Behcet's disease : successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis. Arthritis Care Res (Hoboken) 64 : 607-611, 2012.
PubMed
15) Baki K, et al : Behcet's disease with life-threatening haemoptoe and pulmonary aneurysms : complete remission after infliximab treatment. Ann Rheum Dis 65 : 1531-1532, 2006.
PubMed
P.1006 掲載の参考文献
1) Cogan DS : Syndrome of nonsyphilitic interstitial keratitis and vestibuloauditory symptoms. Arch Ophthalmol 33 : 144-149, 1945.
 
2) Tayer-Shifman OE, et al : Cogan's syndrome-clinical guidelines and novel therapeutic approaches. Clin Rev Allergy Immunol 47 : 65-72, 2014.
PubMed
3) Kessel A, et al : Cogan syndrome-pathogenesis, clinical variants and treatment approaches. Autoimmun Rev 13 : 351-354, 2014.
PubMed
4) Lunardi C, et al : Autoantibodies to inner ear and endothelial antigens in Cogan's syndrome. Lancet 360 : 915-921, 2002.
PubMed
5) Fisher ER, et al : Cogan's syndrome and systemic vascular disease. Analysis of pathologic features with reference to its relationship to thromboangiitis obliterans (Buerger). Arch Pathol 72 : 572-592, 961.
 
6) Gluth MB, et al : Cogan syndrome : a retrospective review of 60 patients throughout a half century. Mayo Clin Proc 81 : 483-488, 2006.
PubMed
7) Orsoni JG, et al : Rituximab ameliorated severe hearing loss in Cogan's syndrome : a case report. Orphanct J Rarc Dis 5 : 18, 2010.
 
8) St Clair EW, et al : Cogan's syndrome. Curr Opin Rheumatol 11 : 47-52, 1999.
PubMed
9) Allen NB, et al : Use of immunosuppressive agents in the treatment of severe ocular and vascular manifestations of Cogan's syndrome. Am J Med 88 : 296-301, 1990.
PubMed
10) Shibuya M, et al : Successful treatment with tocilizumab in a case of Cogan's syndrome complicated with aortitis. Mod Rheumatol 23 : 577-581, 2013.
 
P.1010 掲載の参考文献
1) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
2) Mahr A, et al : Classification and classification criteria for vasculitis : achievements, Iimitations and prospects. Curr Opin Rheumatol 27 : 1-9, 2015.
PubMed
3) Mahr A, et al : L47. Single-organ vasculitis : conceptual and practical considerations. Presse Med 42 : 628-634, 2013.
PubMed
4) Atisha-Fregoso Y, et al : Localized, single-organ vasculitis : clinical presentation and management. Clin Rhcumatol 32 : 1-6, 2013.
PubMed
5) Jennette JC, et al : Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37 : 187-192, 1994.
PubMed
6) Loricera J, et al : Single-organ cutaneous small-vessel vasculitis according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides : astudy of 60 patients from a series of 766 cutaneous vasculitis cases. Rheumatology (Oxford) 54 : 77-82, 2015.
 
7) Furukawa F : Cutaneous polyarteritis nodosa : an update. Ann Vasc Dis 5 : 282-288, 2012.
PubMed
8) Kawakami T, et al : Treatment for cutaneous arteritis patients with mononeuritis multiplex and elevated C-reactive protein. J Dermatol 40 : 955-961, 2013.
PubMed
9) Prete M, et al : Vasculitides : Proposal for an integrated nomenclature. Autoimmun Rev 15 : 167-173, 2016.
PubMed
10) Hajj-Ali RA, et al : Primary angiitis of the central nervous system. In : Textbook of Rheumatology (ed by Firestein GS, et al), p1581-1588, Elsevier, Philadelphia, 2017.
 
11) Espitia O, et al : Comparison of idiopathic (isolated) aortitis and giant cell arteritis-related aortitis. A French retrospective multicenter study of 117 patients. Autoimmun Rev 15 : 571-576, 2016.
PubMed
12) Hernandez-Rodriguez J, et al : Testicular vasculitis : findings differentiating isolated disease from systemic disease in 72 patients. Medicine (Baltimore) 91 : 75-85, 2012.
PubMed
13) Hernandez-Rodriguez J, et al : Single-organ gallbladder vasculitis : characterization and distinction from systemic vasculitis involving the gallbladder. An analysis of 61 patients. Medicine (Baltimore) 93 : 405-413, 2014.
PubMed
P.1015 掲載の参考文献
1) Rahman A, et al : Systemic lupus erythematosus. N Engl J Med 358 : 929-939, 2008.
PubMed
2) Akahoshi M, et al : Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum 42 : 1644-1648, 1999.
PubMed
3) Shiozawa F, et al : Enhanced expression of interferon-inducible protein 10 associated with Th1 profiles of chemokine receptor in autoimmune pulmonary inflammation of MRL/lpr mice. Arthritis Res Ther 6 : R78-R86, 2004.
PubMed
4) Tucci M, et al : Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clin Exp Immunol 154 : 247-254, 2008.
 
5) Yang J, et al : Thl7 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum 60 : 1472-1483, 2009.
 
6) Petri M, et al : Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64 : 2677-2686, 2012.
PubMed
7) Wallace DJ : Clinical Aspects of Vasculitis and Selected Cutaneovascular Manifestations of Systemic Lupus Erythematosus. In : Dubois' Lupus Erythematosus, 7th ed, p700-706, Lippincott Williams and Wilkins, Philadelphia, 2007.
 
8) Ramos-Casals M et al : Vasculitis in systemic lupus erythematosus : prevalence and clinical characteristics in 670 patients. Medicine (Baltimore) 85 : 95-104, 2006.
PubMed
9) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
10) Silpa-archa S, et al : Ocular manifestations in systemic lupus erythematosus. Br J Ophthalmol 100 : 135-141, 2016.
PubMed
11) Zamora MR, et al : Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine (Baltimore) 76 : 192-202, 1997.
PubMed
12) Sultan SM, et al : A review of gastrointestinal manifestations of systemic lupus erythematosus. Rheumatology (Oxford) 38 : 917-932, 1999.
PubMed
13) Jarrot PA, et al : Systemic Lupus Erythematosus and Antineutrophil Cytoplasmic Antibody- Associated Vasculitis Overlap Syndrome in Patients With Biopsy-Proven Glomerulonephritis. Medicine (Baltimore) 95 : e3748, 2016.
PubMed
14) 古川福美, ほか : ヒドロキシクロロキン適正使用の手引き. 日本皮膚科学会雑誌 125 : 2049-2060, 2015.
 
P.1021 掲載の参考文献
1) Sokoloff L, et al : Arteritis of striated muscle in rheumatoid arthritis. Am J Pathol 27 : 157-173, 1951.
PubMed
2) Bevans M, et al : The systemic lesions of malignant rheumatoid arthritis. Am J Med 16 : 197-211, 1954.
PubMed
3) 厚生労働省ホームページ 平成27年1月1日施行の指定難病 (新規) 46 悪性関節リウマチ. [http://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkoukyoku/0000089863.pdf] (2017年5月閲覧)
 
4) Ntatsaki E, et al : Systemic rheumatoid vasculitis in the era of modern immunosuppressive therapy. Rheumatology (Oxford) 53 : 145-152, 2014.
PubMed
5) Turesson C, et al : Association of H L A-C3 and smoking with vasculitis in patients with rheumatoid arthritis. Arthritis Rheum 54 : 2776-2783, 2006.
 
6) Turesson C, et al : Vasculitis in rheumatoid arthritis. Curr Opin Rheumatol 21 : 35-40, 2009.
PubMed
7) Scott DG, et al : IgG rheumatoid factor, complement and immune complexes in rheumatoid synovitis and vasculitis : comparative and serial studies during cytotoxic therapy. Clin Exp lmmunol 43 : 54-63, 1981.
PubMed
8) Turesson C, et al : Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 66 : 59-64, 2007.
PubMed
9) Puechal X, et al : Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis. A clinicopathologic and prognostic study of thirty-two patients. Arthritis Rheum 38 : 1618-1629, 1995.
PubMed
10) Heurkens A H, et al : Anti-endothelial cell antibodies in patients with rheumatoid arthritis complicated by vasculitis. Clin Exp Immunol 78 : 7-12, 1989.
PubMed
11) Scott DG, et al : Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med 76 : 377-384, 1984.
PubMed
12) Puechal X, et al ; Club Rhumatismes et lnflammation (CRI) : Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. Ann Rheum Dis Jun 67 : 880-884, 2008.
 
13) Puechal X, et al : Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis : Results from the Autolmmunity and Rituximab Registry. Arthritis Care Res (Hoboken) 64 : 331-339, 2012.
PubMed
14) Hidaka T, et al : Efficacy of filtration leukocytapheresis on rheumatoid arthritis with vasculitis. Ther Apher 1 : 212-214, 1997.
PubMed
15) 松岡康夫 : 悪性関節リウマチ. 難治性血管炎の診療マニュアル (班長 : 橋本博史), p35-40, 厚生科学研究特定疾患対策研究事業 難治性血管炎に関する調査研究班, 2002.
 
P.1026 掲載の参考文献
1) 武村民子, ほか : サルコイドーシス肺における肉芽腫性血管炎の病理学的検討. 日本サルコイドース学会雑誌 10 : 77-78, 1991.
 
2) Hoitsma E, et al : Impact of pain in a Dutch sarcoidosis paticnt population. Sarcoidosis Vasc Diffuse Lung Dis 20 : 33-39, 2003.
 
3) Negi M, et al : Localization of propionibacterium acnes in granulomas supports a possible etiologic link between sarcoidosis and the bacterium. Mod Pathol 25 : 1284-1297, 2012.
PubMed
4) 難病情報センター特定疾患医療受給者証所持者数. [http://www.nanbyou.or.jp/entry/1356] (2017年6月閲覧)
 
5) 日本サルコイドーシス/肉芽腫性疾患学会 : サルコイドーシスの診断基準. [http://jssog.com/www/top/shindan/shindan2-1.html] (2017年6月閲覧)
 
6) Swanton RH : Sarcoidosis of the heart. Eur Heart J g (Suppl G) : 169-174, 1988.
 
7) 磯部光章 : 心臓限局性サルコイドーシスの臨床. 日本内科学会雑誌 104 : 120-127, 2015.
 
8) Yoshida Y, et al : Incidence of cardiac sarcoidosis in Japanese patients with high-degree atrioventricular block. Am Heart J 134 : 382-386, 1997.
PubMed
9) Kaminaga T, et al : The role of iodine-123-labeled l5-(p-iodophenyl) -3 R, S-methylpentadecanoic acid scintigraphy in the detection of local myocardial involvement of sarcoidosis. Int J Cardiol 94 : 99-103, 2004.
 
10) Uemura A, et al : Histologic diagnostic rate of cardiac sarcoidosis : evaluation of endomyocardial biopsies. Am Heart J 138 : 299-302, 1999.
PubMed
11) Tadamura E, et al : Effectiveness of delayed enhanced MRI for identification of cardiac sarcoidosis : comparison with radionuclide imaging. AJR Am J Roentgenol 185 : 110-115, 2005.
PubMed
12) Smedema JP, et al : Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 45 : 1683-1690, 2005.
PubMed
13) Okumura W, et al : Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 45 : 1989-1998, 2004.
PubMed
14) 石田良雄, ほか : 心サルコイドーシスのPET診断のガイドライン (日本心臓核医学会) 心臓サルコイドーシスに対する18F FDG PET検査の手引き. 日本心臓核医学会ニュースレター 15 : 35-47, 2013.
 
15) Langah R, et al : Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 16 : 801-810, 2009.
PubMed

VIII 動脈・静脈疾患の基礎研究動向

P.1036 掲載の参考文献
1) Yamashita A, et al : Detection of von Willebrand factor and tissue factor in platelets-fibrin rich coronary thrombi in acute myocardial infarction. Am J Cardiol 97 : 26-28, 2006.
PubMed
2) Nishihira K, et al : Organized thrombus in aspirated coronary materials can predict in-hospital mortality of patients with acute myocardial infarction. Circ J 77 : 1275-1280, 2013.
PubMed
3) Yamashita A, et al : Paucity of CD34-positive cells and increased expression of high-mobility group box 1 in coronary thrombus with type 2 diabetes mellitus. Atherosclerosis 224 : 511-514, 2012.
PubMed
4) Vergallo R, et al : Prevalence and Predictors of Multiple Coronary Plaque Ruptures : In Vivo 3-Vessel Optical Coherence Tomography Imaging Study. Arterioscler Thromb Vasc Biol 36 : 2229-2238, 2016.
PubMed
5) Okuyama N, et al : Human coronary thrombus formation is associated with degree of plaque disruption and expression of tissue factor and hexokinase II. Circ J 79 : 2430-2438, 2015.
PubMed
6) Yamashita A, et al : Arterial (18) F-fluorodeoxyglucose uptake reflects balloon catheter-induced thrombus formation and tissue factor expression via nuclear factor-κB in rabbit atherosclerotic lesions. Circ J 77 : 2626-2635, 2013.
 
7) Matsuura Y, et al : Vascular wall hypoxia promotes arterial thrombus formation via augmentation of vascular thrombogenicity. Thromb Haemost 114 : 158-172, 2015.
PubMed
8) Sumi T, et al : Disturbed blood flow induces erosive injury to smooth muscle cell-rich neointima and promotes thrombus formation in rabbit femoral arteries. J Thromb Haemost 8 : 1394-1402, 2010.
PubMed
9) Quillard T, et al : TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment : implications for superficial erosion. Eur Heart J 36 : 1394-1404, 2015.
PubMed
10) Nishimura S, et al : In vivo imaging visualizes discoid platelet aggregations without endothelium disruption and implicates contribution of inflammatory cytokine and integrin signaling. Blood 119 : e45-56, 2012.
PubMed
11) Furukoji E, et al : CDI63 macrophage and erythrocyte contents in aspirated deep vein thrombus are associated with the time after onset : apilot study. Thromb J 14 : 46, 2016.
 
12) Sugita C, et al : Elevated plasma factor VIII enhances venous thrombus formation in rabbits : contribution of factor XI, von Willebrand factor and tissue factor. Thromb Haemost 110 : 62-75, 2013.
PubMed
13) Martinod K, et al : Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc Natl Acad Sci USA 110 : 8674-8679, 2013.
PubMed
14) Takahashi M, et al : Inhibition of factor X I reduces thrombus formation in rabbit jugular vein under endothelial dentldation and/or blood stasis. Thromb Res 125 : 464-470, 2010.
PubMed
15) von Br Uhl ML, et al : Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 209 : 819-835, 2012.
 
P.1042 掲載の参考文献
1) Latz E, et al : Activation and regulation of the inflammasomes. Nat Rev Immunol 13 : 397-411, 2013.
PubMed
2) Takahashi M : NLRP3 inflammasome as a novel player in myocardial infarction. Int Heart J 55 : 101-105, 2014.
PubMed
3) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
4) Saijo S, et al : Dectin-2 recognition of alpha-mannans and induction of Thl7 cell differentiation is essential for host dcfcnse against Candida albicans. Immunity 32 : 681-691, 2010.
 
5) Stock AT, et al : GM-CSF primes cardiac inflammation in a mouse model of Kawasaki disease. J Exp Med 213 : 1983-1998, 2016.
 
6) Libby P : Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 32 : 2045-2051, 2012.
PubMed
7) Michelsen KS, et al : Role of Toll-like receptors in atherosclerosis. Circ Res 95 : e96-97, 2004.
PubMed
8) Stewart CR, et al : CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 11 : 155-161, 2010.
PubMed
9) Tedgui A, et al : Cytokines in atherosclerosis : pathogenic and regulatory pathways. Physiol Rev 86 : 515-581, 2006.
PubMed
10) Duewell P, et al : NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464 : 1357-1361, 2010.
PubMed
11) Karasawa T, et al : Role of NLRP3 inflammasomes in atherosclerosis. J Atheroscler Thromb 24 : 443-451, 2017.
PubMed
12) Usui F, et al : Critical role of caspase-l in vascular inflammation and development of atherosclerosis in Western diet-fed apolipoprotein E-deficient mice. Biochem Biophys Res Commun 425 : 162-168, 2012.
 
13) Razani B, et al : Autophagy links inflammasomes to atherosclerotic progression. Cell Metab 15 : 534-544, 2012.
PubMed
14) Saghazadeh A, et al : Inflammation as a cause of venous thromboembolism. Crit Rev Oncol Hematol 99 : 272-285, 2016.
PubMed
P.1047 掲載の参考文献
1) Ross R : Atherosclerosis-an inflammatory disease. N Engl J Med 340 : 115-126, 1999.
PubMed
2) Brown DI, et al : Regulation of signal transduction by reactive oxygen species in the cardiovascular system. Circ Res 116 : 531-549, 2015.
PubMed
3) Brandes R P, et al : Nox family NADPH oxidases in mechano-transduction : mechanisms and consequences. Antioxid Redox Signal 20 : 887-898, 2014.
PubMed
4) Bedard K, et al : The NOX family of ROS-generating NADPH oxidases : physiology and pathophysiology. Physiol Rev 87 : 245-313, 2007.
PubMed
5) Ago T, et al : Pathophysiological roles of NADPH oxidase/nox family proteins in the vascular system. -Review and perspective-. Circ J 75 : 1791-1800, 2011.
PubMed
6) Sumimoto H : Structure, regulation and evolution of Nox-family NADPH oxidases that produce reactive oxygen species. FEBSJ 275 : 3249-3277, 2008.
PubMed
7) Matsuno K, et al : Noxl is involved in angiotensin II-mediated hypertension : a study in Noxl-deficient mice. Circulation 112 : 2677-2685, 2005.
PubMed
8) Tojo T, et al : Role of gp91phox (Nox2) -containing NAD (P) H oxidase in angiogenesis in response to hindlimb ischemia. Circulation 111 : 2347-2355, 2005.
PubMed
9) Ray R, et al : Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler Thromb Vasc Biol 31 : 1368-1376, 2011.
PubMed
10) Craige SM, et al : NADPH oxidase 4 promotes endothelial angiogenesis through endothelial nitric oxide synthase activation. Circulation 124 : 731-740, 2011.
PubMed
11) Cai H, et al : Endothelial dysfunction in cardiovascular diseases : the role of oxidant stress. Circ Res 87 : 840-844, 2000.
PubMed
12) Dimmeler S, et al : Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399 : 601-605, 1999.
PubMed
13) Landmesser U, et al : Endothelial function : a critical determinant in atherosclerosis? Circulation 109 : II27-33, 2004.
PubMed
14) Deanfield JE, et al : Endothelial function and dysfunction : testing and clinical relevance. Circulation 115 : 1285-1295, 2007.
PubMed
15) Davidson SM, et al : Endothelial mitochondria : contributing to vascular function and disease. Circ Res 100 : 1128-1141, 2007.
PubMed
16) Dikalov SI, et al : Angiotensin II-induced production of mitochondrial reactive oxygen species : potential mechanisms and relevance for cardiovascular disease. Antioxid Redox Signal 19 : 1085-1094, 2013.
 
17) Dikalov S : Cross talk between mitochondria and NADPH oxidases. Free Radic Biol Med 51 : 1289-1301, 2011.
PubMed
18) Yamagishi S : Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol 46 : 217-224, 2011.
PubMed
19) Muniyappa R, et al : Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord 14 : 5-12, 2013.
PubMed
20) Sawamura T, et al : An endothelial receptor for oxidized low-density lipoprotein. Nature 386 : 73-77, 1997.
PubMed
21) Cucoranu I, et al : NAD (P) Hoxidase 4 mediates transforming growth factor-betal-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 97 : 900-907, 2005.
 
22) Tong X, et al : Role of smooth muscle Nox4-based NADPH oxidase in neointimal hyperplasia. J Mol Cell Cardiol 89 : 185-194, 2015.
PubMed
23) Schurmann C, et al : The NADPH oxidase Nox4 has anti-atherosclerotic functions. Eur Heart J 36 : 3447-3456, 2015.
PubMed
24) Sluimer JC, et al : Novel concepts in atherogenesis : angiogenesis and hypoxia in atherosclerosis. J Pathol 218 : 7-29, 2009.
PubMed
25) Bonello S, et al : Reactive oxygen species activate the HIF-lalpha promoter via a functional NFkappaB site. Arterioscler Thromb Vasc Biol 27 : 755-761, 2007.
 
26) Pende A, et al : Role of neutrophils in atherogenesis : an update. Eur J Clin Invest 46 : 252-263, 2016.
PubMed
P.1054 掲載の参考文献
1) Becker RC : Cell-based models of coagulation : a paradigm in evolution. J Thromb Thrombolysis 20 : 65-68, 2005.
PubMed
2) Roberts HR, et al : Newer concepts of blood coagulation. Haemophilia 4 : 331-334, 1998.
PubMed
3) Nakagaki T, et al : Initiation of the extrinsic pathway of blood coagulation : evidence for the tissue factor dependent autoactivation of human coagulation factor VII. Biochemistry 30 : 10819-10824, 1991.
PubMed
4) Pedersen AH, et al : Autoactivation of human recombinant coagulation factor VII. Biochemistry 28 : 9331-9336, 1989.
PubMed
5) Hoffman M : Remodeling the blood coagulation cascade. J Thromb Thrombolysis 16 : 17-20, 2003.
PubMed
6) van Dieijen G, et al : The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 256 : 3433-3442, 1981.
PubMed
7) Jennewein C, et al : Novel aspects of fibrin (ogen) fragments during inflammation. Mol Med 17 : 568-573, 2011.
PubMed
8) Bouma BN, et al : Thrombin activatable fibrinolysis inhibitor (TAFI) -how does thrombin regulate fibrinolysis? Ann Med 38 : 378-388, 2006.
PubMed
9) Soeda T, et al : Mechanisms of factor VIIa-catalyzed activation of factor VIII. J Thromb Haemost 8 : 2494-2503, 2010.
PubMed
10) Lee CD, et al : Activation/inactivation of human factor V by plasmin. Blood 73 : 185-190, 1989.
PubMed
11) Nogami K, et al : Mechanisms of plasmin-catalyzed inactivation of factor VIII : a crucial role for proteolytic cleavage at Arg336 responsible for plasmin-catalyzed factor VIII inactivation. J Biol Chem 282 : 5287-5295, 2007.
PubMed
12) Neuenschwander PF, et al : Phosphatidylethanolamine augments factor VIIa-tissue factor activity : enhancement of sensitivity to phosphatidylserine. Biochemistry 34 : 13988-13993, 1995.
PubMed
13) Jasuja R, et al : Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents. J Clin Invest 122 : 2104-2113, 2012.
PubMed
14) Mackman N, et al : Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. rterioscler Thromb Vasc Biol 27 : 1687-1693, 2007.
PubMed
15) Rautou P E, et al : Microparticles, vascular function, and atherothrombosis. Circ Res 109 : 593-606, 2011.
PubMed
P.1061 掲載の参考文献
1) Inoue O, et al : Vascular Smooth Muscle Cells Stimulate Platelets and Facilitate Thrombus Formation through Platelet CLEC-2 : Implications in Atherothrombosis. PLoS ONE 10 : e0139357, 2015.
PubMed
2) Stefanini L, et al : RASA3 is a critical inhibitor of RAPI-dependent platelet activation. J Clin Invest 125 : 1419-1432, 2015,
 
3) Edelstein LC, et al : Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race. Blood 124 : 3450-3458, 2014.
PubMed
4) Lagarrigue F, et al : The Rap1-RIAM-talin axis of integrin activation and blood cell function. Blood 128 : 479-487, 2016.
PubMed
5) Kato H, et al : Human CalDAG-GEFI deficiency increases bleeding and delays αIIbβ3 activation. Blood 128 : 2729-2733, 2016.
 
6) Fujii T, et al : TMEMI6F is required for phosphatidylserine exposure and microparticle release in activated mouse platelets. Proc Natl Acad Sci U S A 112 : 12800-12805, 2015.
PubMed
7) Smith SA, et al : Polyphosphate : a new player in the field of hemostasis. Curr Opin Hematol 21 : 388-394, 2014.
PubMed
8) Nording HM, et al : Platelets in inflammation and atherogenesis. Front Immunol 6 : 98, 2015.
PubMed
9) Sreeramkumar V, et al : Neutrophils scan for activated platelets to initiate inflammation. Science 346 : 1234-1238, 2014.
PubMed
10) von Br Uhl ML, et al : Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 209 : 819-835, 2012.
 
11) Stark K, et al : Disulfide HMGBI derived from platelets coordinates venous thrombosis in mice. Blood 128 : 2435-2449, 2016.
 
12) Warkentin TE : Aspirin for dual prevention of venous and arterial thrombosis. N Engl J Med 367 : 2039-2041, 2012.
PubMed
13) Wallentin L, et al : Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 : 1045-1057, 2009.
PubMed
14) Gresele P, et al : Anti-platelet therapy : phosphodiesterase inhibitors. Br J Clin Pharmacol 72 : 634-646, 2011.
PubMed
15) Li J, et al : RUC-4 : a novel αIIbβ3 antagonist for prehospital therapy of myocardial infarction. Arterioscler Thromb Vasc Biol 34 : 2321-2329, 2014.
 
16) Xu XR, et al : Platelets and platelet adhesion molecules : novel mechanisms of thrombosis and antithrombotic therapies. Thromb J 14 : 29, 2016.
PubMed
17) Ungerer M, et al : Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation 123 : 1891-1899, 2011.
PubMed
P.1066 掲載の参考文献
1) Gurewich V : Therapeutic Fibrinolysis : How Efficacy and Safety Can Be lmproved J Am Coll Cardiol 68 : 2099-2106, 2016.
PubMed
2) Baglin TP, et al : Discovery and characterization of an antibody directed against exosite I of thrombin. J Thromb Haemost 14 : 137-142, 2016.
PubMed
3) Iwaki T, et al : Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans. J Thromb Haemost 9 : 1200-1206, 2011.
PubMed
4) Shamseldin HE, et al : Alethal phenotype associated with tissue plasminogen deficiency in humans. Hum Genet 135 : 1209-1211, 2016.
 
5) Brzoska T, et al : Imaging analyses of coagulation-dependent initiation of fibrinolysis on activated platelets and its modification by thrombin-activatable fibrinolysis inhibitor. Thromb Haemost 117 : 682-690, 2017.
PubMed
6) Brzoska T, et al : Endogenously generated plasmin at the vascular wall injury site amplifies lysine binding site-dependent plasminogen accumulation in microthrombi. PLoS ONE 10 : e0122196, 2015.
PubMed
7) Whyte CS, et al : Plasminogen associates with phosphatidylserine-exposing piatelets and contributes to thrombus lysis under flow. Blood 125 : 2568-2578, 2015.
 
8) Hosokawa K, et al : Plasminogen activator inhibitor type 1 in platelets induces thrombogenicity by increasing thrombolysis resistance under shear stress in an in-vitro flow chamber model. Thromb Res 146 : 69-75, 2016.
 
9) Schadinger SL, et al : Secretion and antifibrinolytic function of thrombin-activatable fibrinolysis inhibitor from human platelets. J Thromb Haemost 8 : 2523-2529, 2010.
PubMed
10) Mitchell JL, et al : Functional factor XIII-A is exposed on the stimulated platelet surface. Blood 124 : 3982-3990, 2014.
PubMed
11) Morrissey JH : Polyphosphate : a link between platelets, coagulation and inflammation. Int J Hematol 95 : 346-352, 2012,
PubMed
12) Zhu S, et al : FXIa and platelet polyphosphate as therapeutic targets during human blood clotting on collagen/tissue factor surfaces under flow. Blood 126 : 1494-1502, 2015.
PubMed
13) Mitchell J L, et al : Polyphosphate colocalizes with factor XII on platelet-bound fibrin and augments its plasminogen activator activity. Blood 128 : 2834-2845, 2016.
PubMed
14) Colucci M, et al : Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway. J Thromb Haemost 14 : 1603-1614, 2016.
PubMed
15) Burley K, et al : Altered fibrinolysis in autosomal dominant thrombomodulin-associated coagulopathy. Blood, 128 : 1879-1883, 2016.
PubMed
16) Ariens RA : Fibrin (ogen) and thrombotic disease. J Thromb Haemost 11 (Suppl 1) : 294-305, 2013.
 
17) Longstaff C, et al : Basic mechanisms and regulation of fibrinolysis. J Thromb Haemost 13 (Suppl 1) : S98-105, 2015.
 
18) Suzuki Y, et al : Unique secretory dynamics of tissue plasminogen activator and its modulation by plasminogen activator inhibitor-1 in vascular endothelial cells. Blood 113 : 470-478, 2009.
PubMed
19) Suzuki Y, et al : Surface-retained tPA is essential for effective fibrinolysis on vascular endothelial cells. Blood 118 : 3182-3185, 2011.
PubMed
20) Suzuki Y, et al : Activities of wild-type and variant tissue-type plasminogen activators retained on vascular endothelial cells. FEBS Open Bio 6 : 469-476, 2016.
PubMed
P.1074 掲載の参考文献
1) Scherer P E, et al : A novel serum protein similar to Clq, Produced exclusively in adipocytes. J Biol Chem 270 : 26746-26749, 1995.
 
2) Hu E, et al : AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271 : 10697-10703. 1996.
 
3) Maeda K, et al : cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (Adi Pose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221 : 286-289, 1996.
 
4) Nakano, Y, et al : Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J. Biochem. (Tokyo) 120, 803-812, 1996.
PubMed
5) Arita Y, et al : Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 : 79-83, 1999.
PubMed
6) Yamauchi T, et al : The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7 : 941-946, 2001.
PubMed
7) Yamauchi T, et al : Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8 : 1288-1295, 2002.
PubMed
8) Yamauchi T, et al : Globular adiponectin protected ob/ob mice from diabetes and Apo E-deficient mice from atherosclerosis. J Biol Chem 278 : 2461-2468, 2003.
PubMed
9) Yamauchi T, et al : Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 : 762-769, 2003.
PubMed
10) Yamauchi T, et al : Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13 : 332-339, 2007.
PubMed
11) Iwabu M, et al : Adiponectin and AdipoR1 regulate PGC-lalpha and mitochondria by Ca (2+) and AMPK/SIRT1. Nature 464 : 1313-1319, 2010.
 
12) Okada-lwabu M, et al : A small-molecule Adipo R agonist for type 2 diabetes and short life in obesity. Nature 503 : 493-499, 2013.
 
13) Tanabe H, et al : Expression, purification, crystallization, and preliminary X-ray crystallographic studies of the human adiponectin receptors, AdipoR1 and AdipoR2. J Struct Funct Genomics 16 : 11-23, 2015.
PubMed
14) Tanabe H, et al : Crystal structures of the human adiponectin receptors. Nature 520 : 312-316, 2015.
PubMed
P.1079 掲載の参考文献
1) Stenmark KR, et al : The adventitia : essential regulator of vascular wall structure and function. Annu Rev Physiol 75 : 23-47, 2013.
PubMed
2) Spear R, et al : Adventitial Tertiary Lymphoid Organs as Potential Source of MicroRNA Biomarkers for Abdominal Aortic Aneurysm. Int J Mol Sci 16 : 11276-11293, 2015.
PubMed
3) Tsuruda T, et al : Adventitial mast cells contribute to pathogenesis in the progression of abdominal aortic aneurysm. Circ Res 102 : 1368-1377, 2008.
PubMed
4) De Meyer GR, et al : Periadventitial inducible nitric oxide synthase expression and intimal thickening. Arterioscler Thromb Vasc Biol 20 : 1896-1902, 2000.
PubMed
5) Wilcox JN, et al : Perivascular responses after angioplasty which may contribute to postangioplasty restenosis : a role for circulating myofibroblast precursors? Ann N Y Acad Sci 947 : 68-90 ; dicussion 90-92, 2001.
 
6) Majesky MW, et al : The adventitia : adynamic interface containing resident progenitor cells. Arterioscler Thromb Vasc Biol 31 : 1530-1539, 2011.
 
7) Zhou J, et al : CXCR3-dependent accumulation and activation of perivascular macrophages is necessary for homeostatic arterial remodeling to hemodynamic stresses. J Exp Med 207 : 1951-1966, 2010.
PubMed
8) Sakamoto S, et al : Impact of age-dependent adventitia inflammation on structural alteration of abdominal aorta in hyperlipidemic mice. PLoS ONE 9 : e105739, 2014.
PubMed
9) Bot I, et al : Mast cells as effectors in atherosclerosis. Arterioscler Thromb Vasc Biol 35 : 265-271, 2015.
PubMed
10) Scotland RS, et al : Endogenous factors involved in regulation of tone of arterial vasa vasorum : implications for conduit vessel physiology. Cardiovasc Res 46 : 403-411, 2000.
PubMed
11) Kurnamoto M, et al : Intimal neovascularization in human coronary atherosclerosis : its origin and pathophysiological significance. Hum Pathol 26 : 450-456, 1995.
 
12) Taruya A, et al : Vasa Vasorum Restructuring in Human Atherosclerotic Plaque Vulnerability : A Clinical Optical Coherence Tomography Study. J Am Coll Cardiol 65 : 2469-2477, 2015.
PubMed
13) Moulton KS, et al : Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A 100 : 4736-4741, 2003.
PubMed
14) Mollmark JI, et al : Fibroblast growth factor-2 is required for vasa vasorum plexus stability in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol 32 : 2644-2651. 2012.
PubMed
15) Nishimiya K, et al : Enhanced Adventitial Vasa Vasorum Formation in Patients With Vasospastic Angina : Assessment With OFDI. J Am Coll Cardiol 67 : 598-600, 2016.
PubMed
16) Coen M, et al : Myofibroblast-mediated adventitial remodeling : an underestimated player in arterial pathology. Arterioscler Thromb Vasc Biol 31 : 2391-2396, 2011.
PubMed
17) Tsuruda T, et al : Stromal cell biology-a way to understand the evolution of cardiovascular diseases. Circ J 74 : 1042-1050, 2010.
PubMed
18) Hu Y, et al : Adventitial biology : differentiation and function. Arterioscler Thromb Vasc Biol 31 : 1523-1529, 2011.
PubMed
19) Omar A, et al : Proinflammatory phenotype of perivascular adipocytes. Arterioscler Thromb Vasc Biol 34 : 1631-1636, 2014.
PubMed
20) Luo Y, et al : miR-29a-3p attenuates hypoxic pulmonary hypertension by inhibiting pulmonary adventitial fibroblast activation. Hypertension 65 : 414-420, 2015.
PubMed
21) Li M, et al : Metabolic Reprogramming Regulates the Proliferative and Inflammatory Phenotype of Adventitial Fibroblasts in Pulmonary Hypertension Through the Transcriptional Corepressor C-Terminal Binding Protein-1. Circulation 134 : 1105-1121, 2016.
PubMed
P.1084 掲載の参考文献
1) Perez-Rivero G, et al : Mice deficient in telomerase activity develop hypertension because of an excess of endothelin production. Circulation 114 : 309-317, 2006.
PubMed
2) Atturu G, et al : Short leukocyte telomere length is associated with abdominal aortic aneurysm (AAA). Eur J Vasc Endovasc Surg 39 : 559-564, 2010.
PubMed
3) Strazhesko I, et al : Association of Insulin Resistance, Arterial Stiffness and Telomere Length in Adults Free of Cardiovascular Diseases. PLoS ONE 10 : e0136676, 2015.
PubMed
4) Satoh M, et al : Association between oxidative DNA damage and telomere shortening in circulating endothelial progenitor cells obtained from metabolic syndrome patients with coronary artery disease. Atherosclerosis 198 : 347-353, 2008.
PubMed
5) Liu Y, et al : Prelamin A accelerates vascular calcification via activation of the DNA damage response and senescence-associated secretory phenotype in vascular smooth muscle cells. Circ Res 112 : e99-109, 2013.
PubMed
6) Bonello-Palot N et al : Prelamin A accumulation in endothelial cells induces premature senescence and functional impairment. Atherosclerosis 237 : 45-52, 2014.
PubMed
7) Grootaert MO, et al : Defective autophagy in vascular smooth muscle cells accelerates senescence and promotes neointima formation and atherogenesis. Autophagy 11 : 2014-2032, 2015.
PubMed
8) Dai XY, et al : Phosphate-induced autophagy counteracts vascular calcification by reducing matrix vesicle release. Kidney Int 83 : 1042-1051, 2013.
PubMed
9) Kojima Y, et al : CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536 : 86-90, 2016.
PubMed
10) Ota H, et al : Testosterone deficiency accelerates neuronal and vascular aging of SAMP8 mice : protective role of eNOS and SIRT1. PLoS ONE 7 : e29598, 2012.
PubMed
11) Mercken EM, et al : SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass. Aging Cell 13 : 787-796, 2014.
PubMed
12) Benigni A, et al : Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest 119 : 524-530, 2009.
PubMed
P.1090 掲載の参考文献
1) Kuro-o M, et al : Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390 : 45-51, 1997.
PubMed
2) Kurosu H, et al : Suppression of aging in mice by the hormone Klotho. Science 309 : 1829-1833, 2005.
PubMed
3) Kurosu H, et al : Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281 : 6120-6123, 2006.
PubMed
4) Kuro-o M : Apotential link between phosphate and aging-lessons from Klotho-deficient mice. Mech Ageing Dev 131 : 270-275, 2010.
 
5) Ben-Dov IZ, et al : The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117 : 4003-4008, 2007.
PubMed
6) Tohyama O, et al : Klotho is a novel beta-glucuronidase capable of hydrolyzing steroid beta-glucuronides. J Biol Chem 279 : 9777-9784, 2004.
PubMed
7) Bloch L, et al : Klotho is a substrate for alpha-, beta-and gamma-secretase. FEBS Lett 583 : 3221-3224, 2009.
PubMed
8) Goetz R, et al : Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor lg subfamily members. Mol Cell Biol 27 : 3417-3428. 2007.
 
9) Urakawa I. et al : Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444 : 770-774, 2006.
PubMed
10) Hu MC, et al : Fibroblast growth factor 23 and Klotho : physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 75 : 503-533, 2013.
PubMed
11) Lavi-Moshayoff V, et al : PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure : a bone parathyroid feedback loop. Am J physiol Renal Physiol 299 : F882-889, 2010.
PubMed
12) Shimada T, et al : FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19 : 429-435, 2004.
 
13) Ito M, et al : Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am J Physiol Endocrinol Metab 288 : Ell Ol-1109, 2005.
 
14) Stubbs JR, et al : Role of hyperphosphatemia and 1, 25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 18 : 2116-2124. 2007.
PubMed
15) Tsujikawa H, et al : Klotho, a gene related to a syndrome resembling htlman premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 17 : 2393-2403, 2003.
 
16) Ohnishi M, et al : In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1, 25-dihydroxyvitamin d levels. Circ Cardiovasc Genet 2 : 583-590, 2009.
PubMed
17) Razzaque MS, et al : Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J 20 : 720-722, 2006.
PubMed
18) Hesse M, et al : Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix Biol 26 : 75-84, 2007.
PubMed
19) Morishita K, et al : The progression of aging in klotho mutant mice can be modified by dietary phosphorus and zinc. J Nutr 131 : 3182-3188, 2001.
 
20) Kestenbaum B, et al : Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16 : 520-528, 2005.
PubMed
21) Ganesh SK, et al : Association of elevated serum PO (4), CaxP O (4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12 : 2131-2138, 2001.
 
22) Di Marco GS, et al : Increased inorganic phosphate induces human endothelial cell apoptosis in vitro. Am J Physiol Renal Physiol 294 : F1381-1387, 2008.
PubMed
23) Shuto E, et al : Dietary phosphorus acutely impairs endothelial function. J Am Soc Nephrol 20 : 1504-1512, 2009.
PubMed
24) Steitz SA, et al : Smooth muscle cell phenotypic transition associated with calcification : upregulation of Cbfal and downregulation of smooth muscle lineage markers. Circ Res 89 : 1147-1154, 2001.
 
25) Jono S, et al : Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87 : E10-17, 2000.
PubMed
26) Sage AP, et al : Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. Kidney Int 79 : 414-422, 2011.
PubMed
27) Villa-Bellosta R, et al : Phosphonoformic acid prevents vascular smooth muscle cell calcification by inhibiting calcium-phosphate deposition. Arterioscler Thromb Vasc Biol 29 : 761-766, 2009.
PubMed
28) Ewence AE, et al : Calcium phosphate crystals induce cell death in human vascular smooth muscle cells : a potential mechanism in atherosclerotic plaque destabilization. Circ Res 103 : e28-34, 2008.
 
29) Heiss A, et al : Fetuin-A is a mineral carrier protein : small angle neutron scattering provides new insight on Fetuin-A controlled calcification inhibition. Biophys J 99 : 3986-3995, 2010.
PubMed
30) Heiss A, et al : Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem 278 : 13333-13341, 2003.
PubMed
31) Smith E R, et al : Fetuin-A-containing calciprotein particles reduce mineral stress in the macrophage. PLoS ONE 8 : e60904, 2013.
PubMed
32) Hamano T, et al : Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol 21 : 1998-2007, 2010.
PubMed
33) Smith ER, et al : Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrol Dial Transplant 27 : 1957-1966, 2012.
 

IX 特論

P.1099 掲載の参考文献
1) Gupta S, et al : HSP60 trafficking in adult cardiac myocytes : role of the exosomal pathway. Am J Physiol Heart Circ Physiol 292 : H3052-3056, 2007.
PubMed
2) Kim SC, et al : Extracellular heat shock protein 60, cardiac myocytes, and apoptosis. Circ Res 105 : 1186-1195, 2009.
PubMed
3) Zhang X, et al : Hsp20 functions as a novel cardiokine in promoting angiogenesis via activation of VEGFR2. PLoS One 7 : e32765, 2012.
PubMed
4) Cheng Y, et al : A translational study of circulating cell-free micro RNA-1 in acute myocardial infarction. Clin Sci (Lond) 119 : 87-95, 2010.
 
5) Waldenstrom A, et al : Cardiomyocyte microvesicles contain DNA/RNA and convey biological messages to target cells. PLoS One 7 : e34653, 2012.
PubMed
6) Hergenreider E, et al : Atheroprotective communication between endothelial cells and smooth muscle cells through mi RNAs. Nat Cell Biol 14 : 249-256, 2012.
 
7) Wu J, et al : KLF2 transcription factor modulates blood vessel maturation through smooth muscle cell migration. J Biol Chem 283 : 3942-3950, 2008.
PubMed
8) Boon RA, et al : Key transcriptional regulators of the vasoprotective effects of shear stress. Hamostaseologie 29 : 39-40, 41-43, 2009.
 
9) Kuwabara Y, et al : Increased micro RNA-1 and micro RNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet 4 : 446-454, 2011.
PubMed
10) Koyama S, et al : Dynamic changes of serum micro RNA-122-5p through therapeutic courses indicates amelioration of acute liver inj ury accompanied by acute cardiac decompensation. ESC Heart Fail 4 : 112-121, 2017.
 
P.1106 掲載の参考文献
1) Turnbaugh PJ, et al : An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444 : 1027-1031, 2006.
PubMed
2) Yang T, et al : Gut dysbiosis is linked to hypertension. Hypertension 65 : 1331-1340, 2015.
PubMed
3) Santisteban MM, et al : Brain-Gut-Bone Marrow Axis : Implications for Hypertension and Related Therapeutics. Circ Res 118 : 1327-1336, 2016.
PubMed
4) Durgan D J, et al : Role of the Gut Microbiome in Obstructive Sleep Apnea-Induced Hypertension. Hypertension 67 : 469-474, 2016.
PubMed
5) Kimura I, et al : Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc Natl Acad Sci U S A 108 : 8030-8035, 2011.
 
6) Pluznick JL, et al : Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci U S A 110 : 4410-4415, 2013.
 
7) Wang Z, et al : Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472 : 57-63, 2011.
PubMed
8) Koeth RA, et al : Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 19 : 576-585, 2013.
 
9) Tang WH, et al : Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 368 : 1575-1584, 2013.
PubMed
10) Zhu W, et al : Gut Microbial Metabolite T MA O Enhances Platelet Hyperreactivity and Thrombosis Risk. Cell 165 : 111-124, 2016.
 
11) Wang Z, et al : Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis, Cell 163 : 1585-1595, 2015.
PubMed
12) Sasaki N, et al : Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice. Circulation 120 : 1996-2005, 2009.
PubMed
13) Takeda M, et al : Oral administration of an active form of vitamin D3 (calcitriol) decreases atherosclerosis in mice by inducing regulatory T cells and immature dendritic cells with tolerogenic functions. Arterioscler Thromb Vasc Biol 30 : 2495-2503, 2010.
PubMed
14) Yamashita T, et al : Intestinal lmmunity and Gut Microbiota as Therapeutic Targets for Preventing Atherosclerotic Cardiovascular Diseases. Circ J 79 : 1882-1890, 2015.
 
15) Emoto T, et al : Analysis of Gut Microbiota in Coronary Artery Disease Patients : a Possible Link between Gut Microbiota and Coronary Artery Disease. J Atheroscler Thromb 23 : 908-921, 2016.
PubMed
16) Emoto T, et al : Characterization of gut microbiota profiles in coronary artery disease patients using data mining analysis of terminal restriction fragment length polymorphism : gut microbiota could be adiagnostic marker of coronary artery disease. Heart Vessels 32 : 39-46, 2016.
 
17) Karlsson F H, et al : Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun 3 : 1245, 2012.
PubMed
18) Yin J, et al : Dysbiosis of Gut Microbiota With Reduced Trimethylamine-N-Oxide Level in Patients With Large-Artery Atherosclerotic Stroke or Transient Ischemic Attack. J Am Heart Assoc 4 : pii : e002699, 2015.
PubMed
19) Sandek A, et al : Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 50 : 1561-1569, 2007.
PubMed
20) Pasini E, et al : Pathogenic Gut Flora in Patients With Chronic Heart Failure. J ACC Heart Fail 4 : 220-227, 2016.
 
21) Tang WH, et al : Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure : refining the gut hypothesis. J Am Coll Cardiol 64 : 1908-1914, 2014.
PubMed
P.1112 掲載の参考文献
1) Iadecola C, et al : The immunology of stroke : from mechanisms to translation. Nat Med 17 : 796-808, 2011.
PubMed
2) Moskowitz MA, et al : The science of stroke : mechanisms in search of treatments. Neuron 67 : 181- 198, 2010.
 
3) Venereau E, et al : DAMPs from Cell Death to New Life. Front Immunol 6 : 422, 2015.
PubMed
4) Kono H, et al : How dying cells alert the immune system to danger. Nat Rev Immunol 8 : 279-289, 2008.
PubMed
5) Zhang J, et al : Anti-high mobility group box-1 monoclonal antibody protects the blood-brain barrier from ischemia-induced disruption in rats. Stroke 42 : 1420-1428, 2011.
PubMed
6) Shichita T, et al : Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain. Nat Med 18 : 911-917, 2012.
PubMed
7) Ginhoux F, et al : Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330 : 841-845, 2010.
PubMed
8) Elmore MR, et al : Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron 82 : 380-397, 2014.
PubMed
9) Buttgereit A, et al : Salll is a transcriptional regulator defining microglia identity and function. Nat Immunol 17 : 1397-1406, 2016.
PubMed
10) Hanisch UK, et al : Microglia : active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10 : 1387-1394, 2007.
PubMed
11) Yipp BG, et al : Infection-induced NE Tosis is a dynamic process involving neutrophil multitasking in vivo. Nat Med 18 : 1386-1393, 2012.
 
12) Cuartero MI, et al : N2 neutrophils, novel players in brain inflammation after stroke : modulation by the PPARγ agonist rosiglitazone. Stroke 44 : 3498-3508, 2013.
 
13) Prinz M, et al : Microglia and brain macrophages in the molecular age : from origin to neuropsychiatric disease. Nat Rev Neurosci 15 : 300-312, 2014.
PubMed
14) Gliem M, et al : Macrophages prevent hemorrhagic infarct transformation in murine stroke models. Ann Neurol 71 : 743-752, 2012.
PubMed
15) Shichita T, et al : MAFB prevents excess inflalnmation after ischemic stroke by accelerating clearance of damage signals through MSRI. Nat Med, 2017. [Epub ahead of print]
 
16) Zhu Z, et al : Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke : A Pilot Trial. Circulation 132 : 1104-1112, 2015.
PubMed
17) Louveau A, et al : Structural and functional features of central nervous system lymphatic vessels. Nature 523 : 337-341, 2015.
PubMed
P.1119 掲載の参考文献
1) Zicha J. et al : Abnormalities of membrane function and lipid metabolism in hypertension : a review. Am J Hypertens 12 : 315-331, 1999.
PubMed
2) Tsuda K, et al : Membrane fluidity and hypertension. Am J Hypertens 16 : 259-261, 2003.
PubMed
3) Odashiro K, et al : Impaired deformability of circulating erythrocytes obtained from nondiabetic hypertensive patients : investigation by a nickel mesh filtration technique. Clin Hypertens 21 : 17, 2015.
PubMed
4) Satoh N, et al : Unfavorable blood rheology is closely associated with arterial stiffness in obese patients. Endocr J 56 : 915-918, 2009.
PubMed
5) Tsukada K, et al : Direct measurement of erythrocyte deformability in diabetes mellitus with a transparent microchannel capillary model and high-speed video camera system. Microvasc Res 61 : 231-239, 2001.
PubMed
6) Tatsumi K, et al : Numerical and experimental study on the development of electric sensor as for measurement of red blood cell deformability in microchannels. Sensors (Basel) 12 : 10566-10583, 2012.
 
7) Da Costa L, et al : Diagnostic tool for red blood cell membrane disorders : Assessment of a new generation ektacytometer. Blood Cells Mol Dis 56 : 9-22, 2016.
PubMed
8) Agrawal R, et al : Assessment of red blood cell deformability in type 2 diabetes mellitus and diabetic retinopathy by dual optical tweezers stretching technique. Sci Rep 6 : 15873, 2016.
PubMed
9) Shasha SM, et al : Red cell filterability in cigarette smokers and its relations to cardiac hypertrophy. Atherosclerosis 98 : 91-98, 1993.
PubMed
10) Radosinska J, et al : The role of red blood cell deformability and Na, K-ATPase function in selected risk factors of cardiovascular diseases in humans : focus on hypertension, diabetes mellitus and hypercholesterolemia. Physiol Res 65 (Suppl 1) : S43-54, 2016.
 
11) Kazennov AM, et al : Some properties of erythrocyte Na+ -K+ -ATPase in essential hypertension. Clin Exp Hypertens 9 : 1221-1232, 1987.
PubMed
12) Malfatti CR, et al : Decreased erythrocyte Na+, K+- ATPase activity and increased plasma TBARS in prehypertensive patients. Scientific World Journal 2012 : 348246, 2012.
PubMed
13) Buckalew VM : Endogenous digitalis-like factors : an overview of the history. Front Endocrinol (Lausanne) 6 : 49, 2015.
PubMed
14) Tsuda K, et al : The role of endogenous Na+, K (+) -adenos ine triphosphatase inhibitory factor in the regulation of membrane fluidity of erythrocytes in essential hypertension. J Hypertens 10 : 657-661, 1992.
 
15) Amaiden MR, et al : Tubulin pools in human erythrocytes : altered distribution in hypertensive patients affects Na+, K+- ATPase activity. Cell Mol Life Sci 68 : 1755-1768, 2011.
PubMed
16) Namazi G, et al : Increased membrane lipid peroxidation and decreased Na+/K+ -ATPase activity in erythrocytes of patients with stable coronary artery disease. Coron Artery Dis 26 : 239-244, 2015.
PubMed
17) Faloia E, et al : Physicochemical and functional modifications induced by obesity on human erythrocyte membranes. Eur J Clin Invest 29 : 432-437, 1999.
PubMed
18) Shiraishi K, et al : Impaired erythrocyte deformability and membrane fluidity in alcoholic liver disease : participation in disturbed hepatic microcirculation. Alcohol Alcohol Suppl IA : 59-64, 1993.
 
19) Hollan S : Membrane fluidity of blood cells. Haematologia (Budap) 27 : 109-127, 1996.
PubMed
20) Sato B, et al : Electron spin resonance studies of erythrocytes from patients with Duchenne muscular, dystrophy. J Clin Invest 61 : 251-259, 1978.
PubMed
21) Simon I : Differences in membrane unsaturated fatty acids and electron spin resonance in different types of myeloid leukemia cells. Biochim Biophys Acta 556 : 408-422, 1979.
PubMed
22) Tsuda K, et al : Electron spin resonance studies of erythrocytes from spontaneously hypertensive rats and humans with essential hypertension. Hypertension 9 (6 Pt 2) : III 19-24, 1987.
 
23) Tsuda K, et al : Synergistic role of progesterone and nitric oxide in the regulation of membrane 日uidity of erythrocytes in humans : an electron paramagnetic rcsonance investigation. Am J Hypertens 15 : 702-708, 2002.
 
24) Tsuda K, et al : Nitric oxide improves membrane fluidity of erythrocytes in essential hypertension : An electron paramagnetic resonance investigation. Biochem Biophys Res Commun 275 : 946-954, 2000.
PubMed
25) Tsuda K, et al : Leptin improves membrane fluidity of erythrocytes in humans via a nitric oxidedependent mechanism-an electron paramagnetic resonance investigation. Biochem Biophys Res Commun 297 : 672-681, 2002.
 
26) Tsuda K : Adiponectin and membrane fluidity of erythrocytes in normotensive and hypertensive men. Obesity (Silver Spring) 14 : 1505-1510, 2006.
PubMed
27) Tsuda K, et al : Electron paranlagnetic resonance investigation on modulatory effect of 17β-estradiol on membrane fluidity of erythrocytes in postmenopausal women. Arterioscler Thromb Vasc Biol 21 : 1306-1312, 2001.
 
28) Tsuda K, et al : A selective estrogen receptor modulator, tamoxifen, and membrane fluidity of erythrocytes in normotensive and hypertensive postmenopausal women : an electron paramagnetic resonance investigation. Am J Hypertens 18 : 1067-1076, 2005.
PubMed
29) Miller MA, et al : Comparison of calcium, magnesium-ATPase activity and membrane fluidity in patients with essential hypertension and in normotensive controls. J Hypertens 12 : 929-938, 1994.
PubMed
30) Cazzola R, et al : Decreased membrane fluidity and altered susceptibility to peroxidation and lipid composition in overweight and obese female erythrocytes. J Lipid Res 45 : 1846-1851, 2004.
PubMed
31) Anichkov DA, et al : Relationships between erythrocyte membrane properties and components of metabolic syndrome in women. Med Sci Monit 11 : CR203-210, 2005.
PubMed
32) Luneva OG, et al : Ion transport, membrane fluidity and haemoglobin conformation in erythrocyte from patients with cardiovascular diseases : Role of augmented plasma cholesterol. Pathophysiology 14 : 41-46, 2007.
PubMed
33) Tsuda K, et al : Membranefluidity of erythrocytes and its relevance to renin profile in essential hypertension. J Pn Circ J 52 : 1301-1308, 1988.
 
34) Tsuda K, et al : Decreased membrane fluidity of erythrocytes and cultured vascular smooth muscle cells in spontaneously hypertensive rats : an electron spin resonance study. Clin Sci 75 : 477-480, 1988.
PubMed
35) Mitchell GF : Arterial stiffness and hypertension. Hypertension 64 : 13-18, 2014.
PubMed
37) Tsuda K : Independent association between carotid artery atherosclerosis and membrane microviscosity of red blood cells in hypertensive subjects-an electron spin resonance study. Circ J 79 (Suppl I) : 1-949 (abstract), 2015.
 
38) Tsuda K : Cardiac hypertrophy is independently associated with impaired membrane microviscosity of red blood cells in hypertensive subjects-an electron spin resonance study. Circ J 80 (Suppl I) : 1-698 (abstract), 2016.
 
39) Tsuda K : Chronic kidney disease predicts impaired membrane microviscosity of red blood cells in hypertensive and normotensive subjects. Int Heart J 54 : 154-159, 2013.
PubMed
40) Jubelin BC, et al : Erythrocytes may synthesize their own nitric oxide. Am J Hypertens 9 : 1214-1219, 1996.
PubMed
41) Chen LY, et al : Evidence for the presence of Larginine-nitric oxide pathway in human red blood cells : relevance in the effects of red blood cells on platelet function. J Cardiovasc Pharmacol 32 : 57-61, 1998.
PubMed
42) Kleinbongard P, et al : Red blood cells express a functional endothelial nitric oxide synthase. Blood 107 : 2943-2951, 2006.
PubMed
43) Ulker P, et al : Mechanical stimulation of nitric oxide synthesizing mechanisms in erythrocytes. Biorheology 46 : 121-132, 2009.
PubMed
44) Grau M, et al : RBC-NOS-dependent S-nitrosylation of cytoskeletal proteins improves RBC deformability. PLoS ONE 8 : e56759, 2013.
PubMed
45) Ghosh SM, et al : Enhanced vasodilator activity of nitrite in hypertension : critical role for erythrocytic xanthine oxidoreductase and translational potential. Hypertension 61 : 1091-1102, 2013.
PubMed
46) Tsuda K, et al : An association between plasma asymmetric dimethylarginine and membrane fluidity of erythrocytes in hypertensive and normotensive men : an electron paramagnetic resonance investigation. Am J Hypertens 18 : 1243-1248, 2005.
PubMed
47) Kimura K, et al : Involvement of nitric oxide in endothelium-dependent arterial relaxation by leptin. Biochem Biophys Res Commun 273 : 745-749, 2000.
PubMed
48) Tsuda K, et al : Leptin and nitric oxide production in normotensive and hypertensive men. Obes Res 12 : 1223-1237, 2004.
PubMed
49) Tsuda K, et al : Leptin and membrane fluidity of erythrocytes in essential hypertension. An electron paramagnetic resonance investigation. Am J Hypertens 17 : 375-379, 2004.
PubMed
50) Hui X, et al : Adiponectin and cardiovascular health : an update. Br J Pharmacol 165 : 574-590, 2012.
PubMed
51) Tsuda K : Association of resistin with impaired membrane fluidity of red blood cells in hypertensive and normotensive men : an electron paramagnetic resonance study. Heart Vessels 31 : 1724-1730, 2016.
PubMed
52) Stuhlinger MC, et al : Homocysteine impairs the nitric oxide synthase pathway : role of asymmetric dimethylarginine. Circulation 104 : 2569-2575, 2001.
PubMed
53) Tsuda K : Hyperhomocysteinemia and membrane fluidity of red blood cells in normotensive and hypertensive men : an electron paramagnetic resonance investigation. Clin Exp Pharmacol Physiol 34 (Suppl 1) : S70-72, 2007.
 
54) Tsuda K : Oxidative stress and membrane fluidity of red blood cells in hypertensive and normotensive men : an electron spin resonance investigation. Int Heart J 51 : 121-124, 2010.
PubMed
55) Tsuda K : Associations between high-sensitivity C-reactive protein and membrane fluidity of red blood cells in hypertensive elderly men : an electron Spin resonance study. Int J Hypertens 2012 : 292803, 2012.
PubMed
56) Cottone S, et al : Endothelin-1 and F2-isoprostane relate to and predict renal dysfunction in hypertensive patients. Nephrol Dial Transplant 24 : 497-503, 2009.
PubMed
57) Takahashi K, et al : Glomerular actions of a free radical-generated novel prostaglandin, 8-epiprostaglandin F2α, in the rat. Evidence for interaction with thromboxane A2 receptors. J Clin Invest 90 : 136-141, 1992.
 
58) Masuyama Y, et al : Membrane abnormality of erythrocytes is highly dependent on salt intake and renin profile in essential hypertension : an electron spin resonance study. J Hypertens Suppl 6 (4) : S266-268, 1988.
PubMed
59) Tsuda K, et al : Effects of mild aerobic physical exercise on membrane fluidity of erythrocytes in essential hypertension. Clin Exp Pharmacol Physiol 30 : 382-386, 2003.
PubMed
60) Tsuda K, et al : Hormone replacement therapy improves membrane fluidity of erythrocytes in postmenopausal women : an electron paramagnetic resonance investigation. Am J Hypertens 16 : 502-507, 2003.
PubMed
61) Tsuda K : Electron paramagnetic resonance investigation on modulatory effect of benidipine on membrane fluidity of erythrocytes in essential hypertension. Heart Vessels 23 : 134-139, 2008.
PubMed
62) Tsuda K, et al : A calcium channel blocker, benidipine, improves cell membrane fluidity in human subjects via a nitric oxide-dependent mechanism. An electron paramagnetic resonance investigation. Am J Hypertens 17 : 1143-ll50, 2004.
 
63) 津田和志 : 電子スピン共鳴からみた高血圧ならびにメタボリックシンドロームの細胞膜機能. 異常と微小循環障害-内皮機能, 肥満関連血管作動物質の関与を中心とした検討-. 脈管学 55 : 111-116, 2015.
 
.36) Tsuda K : Associations of arterial stiffness with membrane microviscosity of red blood cells and endothelial dysfunction in hypertension-an electron spin resonance study. Circ J 78 (Suppl I) : 1-1783 (abstract), 2014.
 
P.1126 掲載の参考文献
1) Nicoll R, et al : Arterial calcification : A new perspective? Int J Cardiol 228 : 11-22, 2017.
PubMed
2) Demer LL, et al : Vascular calcification : pathobiology of a multifaceted disease. Circulation 117 : 2938-2948, 2008.
PubMed
3) Greenland P, et al : Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 291 : 210-215, 2004.
PubMed
4) Greenland P, et al : 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 122 : e584-636, 2010.
 
5) Yahagi K, et al : Pathology of Human Coronary and Carotid Artery Atherosclerosis and Vascular Calcification in Diabetes Mellitus. Arterioscler Thromb Vasc Biol 37 : 191-204, 2017.
PubMed
6) Yamamoto H, et al : Coronary calcium score as a predictor for coronary artery disease and cardiac events in Japanese high-risk patients. Circ J 75 : 2424-2431, 2011.
PubMed
7) Demer LL, et al : Inflammatory, metabolic, and genetic mechanisms of vascular calcification. Arterioscler Thromb Vasc Biol 34 : 715-723, 2014.
PubMed
8) Whitlock MC, et al : Cancer and Its Association With the Development of Coronary Artery Calcification : An Assessment From the Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc 4 : 2015.
PubMed
9) Seldenrijk A, et al : Psychological distress, cortisol stress response and subclinical coronary calcification. Psychoneuroendocrinology 37 : 48-55, 2012.
PubMed
10) Ko BJ, et al : Relationship Between Low Relative Muscle Mass and Coronary Artery Calcification in Healthy Adults. Arterioscler Thromb Vasc Biol 36 : 1016-1021, 2016.
PubMed
11) Ye S, et al : Intraocular pressure and coronary artery calcification in asymptomatic men and women. Br J Ophthalmol 99 : 932-936, 2015.
PubMed
12) Bos D, et al : Atherosclerotic calcification relates to cognitive function and to brain changes on magnetic resonance imaging. Alzheimers Dement 8 : S104-111, 2012.
PubMed
13) Williams MC, et al : Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax 69 : 718-723, 2014.
PubMed
14) Nakahara T, et al : Fibroblast growth factor 23 inhibits osteoblastic gene expression and induces osteoprotegerin in vascular smooth muscle cells. Atherosclerosis 253 : 102-110, 2016.
PubMed
15) Orita Y, et al : Role of osteoprotegerin in arterial calcification : development of new animal model. Arterioscler Thromb Vasc Biol 27 : 2058-2064, 2007.
PubMed
P.1135 掲載の参考文献
1) Fokkema ML, et al : Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction : a randomized controlled trial. Circ Cardiovasc Interv 2 : 323-329, 2009.
PubMed
2) Javadov S, et al : Mitochondrial permeability transition pore opening as a promising therapeutic target in cardiac diseases. J Pharmacol Exp Ther 330 : 670-678, 2009.
PubMed
3) Tullio F, et al : Redox balance and cardioprotection. Basic Res Cardiol 108 : 392, 2013.
PubMed
4) Caride VJ, et al : Liposome accumulation in regions of experimental myocardial infarction. Science 198 : 735-738, 1977.
PubMed
5) Feld S, et al : Reduction of canine infarct size by bolus intravenous administration of liposomal prostaglandin E1 : comparison with control, placebo liposomes, and continuous intravenous infusion of prostaglandin E1. Am Heart J 132 : 747-757, 1996.
PubMed
6) Takahama H, et al : Prolonged targeting of ischemic/reperfused myocardium by liposomal adenosine augments cardioprotection in rats. J Am Coll Cardiol 53 : 709-717, 2009.
PubMed
7) Kobayashi H, et al : Lirrlitation of infarct size by erythropoietin is associated with translocation of Akt to the mitochondria after reperftlsion. Clin Exp Pharmacol Physiol 35 : 812-819, 2008.
 
8) Nagaoka K, et al : A New Therapeutic Modality for Acute Myocardial Infarction : Nanoparticle-Mediated Delivery of Pitavastatin Induces Cardioprotection from Ischemia-Reperfusion Injury via Activation of PI3K/Akt Pathway and Anti-inflammation in a Rat Model. PLoS One 10 : e0132451, 2015.
 
9) Dobaczewski M, et al : The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J Mol Cell Cardiol 48 : 504-511, 2010.
PubMed
10) Yanagisawa-Miwa A, et al : Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 257 : 1401-1403, 1992.
PubMed
11) Seif-Naraghi SB, et al : Design and characterization of an injectable pericardial matrix gel : a potentially autologous scaffold for cardiac tissue engineering. Tissue Eng Part A 16 : 2017-2027, 2010.
PubMed
12) Seif-Naraghi SB, et al : Injectable extracellular matrix derived hydrogel provides a platform for enhanced retention and delivery of a heparin-binding growth factor. Acta Biomater 8 : 3695-3703, 2012.
PubMed
13) Tambara K, et al : Administration of control-released hepatocyte growth factor enhances the efficacy of skeletal myoblast transplantation in rat infarcted hearts by greatly increasing both quantity and quality of the graft. Circulation 112 (9 Suppl) : I129-134, 2005.
 
14) Ishimaru K, et al : Synthetic prostacyclin agonist, ONO1301, enhances endogenous myocardial repair in a hamster model of dilated cardiomyopathy : a promising regenerative therapy for the failing heart. J Thorac Cardiovasc Surg 146 : 1516-1525, 2013.
 
P.1141 掲載の参考文献
1) Amarenco P : Underlying pathology of stroke of unknown cause (cryptogenic stroke). Cerebrovasc Dis 27 (Suppl 1) : 97-103, 2009.
 
2) Saver JL : CLINICAL PRACTICE. Cryptogenic Stroke. N Engl J Med 374 : 2065-2074, 2016.
PubMed
3) Ruff CT, et al : Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials. Lancet 383 : 955-962, 2014.
PubMed
4) Gladstone DJ, et al : Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 370 : 2467-2477, 2014.
PubMed
5) Sanna T, et al : Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 370 : 2478-2486, 2014.
PubMed
6) Hart RG, et al : Embolic strokes of undetermined source : the case for a new clinical construct. Lancet Neurol 13 : 429-438, 2014.
PubMed
7) Toyoda K, et al : Identification of Covert Atrial Fibrillation in Cryptogenic Ischemic Stroke : Current Clinical Practice in Japan. J Stroke Cerebrovasc Dis 25 : 1829-1837, 2016.
PubMed
8) Perera K S, et al : Global Survey of the Frequency of Atrial Fibrillation-Associated Stroke : Embolic Stroke of Undetermined Source Global Registry. Stroke 47 : 2197-2202, 2016.
PubMed
9) Nakamura A, et al : Causes of Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation. Cerebrovasc Dis 42 : 196-204, 2016.
PubMed
10) Toyoda K : Is anticoagulant therapy unnecessary for lower-risk Japanese patients with atrial fibrillation? Lessons from the SAMURAI-NVAF and BAT studies. Circ J 79 : 307-309, 2015.
PubMed
11) Shibazaki K, et al : Brain natriuretic peptide levels as a predictor for new atrial fibrillation during hospitalization in patients with acute ischemic stroke. Am J Cardiol 109 : 1303-1307, 2012.
PubMed
12) Llombart V, et al : B-type natriuretic peptides help in cardioembolic stroke diagnosis : pooled data meta-analysis. Stroke 46 : 1187-1195, 2015.
PubMed
13) Shaikh Q, et al : Left atrial volumes and associated stroke subtypes. BMC Neurol 13 : 149, 2013.
PubMed
14) Hoshino T, et al : Slow sinus heart rate as a potential predictive factor of paroxysmal atrial fibrillation in stroke patients. Cerebrovasc Dis 36 : 120-125, 2013.
PubMed
15) Hoshino T, et al : Prolonged QTc interval predicts poststroke paroxysmal atrial fibrillation. Stroke 46 : 71-76, 2015.
PubMed
16) Macleod MR, et al : Atheroma of the aortic arch : an important and poorly recognised factor in the aetiology of stroke. Lancet Neurol 3 : 408-414, 2004.
PubMed
17) 内山真一郎 : 障害部位・病態による臨床病型 トルーソー症候群. 日本内科学会雑誌 97 : 1805-1808, 2008.
 
18) Amarenco P, et al : Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. Stroke 45 : 1248-1257, 2014.
PubMed
19) Diener HC, et al : Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS). Int J Stroke 10 : 1309-1312, 2015.
PubMed
20) Geisler T, et al : Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial) : Rationale and study design. Int J Stroke. Nov 23, 2016. [Epub ahead of print]
 
P.1146 掲載の参考文献
1) Tendera M, et al : ESC Guidelines on the diagnosis and treatment of peripheral artery diseases : Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries : the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 32 : 2851-2906, 2011.
 
2) Steg PG, et al : One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297 : 1197-1206, 2007.
PubMed
3) Bhatt D, et al : Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 304 : 1350-1357, 2010,
 
4) Bhatt DL, et al : Prior polyvascular disease : risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J 30 : 1195-1202, 2009.
PubMed
5) Morikami Y, et al : Impact of polyvascular disease on clinical outcomes in patients undergoing coronary revascularization : an observation from the CREDO-Kyoto Registry Cohort-2. Atherosclerosis 228 : 426-431, 2013.
PubMed
6) Aboyans V, et al : Measurement and interpretation of the ankle-brachial index : a scientific statement from the American Heart Association. Circulation 126 : 2890-2909, 2012.
PubMed
7) Chang ST, et al : Ankle-arm index as a predictor of lesion morphology and risk classification for coronary artery disease undergoing angioplasty. Int J Cardiol 113 : 385-390, 2006.
PubMed
8) Lorenz MW, et al : Prediction of clinical cardiovascular events with carotid intima-media thickness : a systematic review and meta-analysis. Circulation 115 : 459-467, 2007.
PubMed
9) Fernandez-Friera L, et al : Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort : The PESA (Progression of Early Subclinical Atherosclerosis) Study. Circulation 131 : 2104-2113, 2015.
 
10) Feringa HH, et al : Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol 47 : 1182-1187, 2006.
PubMed
11) Kumbhani DJ, et al : Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease : insights from the REACH registry. Eur Heart J 35 : 2864-2872, 2014.
PubMed
12) Shimamoto K, et al : The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 37 : 253-390, 2014.
PubMed
13) Bhatt DL, et al : Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49 : 1982-1988, 2007.
 
14) Subherwal S, et al : Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Qual Outcomes 5 : 541-549, 2012.
PubMed
15) Yamazaki T, et al : Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan. Circ J 71 : 995-1003, 2007.
PubMed
P.1152 掲載の参考文献
1) Witte K, et al : Day-night variation in the in vitro contractility of aorta and mesenteric and renal arteries in transgenic hypertensive rats. Chronobiol Int 18 : 665-681, 2001.
PubMed
2) Cohen MC, et al : Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am J Cardiol 79 : 1512-1516, 1997.
PubMed
3) Suarez-Barrientos A, et al : Circadian variations of infarct size in acute myocardial infarction. Heart 97 : 970-976, 2011.
PubMed
4) Braunwald E : On circadian variation of myocardial reperfusion injury. Circ Res 110 : 6-7, 2012.
PubMed
5) King DP, et al : Positional cloning of the mouse circadian clock gene. Cell 89 : 641-653, 1997.
PubMed
6) Okamura H, et al : Mammalian circadian clock system : Molecular mechanisms for pharmaceutical and medical sciences. Adv Drug Deliv Rev 62 : 876-884, 2010.
PubMed
7) Viswambharan H, et al : Mutation of the circadian clock gene Per2 alters vascular endothelial function. Circu1ation 115 : 2188-2195, 2007.
PubMed
8) Anea CB, et al : Vascular disease in mice with a dysfunctional circadian clock. Circulation 119 : 1510-1517, 2009.
PubMed
9) Curtis AM, et al : Circadian variation of blood pressure and the vascular response to asynchronous stress. Proc Natl Acad Sci U S A 104 : 3450-3455, 2007.
PubMed
10) Doi M, et al : Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. Nat Med 16 : 67-74, 2010.
PubMed
11) Okamura H, et al : Hypertension due to loss of clock : novel insight from the molecular analysis of Cry1/Cry2-deleted mice. Curr Hypertens Rep 13 : 103-108, 2011.
PubMed
12) Westgate EJ, et al : Genetic components of the circadian clock regulate thrombogenesis in vivo. Circulation 117 : 2087-2095, 2008.
PubMed
13) Xie Z, et al : Smooth-muscle BMAL1 participates in blood pressure circadian rhythm regulation. J Clin Invest 125 : 324-336, 2015.
PubMed
14) Paschos G K, et al : Obesity in mice with adipocyte-specific deletion of clock component Arntl. Nat Med 18 : 1768-1777, 2012.
PubMed
15) Eckle T, et al : Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia. Nat Med 18 : 774-782, 2012.
PubMed
P.1158 掲載の参考文献
1) Nagashima M, et al : Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia 54 : 2649-2659, 2011.
PubMed
2) Arakawa M, et al : Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59 : 1030-1037, 2010.
PubMed
3) Tashiro Y, et al : A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis. Peptides 54 : 19-26, 2014.
 
4) Gaspari T, et al : The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an Apo E (-/-) mouse model. Diab Vasc Dis Res 10 : 353-360, 2013.
 
5) Krasner NM, et al : Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism. PLoS One 9 : e97554, 2014.
PubMed
6) Ishibashi Y, et al : Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE) -induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun 391 : 1405-1408, 2010.
PubMed
7) Tomoyasu M, et al : Glucagon-like Peptide-1 Suppresses the Proliferation and Migration of Vascular Smooth Muscle Cells : Implications for Preventive Effects on Atherosclerosis. The Showa University Journal of Medical Sciences 26 : 191-199, 2014,
 
8) Lorber D : GLP-1 receptor agonists : effects on cardiovascular risk reduction. Cardiovasc Ther 31 : 238-249, 2013.
PubMed
9) Dicker D : DPP-4 inhibitors : impact on glycemic control and cardiovascular risk factors. Diabetes Care 34 (Suppl 2) : S276-278, 2011.
 
10) White WB, et al : Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 : 1327-1335, 2013.
PubMed
11) Scirica BM, et al : Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 : 1317-1326, 2013.
PubMed
12) Green JB, et al : Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 373 : 232-242, 2015.
PubMed
13) Pfeffer MA, et al : Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 373 : 2247-2257, 2015.
PubMed
14) Marso SP, et al : Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 375 : 311-322, 2016.
PubMed
15) Marso SP, et al : Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 375 : 1834-1844, 2016.
PubMed

書評

最近チェックした商品履歴

Loading...